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Abstract 
Risk prediction models are tools that predict an individual’s risk of developing a health 
outcome.  They were developed to influence patient management by guiding preventive 
interventions, with the goal of reducing the incidence of new diseases.  Studies 
examining their impacts are uncommon, and no consensus regarding their effects has 
been reached.  This systematic review sought to determine the impact of risk prediction 
models for chronic diseases on physician behaviour, patient behaviour, and patient health 
outcomes.  Twenty-two studies were found to be eligible for review.  The results 
demonstrated that: 1) physician behaviour may be positively influenced, though a 
statistically significant result was not found; 2) alterations in patient behaviour were 
inconclusive; and 3) some aspects of patient health outcomes were significantly 
improved, such as changes in blood pressure, but these results may be clinically 
insignificant.  The evidence indicates some effects may exist, though future studies are 
required to confirm this effect. 
 
Keywords 
Risk prediction model, chronic disease, primary care setting, systematic review, meta-
analysis 
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Chapter 1 
1.0 Introduction 
The focus of this thesis is on risk prediction models, which are clinical tools that take 
formal, evidence-based combinations of predictors and risk factors and generate an 
estimated risk for specific, often health-related, endpoints.1  The ability to use patient 
characteristics for estimating the risk of an outcome, or ‘event’, can be applied within 
many healthcare settings and to many clinical outcomes.2  This thesis will concentrate on 
models which are predictive of chronic health outcomes, and that are used mainly in 
primary care settings.   
Though several definitions of chronic diseases exist, the term is generally applied to 
diseases that are of long duration, generally slow progression, and are of noncontagious 
origin.3  The prevalence rate of chronic diseases, such as diabetes or heart disease, has 
been estimated to be as high as one in three persons in Canada.4,5  This represents a 40 
billion CAD economic burden in direct costs for disease management.5,6   Globally, 
chronic diseases were responsible for 38 million (68%) deaths in 2012, with the number 
projected to rise to over 50 million by 2030, representing the leading cause of death 
worldwide.4   
Primary care settings are the main arena within which chronic diseases are managed and 
their onset prevented.7  Chronic disease prevention and management in the given climate 
is gaining increasing importance in primary care settings.6  Given the increasing burden 
of chronic diseases, many chronic diseases and conditions are primarily managed in 
outpatient settings under the supervision of a primary care physician.5,8  This creates a 
collaborative relationship between patient and physician, emphasizing the role of patient 
self-management within the context of primary care settings.9,10  Though numerous health 
care professionals are involved in chronic disease management, the physician is often 
recognized as the locus of care.8  Primary care was selected as the setting of interest with 
a particular emphasis on primary care physicians given the intrinsic relationship between 
chronic disease prevention and management and primary care settings. 
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Risk prediction models may supplement the management of chronic diseases in primary 
care.  They function well as an educational tool by providing both physicians and patients 
with an objective measure of a patient’s risk of disease or outcome.11  They are intended 
to help guide, not replace, the clinical decision-making process involved in disease 
prevention and management.12  To provide context regarding the development of risk 
prediction models, a brief explanation of their history will be provided in the following 
section. 
1.1 The Framingham Heart Study and the birth of prediction models 
The first well-accepted health-related risk prediction model was published in 1976 by 
researchers of the first iteration of the Framingham Study, a prospective cohort study 
seeking to identify the risk factors for cardiovascular disease (CVD).13,14,15  Prior to the 
Framingham Study, the etiology of CVD was unknown.  Indeed, the term “risk factor” 
wasn’t popularized until 1961 with a publication from the Framingham researchers 
identifying the factors of risk of developing coronary heart disease (CHD).16,17   
By the 1940s, CVD was responsible for 1 in 2 deaths amongst Americans, and was the 
foremost cause of mortality in the United States.17  Former US President Franklin Delano 
Roosevelt’s death due to cerebral hemorrhage in 1945 drew greater attention to the 
necessity of identifying the cause or causes of CVD.18,19 
In recognition of the paucity of funds for research to understand and combat CVD, the 
National Heart Act was enacted in 1948, which authorized the funding of the 
Framingham Heart Study.20,19  As a result of the study, researchers identified numerous 
risk factors for CVD, including age, sex, high blood pressure, smoking status, 
dyslipidemia, and diabetes.21,22  The previous medical treatment paradigm began to shift 
towards prevention.23  With the findings of the Framingham Study, the groundwork for 
preventing not just CVD but many other chronic diseases was established. 
1.2 From treatment to prevention 
The identification of the predictive risk factors for CVD as well as risk factors for many 
other chronic diseases helped promote the concept of disease prevention.19   Through 
3 
 
epidemiologic investigation, the prevention of CVD became a possibility by providing a 
range of modifiable, targetable risk factors for intervention.  The identification of risk 
factors allowed physicians to not only to continue to treat those afflicted, but also to 
target individuals at risk of disease.19,24   
The field of risk prediction models is largely focused on CVD, which is understandable 
given its origins, but the principle of identifying risk factors and quantifying their 
independent and cumulative impact on disease risk have been applied to numerous health 
outcomes.  For example, the Gail model was developed to predict breast cancer risk, 
allowing for the appropriate prescription with tamoxifen, a chemopreventive 
medication.25,26  One recent systematic literature search identified 25 models predictive of 
the risk of type 2 diabetes mellitus.27  More recently, the first multivariable risk 
prediction model for chronic obstructive pulmonary disease (COPD) was created in 2015 
incorporating different genotypes in tandem with other clinical variables, such as age or 
smoking status, to generate a person’s long-term risk of developing COPD.28 
Risk prediction models have become a common method of identifying individuals at risk 
for experiencing a targeted health outcome such as cancer or diabetes; they are capable of 
generating an individual’s absolute probability or risk of experiencing an event well 
before the individual experiences disease onset.29,30  The process of estimating the 
absolute risk of particular diseases for individual patients is often recommended as it may 
help guide the preventive care activities by health care practitioners.31   
The interactive, multifactorial nature of the causes of chronic disease indicate that 
preventive measures should target multiple risk factors as opposed to focusing on single 
factors31,32.  For example, the risk factors of blood pressure or cholesterol levels are 
predictive of CVD.  However, interventions focused strictly on reducing blood pressure 
or cholesterol levels only have a limited effect on absolute cardiovascular risk, indicating 
that reductions in multiple risk factors are more effective at preventing cardiovascular 
events.32  Risk prediction models are often multivariable models themselves, accounting 
for several risk factors in one cohesive equation to generate an absolute risk of disease.33  
Reducing a patient’s absolute risk of disease necessitates a multifactorial approach, 
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targeting multiple risk factors rather than single ones, a process that may be guided by 
use of a risk prediction model. 
Clinical guidelines often incorporate and recommend the use of risk prediction models.11  
Indeed, one systematic review published in 2010 identified 27 guidelines that 
recommended cardiovascular risk assessment in asymptomatic adults, indicating a 
movement towards formal risk assessments for patients.34  This shift represents a belief 
that model usage to estimate patient risk of disease will correspondingly affect physician 
behaviour, such as prescription with preventive medications, thereby affecting patient 
behaviours, such as lifestyle modifications, which may result in improved patient health 
outcomes.33,35,36  However, though risk prediction models have become quite 
commonplace and increasingly recommended for use in clinical practice, consensus 
regarding their intended impact has yet to be achieved.37 
1.3 Impact analysis 
There have been several studies conducted regarding the development and, to a lesser 
extent, the validation of risk prediction models.33  Nevertheless, their utility in clinical 
practice is unknown due to a dearth of information regarding their impact.  Though 
systematic reviews have been conducted regarding the impact of risk prediction model 
use for single health outcomes or to assess the health economic impact of model use, no 
systematic review have examined impact analysis studies of risk prediction models 
comprehensively.35,38  There are calls from researchers to assess the impact of risk 
prediction model use in clinical practice.33,38  Given the widespread recommendations to 
use prediction models, there exists a lack of cohesive evidence to support their 
implementation for regular use in the prevention of chronic diseases.   
For this reason, this thesis sought to search, collect, and collate the relevant literature 
pertaining to the impact of chronic disease risk prediction models on the domains of 
practitioner behaviour, patient behaviour, and patient health outcomes to ascertain their 
clinical utility in primary care settings.  In doing so, a unifying perspective is provided 
regarding the potential impact of risk prediction models in primary care settings, thereby 
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establishing a foundation from which prediction models may be implemented and most 
effectively influence the health of the population. 
1.4 Overview of thesis 
This thesis was written in accordance with the requirements set forth by Western 
University’s School of Graduate and Postdoctoral Studies.  The study presented is a 
systematic review and meta-analysis of all studies that have conducted an impact analysis 
of chronic disease risk prediction models in primary care settings.   
The second chapter will explore the often inconsistently used terminology pertaining to 
risk prediction models and present methods for their classification.  Chapter 3 presents 
the literature relevant for the research question, outlines the rationale and need for this 
study, and defines the objectives used to guide the study.  The methodology employed for 
the systematic review and meta-analysis is presented in chapter 4.  The results obtained 
from the systematic review and meta-analysis are detailed in chapters 5 and 6, 
respectively.  A discussion and interpretation of the results follows in chapter 7, outlining 
the strengths and limitations of the reported study, as well as future directions for 
research in this field. 
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Chapter 2 
2.1 Introduction 
The study of risk prediction models is a growing field, with an increasing number of 
models being developed every year for a wide array of outcomes.  However, the field 
itself lacks a consistent method of classification for these models, with several terms (e.g. 
‘risk calculator’, ‘clinical prediction model’, etc.) being used to describe similar tools.  
This chapter seeks to provide an understanding of risk prediction models, provide an 
overview of related terminology, and further classifies risk prediction models according 
to a few of their inherent criteria. 
2.2 Understanding risk prediction models 
The concept of prognosis is central to the practice of medicine, with most diagnostic and 
therapeutic actions aimed at improving a patient’s prognosis, a term used to describe a 
person’s future health based on a series of characteristics.30,39  One example of a tool used 
to improve a patient’s prognosis is a screening test, which allows for the identification 
persons with unrecognized disease—the early identification can afford the person and 
health care provider greater opportunities for treatment than if the disease had been 
identified later.30,40  Similarly, risk prediction models are clinical tools that can improve a 
patient’s prognosis.  They may promote the initiation of risk reduction strategies by 
providing physicians and patients with an absolute risk of developing a specific health 
outcome, motivating those at increased risk to take preventive action.41   
Risk prediction models generate an estimated probability that a disease is present 
(diagnostic models) or will occur in the future (prognostic models) by using an array of 
clinical and non-clinical patient characteristics.42,30,39,37  These tools seek to determine the 
patient’s global risk, a term used to describe the absolute risk of experiencing an event 
over a specific time period, often measured in the magnitude of years for chronic 
outcomes and months for acute outcomes.43,22  Global risk is calculated using the 
algorithms or multivariable equations underlying the prediction models.44  These global 
risk assessment tools often take into account the additive and synergistic effects between 
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individual risk factors, placing increases in individual risk factors, or predictors, into 
context relative to the overall disease, allowing for a continuum of disease risk to be 
expressed and identifying patients most likely to derive benefit from an intervention.45 
With the uncovering of the quantitative relationship between these risk factors for 
disease, physicians and patients are able to more efficiently manage disease risk by 
targeting the global risk.43  The estimates derived from risk prediction models may guide 
the management of therapeutic or ameliorative options through informing and fostering 
the process of shared decision making.37,46,29  Numerous guidelines, such as those 
published by the National Cholesterol Education Program in the United States, the Joint 
National Committee, and the American Diabetes Association recommend modifying the 
intensity of strategies for risk reduction based on the patient’s global risk.47  Indeed, an 
accurate risk prediction model is of no clinical utility if it does not change behaviour and 
ultimately health outcomes.48 
The estimated global risk is often stratified according to risk thresholds, such as an 
individual being at either low, moderate, or high risk of developing the outcome.  
Guidelines often recommend that treatment decisions be influenced by these thresholds; 
the New Zealand guidelines to manage elevated blood pressure recommend initiating 
treatment conversations with patients with a five-year 10% risk of CVD if their blood 
pressure is raised (between 150/90 and 169/99 mm Hg).49  Though these thresholds for 
intervention are not necessarily based on their evidence-based impact on outcomes, but 
rather often representing a vestige from historically-derived levels, they do provide a 
simplified cut-off value from which interventions such as pharmacotherapy may be 
applied.50 
2.3 How have risk prediction models been studied? 
Though research in prediction models is varied, it can be categorized generally in three 
sequential stages: 1) model development, 2) model validation, and 3) impact 
studies.37,51,52  Though the purpose of this thesis is to assess evidence from the third stage, 
a brief overview of the first two stages will be given. 
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2.3.1 Model development 
The purpose of model development involves the steps necessary to create a model that 
can calculate the likelihood of risk with a high level of accuracy for any permutation of 
predictor variables in a specific population.  Steyerberg (2009) outlined seven key steps 
to developing a model (Table 1).30   
Table 1.  Seven steps to developing a prediction model.30,53 
Step Purpose Description 
1 Problem definition and 
data inspection. 
Understanding the research question, what outcome it 
seeks to predict, defining the predictors, with 
consideration of the data under study. 
2 Coding of predictors. The predictors are derived from the dataset, and it 
must be determined how to code the categorical or 
continuous variables. 
3 Model specification. Model specification pertains to predictor selection, 
what methods to use to select predictors, and the 
management of assumptions used in models. 
4 Model estimation. Once the model is specified, parameters such as the 
regression coefficient values must be estimated for 
predictors or combination of predictors. 
5 Model performance. The performance of the model, such as how closely 
predictions are to the actual outcome, as well as 
specific questions regarding the calibration and 
discrimination properties of the model. 
6 Model validation. To reduce the likelihood of overfitting, internal 
validation of the model would ensure the 
reproducibility of the model in the target population. 
7 Model presentation. The model can be presented as its base algorithm, or 
in a different format for use in practice, such as a 
chart, table, or computerized program. 
 
The information necessary to construct a model is derived from a source or development 
population.  The source of data for model development is ideally from a prospective 
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study of sufficient duration to allow for the natural history of disease to progress, which 
allows for optimal documentation of predictors and outcomes, and to obtain a more 
accurate measure of the baseline risk.51  Case-control studies are less ideal as they don’t 
allow for the absolute risk of the outcome to be calculated given that cases and controls 
are sampled from the source population at a ratio not representative of baseline risk. 51,54  
Regardless of the study design from which the data are used to construct a model, it 
generally applies to a specified target population, a group of persons who share similar 
clinical characteristics to the development population.55,56 
Predictors are identified from the data source.  Predictors are factors that may be 
demographic in nature, include clinical history, physical examination results, disease 
characteristics, test results, or previous treatments.51  Predictors are not necessarily 
causally related to the outcome of interest, but indicate that a patient may be at risk of the 
outcome, or in other words, are associated with the outcome.51  Though a greater number 
of predictors that are theoretically associated with the outcome may be identified, not all 
can or will be included in the final model. 
Model performance is measured according to two primary metrics: calibration and 
discrimination.30  Calibration is a measure of agreement, or fit, between the expected and 
observed endpoints.57  For example, if a model predicts that a person will experience the 
outcome with a 5% likelihood, for every 100 people with the same 5% likelihood, 
approximately 5 should experience the event of interest.  Calibration can be assessed 
using the Hosmer-Lemeshow goodness-of-fit test or a calibration plot where predicted 
and observed outcomes are plotted on opposing axes, with perfectly calibrated models 
generating data points along the 45o line.57,58 
Discrimination assesses how well the model can differentiate between those who will 
develop the outcome of interest from those who will not.53  With regards to prediction 
models, a model with high discriminatory ability can well distinguish risk groups from 
one another.59  It is commonly assessed using a performance measure, specifically the 
concordance (c) statistic and the area under the Receiver Operating Characteristic (ROC) 
curve (AUC), which is identical to the c statistic for binary outcomes.57  The prognostic 
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groups may be identified after the creation of a model, such as segmenting the groups 
according to quartiles, where the lower quartiles should have worse outcomes than the 
upper quartiles.30  Defining the prognostic groups inappropriately, however, may result in 
a failure to discriminate between risk levels, with increases in rates of false positives or 
negatives.59 
Model validation ensures that the purpose of predictive models (providing accurate 
predictions of risk for new patients) is met.30  Model development generally concerns 
itself with internal validation more so than external validation, assessing whether the 
estimates derived from the model apply well to the source population.53  Internal 
validation can help identify and in turn, reduce the potential for bias in model 
performance, such as overfitting  which can lead to unfounded optimism on the part of 
the developer.60  Overfitting, or when predictions derived from models are highly 
accurate when evaluated on the source data but have a low accuracy in alternate sets of 
data, can lead to an overly optimistic perception that the model will perform with the 
same high level of accuracy in new subjects from the underlying population.30,61  
Overfitted models tend to overestimate the risk of outcome in high risk patients, and 
underestimate risk in low risk patients, reducing their applicability to novel populations.2  
Identifying and reducing such biases can ensure that the model is applicable and accurate 
within its target population. 
Validation can be conducted by using a split sample approach.  In this case, the dataset is 
divided into the development sample and the validation sample; the model is then 
developed from one segment of data and validated in the next.I  This method can be 
considered inefficient as not all available data are used to develop the model.53,60  
Alternate methods include cross-validation and bootstrap resampling, which are 
validation methods where data are resampled from the development sample.62  In doing 
so, all the data are used for development, and validated within the same pool of data, 
                                                 
I
 In the field of Machine Learning, the “validation sample” is typically referred to as a test set. 
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ensuring the applicability of the model to the source population, as well as reducing the 
potential for overfitting. 
With the model completed, attention is turned to the presentation of the model, or how it 
is presented for clinical use.  Model presentation should be appropriate for its intended 
setting, and ease its implementation and usage.  Risk prediction models generally present 
the absolute risk, or the risk of an event in a single group, as opposed to using a relative 
measure, such as the relative risk, or the ratio of risk of an event in one group to another 
group.63,64  Absolute measures of risk are preferable to inform clinical decision making, 
whilst conversely, relative measures of risk are preferable in etiologic research.64,65  This 
preference is primarily due to the occlusive nature of relative measures of risk; if one 
treatment option reduces risk of adverse outcomes from 5% to 2.5%, in relative terms 
there is a 50% reduction in risk, though in absolute terms the risk is only reduced by 
2.5%.64,66  Presenting absolute measures of risk reduces the possibility of 
misinterpretation compared to presenting relative measures of risk. 
At their core, prediction models should allow physicians to input data and calculate or 
generate a measure of absolute risk.67  Some risk prediction models present solely their 
predictive algorithm, requiring physicians to manually calculate the absolute risk.  For 
example, the GUSTO-I model, which predicts the 30-day risk of mortality in patients 
with acute myocardial infarction, presents to the user simply its regression formula (see 
Appendix A for the complete formula).68 
Similarly, researchers of the Framingham Heart Study published a cardiovascular 
prediction model, predicting for general CVD risk as well as individual CVD events, 
including coronary heart disease, cerebrovascular disease, peripheral arterial disease, and 
heart failure.22  In this model, physicians would input the patient’s values for several 
predictors, and manually calculate the long-term risk.  For example, using a Cox model, a 
61 year old woman who smokes, is not diabetic, total cholesterol of 180 mg/dL, high-
density lipoprotein (HDL) of 47 mg/dL, and systolic blood pressure of 124 mm Hg, 
would have a 10-year estimate of risk of 10.5%.22   
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Though these formulas are potentially accurate, their complexity limits applicability in 
clinical settings.  Simplifications in delivery may increase the accessibility of the model.  
Researchers for the Framingham Heart Study aimed to make their complex statistical 
models more useful by developing and using a “points system” wherein points associated 
with predictors are summed, and the total score corresponds to a calculated 10-year 
coronary risk.67  Technological advancements have further reduced the burden of this 
barrier to use of models in clinical practice, with computer systems reducing the labour 
and likelihood of error associated with manual imputation.69  A transition to simpler 
systems can increase the routine use of prediction models in clinical practice.69,70,71 
The generated output is not the only aspect of model presentation involved in model 
development.  It also includes the medium of delivery. Paper-based options, including 
score charts or nomograms, can be an effective option for easy application in clinical 
settings.53,62,71  The Sheffield Risk Table identifies the absolute risk of coronary death, 
and provides the risk through a table format allowing for printed copies to be easily 
accessible when calculating risk.72  Reflecting technologic advancements, there has been 
a recent trend to program risk prediction models as either mobile phone or tablet apps, or 
providing web-based models that could easily calculate a person’s risk of health 
outcome.53  One model predicting risk of death at 14 days, and for risk of death or severe 
disability at 6 months after traumatic brain injury was developed; the authors chose to 
present the model as a web-based tool with predictors that are easily identifiable.73  
Another model predicting an infant’s risk of childhood obesity is available as a mobile 
phone application.74  Offering multiple formats provides options for physicians in terms 
of their own personal preferences, potentially easing their implementation, allowing these 
tools to help inform decision making and ultimately affect patient outcomes.48,75 
2.3.2 Validation studies 
The literature pertaining to prediction model research heavily favours model development 
studies, with a comparatively small number of studies assessing validation despite the 
importance of assessing model generalizability.37  Further, though numerous guidelines 
detailing model development have been published, guidelines pertaining to the 
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appropriate methodology for validation or impact analysis are scant.76  Most risk 
prediction models are found to be less accurate when used in new populations, possibly 
due to inadequate model development, or differences between the development and 
validation populations.37,77  Despite the models potentially being internally valid, they 
should still be tested or validated in new individuals before implementation in guidelines 
or application in practice to ensure their predictive accuracy.48 
Validation studies pertain primarily to the external validation of the model.  Though 
internal validation, or assessing the accuracy of the model within the development 
dataset, is equally important to the development of the model, external validation takes 
the developed model with the same predictors and assigned weights and is applied to 
external datasets, which provide the heterogeneity necessary to mimic real life 
applications to determine the model’s predictive performance.37,33 
There are generally three forms of external validation: 1) temporal, 2) geographical, and 
3) domain validation (Table 2).33  Geographical and domain validation tend to be more 
robust forms, taking drastically different populations within which to examine the 
performance of the model, compared to temporal validation, which remains within the 
same institution from which the model was developed. 
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Table 2.  Forms of external validation conducted in prediction model studies.  Adapted 
from Moons et al.33 
Type of Validation Description 
Temporal External validation conducted on individuals from the 
same institution in a different time period.  There generally 
is not any crossover of data from the development dataset 
and the validation dataset.  It can be conducted through 
non-random splitting of the existing dataset based on the 
moment of inclusion, but reduces the amount of data used 
for development, with greater similarities between the 
development and validation populations.  It can be 
conducted by collecting data prospectively for the purpose 
of validation after model development as well. 
Geographical Geographical validation examines the transportability of 
the model to different institutions or countries, often 
applying different inclusion or exclusion criteria as well as 
different methods of measuring predictors in those 
populations compared to the development population.   
Domain Domain validation is an extension of temporal or 
geographical validation, where the validation population 
differs greatly from the development population.  An 
example of this would be assessing the predictive 
performance of a model for CVD that was developed in a 
healthy population amongst individuals with type 2 
diabetes mellitus. 
 
2.3.3 Impact analysis 
Impact analysis or model impact studies determine whether or not the model: 1) is 
actually used by physicians; 2) guides clinical decision making; 3) modifies behaviour; 
4), improves clinically relevant processes; or 5) reduces costs.37,33  Indeed, physicians 
will be unlikely to use risk prediction models to inform their decision making without the 
evidence to support the effectiveness of models, which would be analogous to prescribing 
drugs on the basis of in vitro testing alone.75  Validation and impact analysis have 
different goals, and therefore different study designs. Validation studies are preferably 
conducted on a cohort of individuals with a specific set of inclusion and exclusion criteria 
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applied, whereas impact studies require a comparator population.48,78  In other words, the 
two groups assessed in impact studies are generally those who receive an estimated risk 
score (intervention) and those who do not (control).33  At present, there are no formal 
guidelines for the conduct of impact analysis studies; however, there are suggestions for 
how to assess the impact of the use of models on clinical practice. 
The provision of information is the source of the first categorization of model impact 
studies; is any information in addition to the estimated risk provided?  Two approaches 
exist: directive and assistive.33,37,78  In the assistive approach, the probability of outcome 
is the only generated information, while the directive approach is more suggestive, 
providing treatment recommendations in addition to the absolute risk.48,79  The assistive 
approach is considered more respectful of physician judgment and autonomy allowing for 
greater interpretation of the patient’s risk and subsequent treatment decisions, although 
the evidence suggests a greater effect is found through the directive approach.78,80 
Comparisons between groups, namely the intervention and control groups, are 
scientifically strongest when the study design is a randomized trial.48  A variant, the 
cluster randomized trial where the unit of randomization is the clinic or hospital, may be 
preferable to avoid contamination, or a learning effect where the physician alternately 
applies and does not apply the model in alternating patients, as well as the possibility for 
exchange of information between physicians at a single centre.37,81 
Non-randomized studies, such as pre-post studies, can be conducted as an alternative to 
randomized studies, which can be time-consuming and costly.33  For example, the impact 
of the Ottawa ankle rule, a diagnostic risk prediction model assessing for risk of fracture 
amongst patients experiencing ankle and foot injuries, was assessed using a pre-post 
study.82,83  Where the outcome of interest does not require long-term follow-up, such as 
the decision making of physicians, a cross-sectional study can suffice to capture decisions 
immediately upon provision of the patient’s absolute risk.33 
Appropriate conduct of model impact studies can prove to be vital to the uptake of risk 
prediction models in clinical practice, ensuring that (validated) models help guide 
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treatment decisions, affect the behaviour of both physician and patient, and improve the 
long-term health of patients assessed for absolute risk. 
2.4 Terminology 
The terminology used in the study of risk prediction models is varied with many names 
used to describe the same basic tool.84  Risk prediction models are often operationalized 
dependent on their function, presentation, or setting, which is where much of the 
ambiguity resides.  This section presents a list of terms commonly used for risk 
prediction models as well as poses reasons for their distinction. 
Regression models that apply to health outcomes are denoted as prediction models, the 
root term used for these tools.77  Prediction models generate an individual’s risk, creating 
the amalgam of risk prediction model.84  The addition of the term ‘risk’ can be considered 
unnecessary, as models usually only provide a probability as their output, hence they are 
often simply referred to as prediction models in the literature.  The term clinical 
prediction model can also be used, and is contingent upon the setting, specifically a 
clinical setting.52  Clinical prediction models are thus tools or rules derived from 
systematic clinical observations, with the intention of assisting physicians in identifying 
patients who require diagnostic tests, treatment, or hospitalization.46 
One commonly used set of adjectives is dependent on the function of the output.  In this 
instance, whether the model predicts the risk that a person has the health outcome or will 
develop the health outcome over a prespecified period of time warrants the addition of an 
adjective to the root term: diagnostic or prognostic prediction model.30,33,56  The inclusion 
of either adjective can specify the temporal function of the model. 
There exist a few terms that focus on the multivariable model created to derive the 
projected risk.  These terms include risk algorithm, risk function, and risk equation, 
among others.85–88 More attention is directed to the statistical relationship between the 
predictors and the outcome and how they can, in turn, generate a predicted risk. 52,89  
These terms do not address the presentation of the model, such as whether the risk is 
presented in nomogram format or icon arrays, for example. 
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Conversely, terms pertaining to the presentation of the model exist as well.  These terms 
include risk chart, risk score, risk calculator, risk engine, and score cards.86,87,90,91,92  
Risk charts and risk scores are both tools that simplify the derivation of absolute risk.  
Risk scores, as previously mentioned, are simplifications to the calculation of the 
patient’s absolute risk, attributing points for each predictor, with the summed total points 
corresponding to the absolute risk of outcome.67,71  Risk charts, conversely, simplify the 
process by providing a visual aid where absolute risk is presented based on the values of 
predictors.86  Though they may both simplify the process, risk charts are absolute global 
risks derived from combinations of classes of risk factors, whilst risk scores are more 
precise evaluations derived from absolute global risks calculated by continuous levels of 
risk factors.93  Risk scores can be depicted in a visual fashion through the use of score 
cards, which  provide the score associated with absolute risk on individual cards with 
each card pertaining to a combination of classes of predictors.94 
Risk calculators are tools that make risk prediction models accessible to broader 
audiences.89  Risk prediction models at their core can be difficult to understand; the 
simplification of the model to a more user-friendly format can ease their implementation 
in practice.  Risk calculators allow for healthcare providers to easily input the predictor 
values, automatically generating the estimated risk of outcome.  In essence, they are 
standalone tools that can be electronic or paper-based.95 
Risk engines are similar to risk calculators in terms of simplifying the calculation of risk.  
They are often used to describe a relationship through the use of technology, such as the 
development of mobile phone applications or web-based tools that calculate risk upon 
input of predictors.96  One of the more prominent examples is the UKPDS Risk Engine, a 
model that predicts coronary heart disease amongst patients with type 2 diabetes, using a 
web-based automated calculation format.97,98 
This series of terms is by no means exhaustive, but does provide an overview of the most 
commonly used terms.  Despite the wide range of terms used in the field of prediction 
model research, they exist to describe the same basic tool with the same goal: to provide 
an accurate measure of risk of health outcome in patients based on the use of predictor 
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variables.52  As such, a potentially more useful method of understanding prediction 
models is to provide an overarching classification under which models can be 
categorized. 
2.5 Classifying risk prediction models according to their dominant characteristics 
As previously seen, there exists numerous disparities in how researchers refer to risk 
prediction models.  As such, it may be more useful to focus on a few key characteristics 
that define these tools rather than focusing on the terminology. 
There are four primary ways that risk prediction models in present use can be classified 
(Figure 1).  The classifications were selected because they encompass all existing 
prediction models in use.  Note that the four peripheral nodes in the figure are not 
mutually exclusive of one another; rather, each risk prediction model can be classified 
according to one or more categories. 
2.5.1 Temporality 
All risk prediction models can be viewed through the lens of temporality.  As previously 
described, they can be dichotomized as being prognostic or diagnostic, depending on 
whether the prediction is for a health outcome that is present or will occur in the future.  
Given that all risk prediction models calculate the risk for an outcome occurring, 
applying the concept of temporality on this outcome-dependent categorization provides 
an irrevocable measure of classification. 
2.5.2 Type of outcome 
Risk prediction models can also be classified according to the outcome for which they 
predict risk.  Prediction models apply to several fields apart from medicine, including 
physics, meteorology, and astronomy.30  When applied to medicine, they can be 
developed for several different health outcomes, including both acute and chronic 
conditions.  One systematic review sought to synthesize all studies assessing the accuracy 
of tools predicting fracture risk, an acute outcome, such as the FRAX score, identifying 
13 unique tools in 45 different studies that met their inclusion criteria.99,100  Chronic 
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health outcomes, such as breast cancer, have been predicted quite extensively; one 
systematic review and meta-analysis identified 17 unique breast cancer models.101  
Indeed, given that all risk prediction models predict for at least one outcome, we can 
group models according to the nature of the outcome they seek to predict. 
2.5.3 Setting of use 
Risk prediction models can also, albeit to a lesser extent, depend on the setting of most 
appropriate implementation.  Though many models apply to a primary care setting, such 
as most cardiovascular prediction models, a number apply to secondary and tertiary care 
settings.24  For example, the miniPIERS risk prediction model is used in tertiary care 
settings to identify pregnant women at increased risk of death or complications due to 
hypertension.102  Some overlap exists; the CHAD2 score, a prediction model assessing 
for risk of stroke, can be used in primary or tertiary care settings.103  These tools may also 
be used in non-clinical settings.  There is a growing trend towards publishing prediction 
models online, allowing members of the general public to calculate their risks of health 
outcome in the comfort of their own homes.104  However, the models published online are 
typically less invasive and rely on more easily discernable risk factors, such as age or sex. 
2.5.4 Format of presentation 
Lastly, there are only a limited number of ways that clinicians can use a prediction model 
to ascertain the absolute risks of their patients.  As such, the format of the risk prediction 
models can be used as another method of categorization.  The two primary subgroups 
here would be whether the tool is used as either a paper- or electronic-based one.  Within 
each group would fall the various specific risk prediction models, such as risk tables or 
charts, or risk engines, depending on the medium through which they are used.  As such, 
one could see the most popular methods of delivery, allowing for the potential to 
determine if one is more effective than others. 
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Figure 1.  The four proposed methods of classifying risk prediction models. 
2.6 Conclusion 
Prediction models are becoming a common mainstay in clinical settings, being 
recommended by health policy makers and clinical guidelines globally.  They provide an 
objective, evidence-based measure of patient risk of health outcome, and are capable of 
informing physicians and patients in making impartial judgements regarding patient 
management, potentially reducing the burden of disease faced by populations globally.  
Though the literature may be inconsistent in its terminology, agreement regarding the 
intended purpose of risk prediction models is consistent across studies, providing a strong 
basis for the independent examination of the impact of prediction models. 
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Chapter 3 
3.0  Introduction 
This chapter presents background information regarding chronic disease and the primary 
health care setting, particularly as they relate to the focus of this thesis. The literature 
regarding the role of risk prediction models in primary prevention, and more broadly in 
clinical practice, is explored. This is followed by a description of the rationale for the 
study as well as the study objectives. 
This chapter explores the literature surrounding features associated with risk prediction 
models. It begins with an assessment of the term chronic disease as it has been used in 
the literature and for the purposes of the systematic review and meta-analysis.  Next will 
be a description of primary care settings, the setting within which most preventative 
measures against chronic diseases are applied.  Following is an exploration of the role of 
risk prediction models in terms of primary prevention, as well as reasons for their 
possible underuse in clinical practice.  To close, the rationale for the study as well as the 
study objectives will be outlined. 
3.1 Chronic disease 
The burden of chronic diseases is vast and increasing rapidly globally.  Though reporting 
differs dependent upon the source, it has been estimated that in 2001, of the 56.5 million 
total reported deaths, approximately 60% were attributed to chronic diseases, increasing 
to 68% in 2012.4,105  By 2020, projections indicate that approximately 75% of deaths will 
be attributed to chronic diseases.106  The reported prevalence amongst Canadians range 
from one in five to one in three living with a chronic disease, with up to four in five 
Canadians having at least one modifiable risk factor, such as tobacco smoking, poor diet, 
sedentary lifestyle, and harmful alcohol consumption.4,5,107  Though a century ago, 
infectious diseases were the eminent causes of mortality, an epidemiologic transition has 
occurred in recent years, with chronic diseases dominating the landscape of illness 
worldwide.108,109,110  Chronic diseases represent the largest cause of mortality nationally 
and internationally, a trend that will continue for the foreseeable future. 
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3.1.1 Chronic disease definitions 
The term “chronic disease” is etymologically simple, with implications of temporality 
and of illness.  However, there is lack of a consistent definition for chronic disease.  
Indeed, the lack of consistency in key definitions poses a barrier to the prevention and 
mitigation of any chronic condition, as it reduces the ability to measure them 
effectively.111,112 
Researchers often create their own unique definitions to examine chronic diseases or 
chronic conditions.  One study examining out-of-pocket expenditures for chronic disease 
management chose to define chronic conditions as, “…a person…having a chronic 
condition if that person’s condition had lasted or was expected to last twelve or more 
months and resulted in functional limitations and/or the need for ongoing medical 
care.”113  To compile a list of specific chronic conditions, the researchers established a 
panel of ten physicians to judge whether the International Classification of Diseases, 
Ninth Revision (ICD-9) codes met their definition, resulting in 177 codes being classified 
as chronic conditions in adults.113 
One systematic review sought to provide an overview of all definitions used for chronic 
conditions in children in an effort to establish the prevalence of chronic health conditions 
in that population.114  The most frequently used terms were chronic conditions, chronic 
health conditions, chronic illness, and special health care needs.  Four core definitions 
were identified, though not all included articles (64) adhered strictly to these (Table 3).   
 
 
 
 
 
 
23 
 
Table 3.  Four most frequently used definitions of chronic conditions (for children).  
Adapted from van der Lee et al 2007.114 
Source Year Term Definition 
Pless & 
Douglas115 
1971 Chronic 
illness 
“A physical, usually nonfatal condition that 
has lasted longer than 3 mo in a given year or 
necessitated a period of continuous 
hospitalization of more than 1 mo; of 
sufficient severity to interfere with the child’s 
ordinary activities to some degree.” 
Perrin et al.116 1993 Chronic 
health 
conditions 
“A condition is considered chronic if (1) it has 
lasted or is expected to last more than 3 mo 
and (2) the definition takes into account the 
impact of the condition on the child, e.g., level 
of functional impairment or medical need 
greater than expected for a child of that age.” 
Stein et al.117 1993 Chronic 
health 
conditions 
“Conditions must have a biological, 
psychological, or cognitive basis; have lasted 
or are virtually certain to last for 1 y; and 
produce ≥ 1 of the following sequelae: (1) 
limitations of function, activities, or social role 
in comparison with healthy age peers in the 
general areas of physical, cognitive, 
emotional, and social growth and 
development; (2) dependency on 1 of the 
following to compensate for or minimize 
limitations of function, activities or social role: 
medications, special diet, medical technology, 
assistive device, or personal assistance; and 
(3) need for medical care or related services, 
psychological services, or educational services 
above the usual for the child’s age or for 
special ongoing treatments, interventions, or 
accommodations at home or in school.” 
McPherson et 
al.118 
1998 Children 
with 
special 
health 
care 
needs 
“Children who have or are at increased risk of 
a chronic physical, developmental, behavioral, 
or emotional condition and who also require 
health care and related services of a type or 
amount beyond that required by children 
generally.” 
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Of particular interest is the change in definitions presented over time, demonstrating the 
plasticity of the definition and its non-uniform use over time and amongst researchers.  
The earliest definition devised in 1971 addressed longevity and its impact on daily 
activities, with later definitions addressing the child’s health care needs and functioning, 
as well as eventually addressing children at risk for conditions.115,116,117,118 
Medicare, the largest health insurance program in the United States, has established their 
own categorizations of diseases.  Medicare provides health insurance to approximately 40 
million beneficiaries amounting to an annual spending exceeding 200 billion USD, 
placing an enormous financial responsibility on Medicare managed care and other 
capitated programs.119  To ensure the appropriate allocation of benefits, a health-based 
Medicare capitation system was adopted creating a diagnostic classification system.119  
This system aggregated over 15,000 ICD-CM codes (International Classification of 
Diseases, Ninth Revision, Clinical Modification) into 70 Hierarchical Condition 
Categories (HCC).  For example, the HCC “Acute Liver Failure/Disease” includes the 
ICD codes for “Viral Hepatitis, Acute or Unspecified” and “Hepatic Coma”.119 
The Centers for Disease Control and Prevention also compiled a list of select definitions 
of chronic diseases representing the definitions used in settings including academia and 
the government (Table 4).111 
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Table 4.  List of commonly used definitions for chronic diseases.  Adapted from 
Goodman et al 2013.111 
Source Year Definition 
Hwang et al.113 2001 “We defined a person as having a chronic condition if that 
person’s condition had lasted or was expected to last 12 or 
more months and resulted in functional limitations and/or the 
need for ongoing medical care.” 
Bernstein et al.120 2003 “A chronic disease or condition has 1 or more of the following 
characteristics: is permanent; leaves residual disability; is 
caused by nonreversible pathological alteration; requires 
special training of the patient for rehabilitation; or may be 
expected to require a long period of supervision, observation, 
or care.” 
Friedman et al.121 2008 “Chronic condition is defined as a condition that lasts 12 
months or longer and meets 1 or both of the following tests: 1) 
it places limitations on self-care, independent living, and 
social interactions; and 2) it results in the need for ongoing 
intervention with medical products, services, and special 
equipment.” 
National Center for 
Health Statistics122 
2011 “A health condition is a departure from a state of physical or 
mental well-being. In the National Health Interview Survey, 
each condition reported as a cause of an individual’s activity 
limitation has been classified as chronic, not chronic, or 
unknown if chronic, based on the nature and duration of the 
condition. Conditions that are not cured once acquired (such 
as heart disease, diabetes, and birth defects in the original 
response categories, and amputee and old age in the ad hoc 
categories) are considered chronic, whereas conditions related 
to pregnancy are not considered chronic. Other conditions 
must have been present for 3 months or longer to be 
considered chronic.” 
McKenna and 
Collins123 
2010 “They are generally characterized by uncertain etiology, 
multiple risk factors, a long latency period, a prolonged course 
of illness, noncontagious origin, functional impairment or 
disability, and incurability.” 
World Health 
Organization3 
2017 “Noncommunicable diseases, also known as chronic diseases, 
are not passed from person to person.  They are of long 
duration and generally slow progression.” 
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Universal within these definitions are the concept of longevity, ranging from greater than 
three months to greater than twelve months to a permanent affliction.  Some incorporate 
aspects of impairment, others mention the need for ongoing medical care, whilst others 
still place emphasis on communicability, or rather, lack thereof.  Some of these concepts 
are in contradiction with one another.  For example, human immunodeficiency virus 
(HIV) infection has in recent years, due to the advent and introduction of combination 
antiretroviral (ART) therapy, prolonged life in HIV-infected patients by a measure of 
decades.124  As such, due to its lengthy duration and the need for medical products (ART 
therapy), it would meet the Friedman definition of chronic diseases.121  However, due to 
its certain etiology and its contagious origin, it would fail to meet the McKenna and 
Collins definition.123  In other words, there exists no consistent universal definition of 
what comprises a chronic disease. 
3.1.2  Chronic disease definition used in thesis 
In recognition of this lack of consistency, a different approach was chosen for this 
systematic review.  Rather than taking an approach similar to Hwang et al.113, for 
example, where potential chronic diseases were vetted by physicians, this systematic 
review chose to focus on overarching categorizations of chronic diseases.  The method 
used by Hwang et al. takes a top-down approach where characteristics of what constitute 
a chronic disease are applied to specific diseases in order to decide amongst a panel of 
individuals whether they are classified as chronic.  This process is prone to bias and is 
time-consuming given the enormity of conditions or diseases that may be considered 
chronic.  Instead, the World Health Organization (WHO) categories of chronic disease 
were used herein. 
The WHO recognizes four main types of chronic diseases (referred to as 
noncommunicable diseases, or NCDs, by the WHO), which are: 1) cardiovascular 
diseases, 2) cancers, 3) chronic respiratory diseases, and 4) diabetes.125  In 2012, 56 
million deaths occurred globally, with 38 million of those as a result of NCDs; 82% of 
these were attributed to the four aforementioned NCDs.126  The broadness of these 
categories, their large rates of morbidity and mortality, and the fact that they make up a 
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sizable majority of diseases, make this system of classification more feasible and 
practical for the conduct of this systematic review. 
3.1.3 How does risk prediction modelling apply to chronic diseases? 
Previously when the types of diseases that affected populations were of a primarily 
infectious nature, such as diarrheal diseases, applicable risk factors, commonly referred to 
as “traditional risks”, were undernutrition, unsafe sex, unsafe water, poor sanitation and 
hygiene, and indoor smoke, and were often associated with low-income populations.109  
However, with the epidemiologic shift towards chronic diseases and away from 
communicable diseases, there has been a corresponding shift in the prevalence of 
different risk factors.127  The leading global risks for chronic diseases are high blood 
pressure, tobacco use, alcohol use, high blood glucose, physical inactivity, high 
cholesterol, and overweight/obesity.109,127,128   
As a relatively small number of risk factors can cause or are predictive of several chronic 
diseases, and may interact in their impact on the risk of disease, the attributable risk of 
individual risk factors add up to more than 100%.109  Otherwise, the assumption would be 
that each case of disease has but a single cause, and that multiple risk factors cannot 
cause the same case of disease.109,129  This makes it difficult to quantify the impact of 
single risk factors on an individual’s absolute risk of disease.  This lends credence to the 
concept of targeting the absolute risk of chronic disease for intervention as opposed to 
individual risk factor levels.22,130,131  Risk prediction models account for the additive and 
interactive effects of predictors, where they exist, on the absolute risk of disease, 
providing an objective measure for physicians and patients to target for intervention.45,132 
For example, the Harvard Cancer Risk Index assesses for a person’s risk of 12 forms of 
cancer, including lung, breast, and colon cancer.133  Epidemiologic investigation revealed 
a set of risk factors, including: sex, age, height, weight, medication use, medical history, 
diet, physical activity, family history, and prior screening.  Using this knowledge of the 
effects of risk factors and their synergistic effect, an objective measure of cancer risk can 
be determined, allowing for multitargeted interventions to reduce the absolute risk.133  
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These known relationships between both modifiable and non-modifiable risk factors 
allow for the prediction of the development of chronic diseases in individuals. 
3.2 Primary care settings 
The Declaration of Alma-Ata of 1978, adopted at the International Conference on 
Primary Health Care, stated the goal of the WHO and United Nations was to achieve, 
“Health for All by 2000,” positioning primary health care as the strategy to achieve their 
goal.134,135  The role of primary health care was to ensure equitable provisions of quality 
health services to all persons in an efficient, sustainable, and universal manner.135  It was 
considered the most effective strategy to ensure health for all was obtainable, and was 
grounded upon a set of principles including universal access, addresses the movement 
toward health equity, and the intersectoral approach to health.134,136  However, despite 
primary care taking the foremost role in achieving equitable global health, dependent 
upon the setting, it can stand to mean something quite different.  For instance, in areas 
with higher levels of healthcare accessibility (i.e. high- and middle-income countries), 
primary health care can be viewed as the first level of care; conversely, where challenges 
in accessibility are highly prevalent (i.e. low-income countries), it can be viewed as a 
system-wide approach.136 
It can thus be useful to view primary care as a set of activities as well as a set of 
principles.  In terms of the activities engaged within primary care are the delivery of first-
contact medicine, the assumption of longitudinal responsibility by practitioners for the 
patient, as well as responsibility of health (defined as the complete physical, mental and 
social wellbeing and not merely the absence of disease or infirmity) within the limits of 
health personnel.136,137  Primary care can be condensed to its four essential components: 
first contact, longitudinality, comprehensiveness, and coordination.137 
3.2.1 Primary care as an avenue for prevention 
The functions of primary care are enormous, providing a wide spectrum of services 
ranging from acute and chronic health care to preventive care and health promotion.138  
As the point of first contact for patients with the health care system, primary care seeks to 
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coordinate use of other levels of care (secondary and tertiary, respectively), making 
arrangements with specialists where necessary.137,138  The varying levels of care represent 
different functions; where primary care physicians, for example, are considered 
generalists, resource and knowledge constraints may necessitate a referral to a specialist 
with a higher degree of skill in a particular area of medicine.137   
On the other hand, specialized care often receives “sicker” patients, and thus the 
emphasis of care is to sustain life in the ill individual.137  As such, little emphasis is 
placed on the prevention of disease onset in specialist settings, while comparatively, a 
greater amount of energy is dedicated to the prevention of illness in primary care.137,139  
As such, the primary care physician plays an integral role in the prevention of disease.34 
Continuity of care, or longitudinality, is more likely to occur in primary care settings, 
which has been associated with a greater use of preventive services, compared to 
different subspecialty practices, which see more first-time patients.137,140,141,142  Indeed, in 
one study examining factors associated with preventive services, having a regular place 
of care was most associated with receipt of preventive care when adjusted for 
demographic and financial characteristics as well as health status.140  A larger percentage 
of visits to primary care practices are related to prevention when compared to more 
specialized care.137  As a result of its very nature, primary care settings are well 
established to help prevent the onset of chronic disease. 
3.3  Risk prediction models as a tool for prevention 
Risk prediction models have the potential to play an integral role in prevention.  Within 
the constructs of public health and healthcare in general, prevention is often segmented as 
either primary, secondary, or tertiary prevention, categorizations that pertain to the state 
of disease or injury.  Secondary and tertiary prevention aim to reduce the impact of 
disease or injury either early in its course (secondary) or when it is already established 
(tertiary).143  Conversely, primary prevention aims to prevent disease or injury in healthy 
individuals.143,144 
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Two options exist when addressing primary prevention: 1) the “population-based” 
approach, where preventive actions are generally applied to groups of people, and 2) the 
“high risk” approach, where interventions are targeted to those at highest risk of 
developing the outcome.145,146  Primary prevention in a healthcare setting seeks to 
identify high risk individuals, thereby allowing the targeting of interventions to those 
who would benefit greatest.93,147  Given the limited preventive resources available, taking 
a high risk approach and allocating those resources to high risk individuals can 
potentially enable the greatest reduction in adverse events for patients treated in primary 
care.148  This can provide a complement to a public health approach where interventions 
are generally ‘targeted’ to the population.149 
Due to the enormous burden of disease-related morbidity and mortality associated with 
chronic diseases, their primary prevention is of high importance.150,151  As the patient’s 
medical “home”, primary care is well-positioned to prevent the onset of these diseases 
through the provision of evidence-based preventive care.147,152  Though time constraints 
reduce the ability of primary care physicians to recommended preventive services to their 
patients, within the present construct of medical care, primary care settings still play an 
important role in primary prevention.153  Indeed, numerous national guidelines suggest 
implementation of preventive services in primary care.  The National Health Service in 
the United Kingdom, for example, recommends that primary prevention for CVD occur 
in primary care.154 
The interventions employed in primary care settings for the primary prevention of 
chronic diseases should be cost-effective, practical, possible, and positively affect risk 
status and outcomes.155  For example, tobacco cessation can be promoted through brief 
counselling and cessation advice, which may result in a lifestyle modification, ultimately 
reducing the patient’s risk of several chronic diseases.155,156  Pharmacotherapy may 
indicated for the prevention of cardiovascular disease and type 2 diabetes.155,157  Any 
number of interventions may be used in primary care settings dependent upon the 
resources available and the disease outcome of interest. 
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Numerous guidelines have been published with the goal of preventing the onset of 
chronic diseases.  Several of these recommend the usage of risk prediction models to 
predict patients’ absolute risk of developing chronic diseases.  Guidelines published by 
the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom, 
the American Heart Association (AHA) in the United States, the New Zealand Guidelines 
Group (NZGG) in New Zealand, and the Canadian Cardiovascular Society (CCS) in 
Canada, amongst several others, each recommend the assessment of absolute 
cardiovascular risk using a risk prediction model.158,159,160,161  Given that these tools can 
stratify patients, determining who is at greatest risk for chronic disease, they can provide 
appropriate and objective guidance to assist in the prevention of disease. 
3.4 Intended effects and explanations 
Despite the numerous recommendations to incorporate risk prediction models in clinical 
practice, few studies have assessed whether they have an effect.78,162  Risk prediction 
models are intended to guide clinical decision-making and patient management, such as 
conducting additional testing, issuing prescriptions, as well as informing patients of their 
risk of outcome.48  They are not intended to replace physicians, but to complement and 
assist their clinical judgment.48,163  When appropriately applied and interpreted, physician 
judgement of clinical information can be made more accurate and efficient.164  The 
Evidence-Based Medicine Working Group stated that risk prediction models can, 
“…change clinical behavior and reduce unnecessary costs while maintaining quality of 
care and patient satisfaction.”162 
Risk prediction models provide an absolute measure of risk for outcomes.  In doing so, 
they reduce the amount of uncertainty faced in medical practice by making apparent and 
evident the impact of clinical findings on long-term risk.164  This is in contrast to the use 
of clinical experience, whereby intuition, a more subjective method of evaluation, is the 
final arbiter of medical decision-making.162  Though clinical judgment through use of 
heuristics may sometimes provide an accurate measure of absolute risk, statistical models 
are capable of integrating data quickly and accurately, providing an objective measure.165 
32 
 
The implementation of risk prediction models can assist in shared decision-making.  
Shared decision-making is defined as: “…an approach where clinicians and patients share 
the best available evidence when faced with the task of making decisions, and where 
patients are supported to consider options, to achieve informed preferences.”166  Risk 
prediction models can be used as shared decision-making tools.  Shared decision making 
tools are intended to foster a consideration of the risk, benefits, and trade-offs associated 
with a decision, and the way in which a patient’s preferences are incorporated into the 
discussion and decision process.167,168  In this fashion, there can be improvements in risk 
communication and objective discussions between physician and patient, allowing 
patients to participate informedly in shared decision-making.169 
The information provided to patients by physician and model can improve risk 
perception, and with increased risk perception, there is the possibility of associated 
behaviour change.  The ‘teachable moment’, an event or circumstances leading persons to 
alter their behaviour, can promote health behaviour change in numerous settings.170  
Medical procedures, such as cancer screening, have been posited to constitute a teachable 
moment.171  Teachable moments may also be created by physicians rather than waiting 
for an unpredictable opportunity, leading to patient activation, or instilling in patients the 
knowledge, skills, and confidence to effectively manage their health.172,173  Though 
analogous, the provision of personalized risk estimates may constitute a teachable 
moment, providing patients with the knowledge associated with their health thereby 
improving their risk perception.  In this fashion, patients may thus feel more confident in 
their ability to improve their long-term risk of disease. 
3.5 Barriers to model usage in clinical practice 
Though model usage in clinical practice is often recommended in clinical guidelines, 
evidence suggests that practitioners often do not adhere to guideline recommendations.  
One study of Belgian general practitioners found that 53% of participants reported having 
never used a tool for global cardiovascular risk assessment, with 80% of participants 
erroneously believing total cholesterol is an accurate proxy for cardiovascular risk.174  
Further, it has been noted that physicians often take poor account of increasing age and 
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other risk factors, indicating there is a need for models to help in the assessment of 
risk.175 
Numerous reasons have been given for why models are not used in clinical practice.  
Some physicians experience a lack of belief in the risk estimates, fearing that they do not 
account for other factors that are crucial, while others believe they are more capable of 
estimating the global risk without the model.176  Some physicians believe models 
overpredict CVD risk because of these models were developed using older data.177,178  
One study examined automated prompts to conduct risk assessments, which led to what 
they referred to as “prompt fatigue”, or a form of clinical inertia where physicians failed 
or refused to answer computerized prompts despite recommendations to do so.179   
Others still cite a lack of time or lack of physician knowledge and training as key reasons 
for their lack of use.180  It is possible that the use of educational interventions targeted at 
physicians could increase the uptake of risk prediction models in clinical settings.  One 
study examining the impact of a continual medical education session training general 
practitioners on the use of global cardiovascular risk found that trained physicians used a 
tool to assess risk more often than untrained physicians (76% vs. 52%).181 
Even with the use of risk prediction models, adherence to treatment guidelines based on 
risk stratification remains poor.  One examination of the CHA2DS2VASc tool, a model 
predicting the risk of stroke in patients with atrial fibrillation, found that low-risk patients 
were being treated with warfarin, an anticoagulant, despite a lack of evidence regarding 
its clinical benefit.182  The misinterpretation of generated outputs from risk prediction 
models may be to blame, with some studies demonstrating that physicians experience 
some difficulties with statistical concepts.183 
The presentation of risk may or may not have an impact on outcomes.  For example, one 
study conducted in the United Kingdom assessed for changes in prescribing patterns and 
changes in risk factor levels following the presentation of risk as either an absolute risk 
level or a number needed to treat, and found no differences between the two groups.184  
Some clinicians have called for the number needed to treat (NNT) to be presented as well 
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to improve the dialogue between physician and patient, though they recognized that 
individual patients may not understand the concept.177 
Several barriers exist preventing the uptake of risk prediction models in clinical practice.  
Though these factors are not necessarily insurmountable, they provide a greater 
understanding of the issues faced by physicians when presented with novel tools for use, 
as well as areas for interventions to increase their uptake. 
3.6 Study rationale and objectives 
There is a growing body of literature surrounding risk prediction models.  Though a 
negligible number of studies with the terms ‘prognostic model’ or ‘prediction model’ 
were found dating from the 1970s and 1980s, an exponential increase has occurred in 
recent years, with well over half a million studies identified in the year 2005.30  This 
increase in literature parallels the growing movement towards evidence-based medicine 
and the corresponding incorporation of risk prediction models in clinical 
guidelines.34,96,185  Further, the Cochrane Collaboration has recently developed reporting 
guidelines for prediction modelling studies, which could help shape the conduct of future 
research and reporting.60   
However, a lack of evidence and poor reporting remain prevalent in the realm of 
prediction model research.12,186  Despite numerous tools being available, few are used in 
clinical practice, indicating physicians may lack confidence regarding model usage for 
preventive patient management.186  Though risk prediction models have been 
recommended for use in clinical practice by several guidelines to calculate the absolute 
risk of several chronic health outcomes, it has been suggested that physicians fail to use 
them consistently when indicated.  Their implementation and use should help guide 
physician’s behaviour, thus affecting patient behaviour, and ultimately showing an 
improvement in patient health outcomes.187   
The recent paradigm shift towards evidence-based medicine provides one potential 
reason for their underuse.  Clinicians are recommended to evaluate the weight of the 
evidence from which the guidelines are derived in keeping with the tenets of evidence-
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based medicine, and to examine whether the incorporation of models can affect a positive 
change.  At present, few impact analysis studies have been conducted, with no consensus 
amongst clinicians and researchers regarding the impact of model use.188   
Therefore, the objective of this study was to: conduct a systematic review and meta-
analysis to assess whether or not risk prediction model use in primary care settings can 
positively influence the prevention of chronic diseases.  The study research question was: 
What is the impact of chronic disease risk prediction model use in primary care settings 
on: 1) physician behaviour, 2) patient behaviour, and 3) patient health outcomes?   
In conducting this systematic review and answering the research question, uncertainties 
regarding the third domain of risk prediction model research, or assessing the impact of 
model use, would be addressed.  Though a tremendous number of models for several 
outcomes have been developed, the literature remains unclear regarding the impact of 
model use on clinical practice.  Answering this knowledge gap will help to inform the 
future use and implementation of models, and may ultimately help to reduce the global 
burden of chronic disease. 
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Chapter 4 
4.0 Methods 
This chapter provides a detailed account of the steps undertaken in the conduct of the 
systematic review and meta-analysis.  The presented research study was conducted in 
accordance with the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines, the Meta-analysis Of Observational Studies in 
Epidemiology (MOOSE) Guidelines, and the CHecklist for critical Appraisal and data 
extraction for systematic Reviews of prediction Modelling Studies (CHARMS Checklist), 
developed by the Cochrane Collaboration Prognosis Reviews Methods Group.60,189 
A systematic review aims to provide an unbiased answer to a specific research question 
by collecting and synthesizing all evidence presently available in the literature that meet 
an a priori specified eligibility criteria.190  This review seeks to answer: what is the 
impact of chronic disease risk prediction models on physician behaviour, patient 
behaviour, and patient health outcomes?  Addressing the components of checklists such 
as PRISMA allows for the reproducibility of the review by providing an explicit, 
transparent methodology, including but not limited to the systematic search of the 
literature, or assessments of the validity of findings through means such as a risk of bias 
tool.190  Where possible, a meta-analysis may be conducted, which is a statistical 
summary of the results of independent studies, therefore producing a more precise 
summary estimate of the impact of healthcare interventions.190  The generation of figures 
such as forest plots may allow readers to examine the consistency of the evidence and 
provide insight into the differences between studies. 
4.1 Search strategy 
A search strategy was iteratively created in consultation with a research librarian.  Search 
terms were developed for the following databases: MEDLINE, Embase, the Cochrane 
Library, CINAHL, and Web of Science.  Additional e-sources were searched for grey 
literature, specifically The Canadian Agency for Drugs and Technologies in Health 
(CADTH), OpenGrey.eu, and ClinicalTrials.gov.  Medical subject headings (MeSH), 
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where applicable, and keywords were tailored to each database to ensure the 
comprehensiveness of the search.  The search was restricted to publications from 1976 to 
2017, those in the English language, and those assessing human subjects.  Four primary 
concepts pertaining to the PICOS, or the types of Participants, the Intervention and 
Comparison, the Outcomes, and Study design, of the research question to inform the 
search strategy, specifically: 1) risk, 2) prediction model, 3) chronic disease, and 4) 
primary care setting. The search terms used for the three databases using MeSH terms or 
subject headings are included below in Table 5. 
Table 5.  MeSH terms and keywords used for Medline, Embase, and CINAHL. 
Concept Medline Embase CINAHL Keywords 
Risk  Risk/ OR Risk 
Factors/ OR Risk 
Adjustment/ 
Risk/ OR Patient 
Risk/ OR 
Expectancy/ OR 
Risk Factor/ 
(MH “Risk 
Factors+”) OR 
(MH “Health 
Screening+”) OR 
(MH “Patient 
Assessment+”) 
Risk adj3 
(adjust* OR 
factor*) OR 
Probabilit* OR 
Likelihood 
 
 
Prediction 
models 
Technology 
Assessment, 
Biomedical/ OR 
Algorithms/ OR 
Probability/ OR 
Bayes Theorem/ 
OR Likelihood 
Functions/ OR 
Proportional 
Hazards Models/ 
OR “Sensitivity 
and Specificity”/ 
OR ROC Curve/ 
OR exp Decision 
Support 
Techniques/ OR 
Area Under 
Curve/ OR 
Clinical 
Decision-
Making/ OR exp 
Risk Assessment/ 
Cardiometabolic 
Risk/ OR 
Cardiovascular 
Risk/ OR 
Coronary Risk/ 
OR Probability/ 
OR Reynolds risk 
score/ OR 
Framingham risk 
score/ OR 
CHADS2 Score/  
OR 
Cardiovascular 
Disease 
Assessment/ OR 
PROCAM Score/ 
OR QRISK 
Score/ OR 
Multiple 
Regression/ OR 
Receiver 
Operating 
Characteristic/  
OR exp Area 
Under the Curve/ 
OR exp 
“prediction and 
(MH "Predictive 
Value of Tests") 
OR (MH 
“Predictive 
Research”) OR 
(MH “Models, 
Statistical”) OR 
(MH “Decision 
Support 
Techniques+”) 
OR (MH 
“Decision 
Making, 
Clinical”) OR 
(MH “Clinical 
Assessment 
Tools”) OR (MH 
“Risk 
Assessment”) OR 
(MH “ROC 
Curve”) OR (MH 
“Regression+”) 
OR (MH 
“Survival 
Analysis+”) 
“Risk scor*” 
OR  
risk tool* OR 
risk estimat* 
OR risk assess* 
OR risk 
function* OR 
risk equation* 
OR risk calc* 
OR risk scor* 
OR risk 
predict* OR 
risk factor calc* 
OR risk chart* 
OR risk engine* 
OR risk 
appraisal* OR 
prediction 
model* OR risk 
algorithm* OR 
scoring* 
method* OR 
scoring 
scheme* OR 
roc curve OR 
area under 
curve OR AUC 
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forecasting”/ OR 
survival 
prediction/ OR 
survival rate/ OR 
exp decision 
support system/ 
OR clinical 
decision making/ 
OR medical 
decision making/ 
OR medical 
assessment/ 
OR c-statistic* 
OR C index* 
OR C indices* 
OR hazard ratio 
Chronic 
disease 
Chronic Disease/ 
OR 
Cardiovascular 
Diseases/ OR exp 
Heart Diseases/ 
OR exp Vascular 
Diseases/ OR exp 
Lung Diseases, 
Obstructive/ OR 
Diabetes 
Mellitus/ OR 
Diabetes 
Mellitus, Type 1/ 
OR exp Diabetes 
Mellitus, Type 2/ 
Chronic Disease/ 
OR 
Cardiovascular 
Disease/ OR 
Heart Disease/ 
OR Vascular 
Disease/ OR 
Lung Disease/ 
OR Chronic Lung 
Disease/ OR 
Chronic 
Obstructive Lung 
Disease/ OR 
Asthma/ OR 
Diabetes 
Mellitus/ OR 
Insulin 
Dependent 
Diabetes 
Mellitus/ OR Non 
Insulin 
Dependent 
Diabetes 
Mellitus/ 
(MH “Chronic 
Disease”) OR 
(MH 
“Cardiovascular 
Diseases”) OR 
(MH “Heart 
Diseases”) OR 
(MH “Vascular 
Diseases”) OR 
(MH “Lung 
Diseases”) OR 
(MH “Lung 
Diseases, 
Obstructive+”) 
OR (MH 
“Diabetes 
Mellitus”) OR 
(MH “Diabetes 
Mellitus, Type 
1”) OR (MH 
“Diabetes 
Mellitus, Type 
2”) 
Chronic 
disease* OR 
Chronic illness* 
OR chronically 
ill OR non-
communicable 
disease* OR 
cardiovascular 
disease* OR 
vascular 
disease* OR 
heart disease* 
OR stroke OR 
respiratory 
disease* OR 
asthma OR 
COPD OR 
chronic 
obstructive 
pulmonary 
disease* OR 
diabetes OR 
diabetes 
mellitus OR 
diabetic    
Primary care Primary Health 
Care/ OR 
Comprehensive 
Health Care/ OR 
Continuity of 
Patient Care/ OR 
Patient-Centered 
Care/ OR exp 
General Practice/  
 
 
Exp Primary 
Health Care/ OR 
General Practice/   
(MH “Primary 
Health Care”) OR 
(MH “Family 
Centered Care+”) 
Primary health 
care OR 
primary care 
OR primary 
healthcare OR 
primary medical 
care OR family 
practice OR 
family medicine 
OR general 
practi*  
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To ensure the completeness of the search, backward and forward searching was 
conducted, whereby backward searching was conducted through examination of included 
articles’ bibliographies, and forward searching was conducted through use of Google 
Scholar to determine where the article had been cited in the literature.  Forward and 
backward searching provides an additional opportunity to identify studies that fulfill the 
eligibility criteria of the review that may not have been captured in the initial search.  
4.2 Eligibility criteria 
The eligibility criteria through which articles were screening (section 5.3) were selected 
to align with the objectives of the study by identifying the key components associated 
with the research question through adaptation of the PICOS framework.   
4.2.1 Participants 
There are two main groups of participants associated with the research question: 
physicians and patients.  The physician population applicable to the research question 
were those practicing in primary care settings, which generally refers to family 
physicians or general physicians.  A preliminary search found that the type of physician 
was not consistently specified in studies, so the criterion was expanded to include the 
primary care setting.  Specifically, a primary care setting was defined as the first point of 
contact for patients into the health care system, and includes rural and urban general 
practice clinics, either group or solo physician practices, as well as community-based 
programs. 
The second group of participants are the patients.  Patients were not restricted by any 
demographic characteristic, such as age or sex.  Patients were required to be 
asymptomatic for the disease outcome of interest at study intake, however, because to 
assess a patient presenting with symptoms of the disease outcome for the risk of 
developing the disease is unlikely when compared to alternative measures, such as the 
conduct of diagnostic testing.  Of most importance is that patients assessed were 
appropriate for the prediction model assessed in each study. 
40 
 
4.2.2 Intervention 
The present study aims to assess the impact of risk prediction models, specifically the 
provision of long-term risk of health outcomes as a result of risk prediction model use.  
The intervention was restricted to prognostic—not diagnostic—models that predict for 
the long-term risk of a chronic disease.  The chronic diseases of interest were those that 
fall under the four main categories of NCDs as per the WHO: CVD, cancers, diabetes, 
and chronic lung diseases.  Though there are several models that are diagnostic or assess 
for non-chronic health outcomes, they were excluded in this systematic review.  
Therefore, models assessing for the risk of behavioural, mental, or acute health outcome, 
such as risk of sexually transmitted infections, risk of schizophrenia, or risk of fracture, 
were excluded.  The comparison group were patients who were treated without risk 
prediction models. 
4.2.3 Outcome 
Three outcomes were assessed: 1) physician behaviour, 2) patient behaviour, and 3) 
patient health outcomes.   
1) Physician behaviour: any study that evaluated the impact of physician use of a 
risk prediction model on either behavioural outcomes or health outcomes was 
considered.  The specific types of outcomes of interest were those with the 
potential to impact the patient’s risk of developing a chronic disease.  Therefore, 
physician behaviours of interest include prescribing behaviours, provision of 
lifestyle or dietary counselling, and referrals to specialists or other healthcare 
providers.   
2) Patient behaviour: behaviours of interest include fulfilment or dispensing of 
prescriptions, medication adherence, lifestyle changes such as smoking cessation, 
and dietary changes.   
3) 3) Patient health outcomes: these outcomes were defined as risk factor levels, 
absolute risk of disease, and event rates.   
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Though examples of each outcome are provided, the examples only provided a measure 
of guidance.  Given the sparsity of studies assessing model impact and the differences in 
methodology, specific outcomes not previously stated were independently assessed to 
determine their eligibility to be classified as one of the three outcomes.    
4.2.4 Study design 
All study designs were considered including experimental, observational, and qualitative 
designs.  For experimental and observational studies, the design was considered 
appropriate only if it contained a comparison group to provide a measure of risk 
difference attributable to the intervention.  Therefore, case studies and narrative reviews 
were excluded.  Pre-post studies were included for data synthesis as per the systematic 
review, but were not considered appropriate for meta-analysis due to the lack of a control 
group.  Pre-post studies are used to demonstrate causality between an intervention and an 
outcome; however, they are prone to errors such as regression to the mean or 
confounding.191  Further, as per the statistical analysis plan (Section 4.5), the effect sizes 
are generated by comparing the absolute change from baseline to follow-up between the 
intervention and control group, allowing the final effect size to represent both the 
direction and magnitude of effect.  Studies were restricted to those published on or after 
1976, the year the first prediction model was published.13  No geographic restrictions 
were placed on the location of studies to ensure comprehensiveness of the search.   
4.3 Screening 
Citations identified from the search were imported into Covidence, a systematic review 
software, which automatically eliminated duplicated articles, followed by a manual 
search for duplicates.192  Two levels of screening were employed to identify studies that 
met the prespecified eligibility criteria.  The first level of screening was conducted by 
two reviewers (PK, JB) independently through an assessment of the titles and abstracts of 
the citations.  Once the title/abstract screening was completed by both reviewers, 
disagreements were reconciled through discussion of each conflict, with any unresolved 
articles being reviewed by a third party (DL) to reach consensus.  Studies that proceeded 
to the second level screening were reviewed by two reviewers (PK, KN), who first 
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conducted a pilot of 15 articles to ensure reliability, then completed the screening of full-
text articles with conflict resolution occurring upon completion.  Any irreconcilable 
conflicts were resolved by a third party (DL).  The specific criteria by which articles were 
screened derived from the eligibility criteria are listed in Appendix C. 
4.4 Data extraction 
Data were extracted from the complete list of included articles using a form based on the 
Cochrane Consumers and Communication template.193  The Cochrane template 
recommends that data be extracted according to seven categories: 1) general review 
information, 2) methods of the study, 3) risk of bias assessment, 4) study characteristics – 
participants, 5) study characteristics – interventions and comparisons, 6) study 
characteristics – outcomes, and 7) data and results.193  The risk of bias assessment step 
was conducted using an independent tool as the Cochrane template outlines bias 
assessment items that are not applicable to observational studies.  The data extraction 
form was tested using three of the included studies.  A panel of researchers reviewed the 
results to ensure the comprehensiveness and appropriateness of the form.  The form was 
amended based on this feedback.  Subsequently, data were extracted by one reviewer 
(PK) from all the included studies using this form. 
4.4.1 Items extracted 
Items were extracted based on the seven categories outlined in the Cochrane template.   
1) General review information: To identify the article and associated study.  Items 
extracted were DOI, author(s), year of publication, country, and name of study 
where applicable. 
2) Methods of study: To determine what methodology was employed per each study.  
Items extracted for the methods of the study category included study objective(s), 
study setting, and study design.   
3) Risk of bias assessment: Data were not extracted specifically for risk of bias 
assessment as a separate risk of bias assessment tool was used.  
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4) Study characteristics were divided into three categories: participants, 
interventions and comparisons, and outcomes.   
a. Participants: Items extracted pertaining to the participants and 
interventions were participant demographics including age and sex, as 
well as all numbers pertaining to participants (e.g. number of participants 
recruited, number of participants lost to follow-up). 
b. Interventions and comparisons: Items extracted included the name of 
prediction model used, health outcome of model, a brief description of the 
intervention as well as any procedures in addition of the provision of 
projected risk (e.g. dietary counseling, lifestyle recommendations).   
c. Outcomes: The outcomes extracted were categorized into physician 
behaviour, patient behaviour, and patient health outcomes.  Both 
qualitative and quantitative data were extracted.  Information pertaining to 
methods of outcome assessment (e.g. survey, face-to-face), methods of 
follow-up, and frequency and length of follow-up were also recorded.   
5) Data and results: Items extracted were dependent upon study design, though 
generally provided the absolute numbers as opposed to relative measures where 
possible to allow for accurate comparisons between studies in addition to mean 
differences and standard deviations, where reported.  For example, where an 
outcome assessed for changes in systolic blood pressure, dependent on study 
design, baseline and follow-up blood pressure in the intervention and control 
group were recorded, in addition to standard deviations.  Where available, 
absolute changes in blood pressure with the corresponding standard deviation 
were recorded.  In the case of dichotomous outcomes, number of baseline and 
follow-up events in both the intervention and control group were recorded in 
place of risk or odds ratios.  Further, where applicable, qualitative themes were 
recorded in the data extraction form with notations denoting their location in the 
original article. 
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4.5 Statistical analysis plan 
A meta-analysis was conducted to allow for the statistical synthesis of outcome data 
presented in the identified studies.  At its core, a meta-analysis is a statistical process 
whereby the effect sizes of two or more studies may be combined, creating a summary 
effect measure.194  This process is supported by weighting studies by placing greater 
importance or impact on the summary effect on studies with relatively good precision.194  
The analysis was completed using Stata v. 14.195 
Firstly, the number of studies reporting on the same outcome measure was tallied; where 
two or more studies reported on the same outcome, they were explored for numeric 
similarities, which would allow for the calculation of a summary effect measure.  When 
conducting a meta-analysis for dichotomous data, the number of events and non-events 
are required in order to calculate a measure of effect, such as an odds ratio or relative 
risk.  For continuous data, for each group, the sample size, mean value, and standard 
deviation are required to calculate the standardized mean difference.   
Where only proportions of binary data were reported, the number of new events was 
calculated by subtracting the follow-up number of events from the baseline, while the 
number of non-events was calculated by subtracting the total number of participants by 
the number of new events.  For continuous outcomes, where only baseline and follow-up 
mean values were provided, with no measure of absolute change reported, it was 
calculated by subtracting the follow-up value from the baseline value.  The standard 
deviation of the absolute change was calculated by imputing a correlation coefficient 
value derived from studies reporting absolute changes in the continuous outcome into 
equations provided by the Cochrane Handbook for Systematic Reviews of Interventions 
and Borenstein et al.190,194 
The calculated data were then inputted in Stata.  For binary data, the two-by-two 
contingency tables of each study were generated, whereas for continuous data, the 
calculated sample sizes, means, and standard deviations of the absolute change were 
imported.  Using the metan function, forest plots, a visual representation of the magnitude 
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and direction of effect, were generated, as well as measures of uncertainty (i.e. 95% 
confidence intervals).   
For the binary data, the odds ratio was selected as the measure of effect.  The designs of 
studies included for meta-analysis were varied, and included case-control studies, where 
the prevalence of the outcome of interest was artefactually created.  Relative risks are 
only appropriate where the true prevalence can be calculated, while odds ratios are robust 
to fabricated prevalence rates, hence their selection to calculate a summary effect 
measure.190   
The calculation of a summary effect measure requires a distinction between fixed- and 
random-effect models.  Fixed-effect models assume that there is one true effect size 
across all studies in the analysis, and that any differences between studies in terms of 
observed effect is attributable to sampling error.194  The random-effect model, 
conversely, assumes that the observed effect differs across included studies, and aims to 
estimate the mean of this distribution.194  Fixed-effect models are generally considered 
appropriate if all studies are essentially identical; however, the studies included for 
analysis, though similar in terms of outcome, were performed in independence of one 
another on varying populations, and thus an assumption of a true or common effect size 
would be inappropriate.194  Therefore, a random-effect model was used to conduct the 
meta-analysis to account for the heterogeneity between studies. 
4.6 Risk of bias assessment 
A risk of bias assessment was conducted using the Downs and Black tool, and checklist 
assessing the methodological quality of randomized and non-randomized studies.196  The 
Downs and Black tool consists of 27 items assessing the quality of five domains: 1) 
reporting, 2) external validity, 3) bias, 4) confounding, and 5) power.196  The completion 
of the checklist allows for the calculation of an overall, composite score for study quality, 
but also scores for each of the five aforementioned domains.   
The Downs and Black tool is one of the most commonly used numerical rating scales 
with frequent application in systematic reviews, and is well-validated with a high degree 
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of interrater reliability.197,198  Further, it is one of the few tools capable of assessing the 
risk of bias of both randomized and non-randomized studies.197  Therefore, the Downs 
and Black tool was selected to assess the risk of bias for studies included in this 
systematic review. 
The checklist was used for each of the 22 included studies.  A cumulative summary score 
was calculated by averaging the total scores derived from the checklist for each study.  
However, a summary score is discouraged by the Cochrane Handbook, as it differentially 
assigns a weight to different aspects of the checklist.190  Hence, a bar graph was 
constructed to demonstrate the risk of bias in each domain. 
Chapter 5 
5.0 Results 
Presented in this chapter are the results of the systematic review and meta-analysis.  It 
begins by describing the results of the study selection process, and the characteristics of 
the included studies.  The results of the individual studies are then assessed as per their 
outcomes in alignment with the study objectives in the form of a qualitative synthesis and 
the meta-analysis.  Lastly, the risk of bias assessment is also presented. 
5.1 Study selection 
The database search was conducted on March 3rd, 2017, identifying 10,403 citations. 
Among these citations 1,971 duplicates were removed, leaving 8,432 citations.  After the 
first level of screening, 124 citations proceeded to the full-text level of screening. A total 
of 22 remained after this level of screening. The following reasons for exclusion were as 
follows: the risk prediction model was not the primary intervention (n=43); the study was 
not conducted in primary care (n=11); the study assessed for outcomes not applicable to 
this study (n=13); the article only described the methods (n=6); the method of risk 
assessment did not incorporate a prediction model (n=16); the study only assessed for 
behavioural intentions, perceived risks, or knowledge (n=9); the model used measured a 
non-chronic outcome (n=1).  The PRISMA flow chart depicting the screening process as 
per the PRISMA template is presented in Figure 2.189 
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Figure 2.  PRISMA flow chart. 
5.2 Risk of bias assessment 
The Downs and Black tool was used to assess the risk of bias for the included studies.  
Figure 11 displays the information using a bar graph.  The risk of bias is presented as per 
the five domains assessed by the Downs and Black tool: 1) reporting, 2) external validity, 
3) bias, 4) confounding, and 5) power.  Cumulative scores are presented for each domain 
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pertaining to the level of bias present in the included studies.  Overall, the score for risk 
of bias is 67.7%, indicating a moderate risk of bias. 
 
Figure 3.  The risk of bias of the systematic review measured by compounding the risk of 
bias of individual studies. 
5.3 Study characteristics 
The study characteristics are presented according to demographic characteristics (Table 
6) and intervention characteristics (Table 7). 
5.3.1 Demographic characteristics 
The studies were geographically diverse across developed nations, with representation 
from the United Kingdom (n=5), the United States (n=4), Canada (n=4), Denmark (n=3), 
the Netherlands (n=2), Australia (n=2), Hong Kong (n=2), Italy (n=2), and New Zealand 
(n=1).  All the studies took place in a primary care setting under the supervision of one or 
more physicians, and reported on 400,758 patients.  After accounting for loss to follow-
up, a total of 383,005 patients remained.  There was inconsistent reporting of number of 
physicians, with nine studies not providing a number of physicians, and five only 
providing the number of practices included.  Six studies reported that there were 555 
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general practices.  Of the 11 studies that reported a number of physicians, there were 
3801 primary care physicians.   
Most studies included patients who had a mean age over 50 years, with only 1 study 
including patients under the age of 18 years (Burgess et al., 2011).  Distribution of patient 
sex varied greatly between studies.  The full table of demographic characteristics is 
provided in Table 6. 
Table 6.  Demographic characteristics of studies included in the systematic review. 
Author, 
country, 
year 
Name of 
study 
Patient inclusion Number of 
participants 
(lost to follow-
up) 
% of male 
patients 
Age of 
patientsa 
Bach-
Nielsen et 
al., 
Denmark, 
2005199 
The Ebeltoft 
Project 
- Receipt of elevated 
cardiovascular risk score 
Patients: 
14 
64.3% 33-50 years 
Bellows et 
al., USA, 
2014200 
IndiGO - IndiGO total benefit 
score in top third 
Patients: 489 
 
Physicians: 10 
66% 59 
van den 
Brekel-
Dijkstra et 
al., 
Netherlands, 
2016201 
Personalized 
Prevention in 
the Local 
Community 
(PPLC) 
Programme 
- 45-70 years 
- No CVD or diabetes 
Patients: 230 
(101) 
47.80% 52.2 (6.3) 
Burgess et 
al., 
Australia, 
2011202 
AHC Study - Residence in 
community for 3 years 
prior and post AHC 
participation 
- Elevated CVD risk 
- Participation in AHC 
program 
Patients: 64 (6) 
 
Physicians: 15 
67% 15-54 
Chang et al., 
UK, 2016 
UK203 
NHS Health 
Check 
- 40-74 years 
- Registered with 
practice participating in 
the Clinical Practice 
Research Datalink from 
April 1, 2009 to March 
31, 2013 
- No CVD or diabetes 
Patients: 
138,788 
 
General 
practices: 462 
Before 
matching: 
Attendees: 
47.4% 
Nonattendees: 
50% 
 
After 
matching:  
Attendees: 
47.4% 
Nonattendees: 
47.4% 
Before 
matching: 
Attendees: 53.5 
Non-attendees: 
50.1 
 
After matching: 
Attendees: 53.5 
Non-attendees: 
53.4 
Cochrane et 
al., UK, 
2012204 
NHS Health 
Check 
- Elevated CVD risk 
(≥20%) 
Patients: 
Intervention: 
365 (11) 
Intervention: 
90.1% 
Intervention: 
63.9 (6.5) 
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Author, 
country, 
year 
Name of 
study 
Patient inclusion Number of 
participants 
(lost to follow-
up) 
% of male 
patients 
Age of 
patientsa 
Intervention 
plus: 236 (9) 
 
General 
practices: 38 
Intervention 
plus: 86.4% 
Intervention 
plus: 63.3 (6.4) 
Courtney et 
al., US, 
2015205 
NA - ≥30 years 
- No diabetes 
- Received PreDx test 
from June 2010 to 
December 2010 
Patients: 
Intervention: 
696 (139) 
Control: 2002 
(1147) 
Intervention: 
60.1% 
Control: 
60.0% 
Intervention: 53 
Control: 53 
Engberg et 
al., 
Denmark, 
2002206 
NA - 30-49 years by January 
1, 1991 
Patients: 
Intervention: 
1006 (282) 
Control: 501 
(132) 
 
Physicians: 9 
Intervention: 
48.8% 
Control: 
48.3% 
Intervention: 
40.5 years (5.6) 
Control: 40.4 
(5.8) 
Ford et al., 
UK, 2001207 
NA - Patients who had a 
CHD risk request in 1998 
at the Birmingham 
Heartlands Hospital 
Patients: 906 
 
General 
practices: 14 
55.2% NA 
Grover et 
al., Canada, 
2007208 
 
The CHECK-
UP Study 
- 30-70 years Patients: 
Intervention: 
1510 (166) 
Control: 1543 
(200) 
 
Physicians: 230 
Intervention: 
66.9% 
Control: 
70.0% 
Intervention: 
56.4 (8.3) 
Control: 56.3 
(7.9) 
 
Grover et 
al., Canada, 
2008209 
The CHECK-
UP Study 
- 30-70 years Patients: 2631 
 
Physicians: 230 
NA Treatment 
initiation: 
Intervention: 56 
(7.6) 
Control: 55.8 
(7.9) 
 
Treatment 
modification: 
Intervention: 
58.2 (7.6) 
Control: 58.3 
(7.4) 
Jiao et al., 
Hong Kong, 
2014210 
 
The RAMP-
DM 
- All persons with 
diabetes covered under 
general out-patient 
clinics in Hong Kong 
Patients:  
Intervention: 
1248 (176) 
Control: 1248 
(176) 
Intervention: 
49.8% 
Control: 
49.8% 
Intervention: 
64.3 (10.9) 
Control: 65.3 
(11.7) 
Jiao et al., 
Hong Kong, 
2015211 
 
The RAMP-
DM 
- ≥18 years 
- International 
Classification of Primary 
Care codes T89/T90 
before participation 
Patients: 
Intervention: 
9094 
Control: 9094 
Intervention: 
48.2% 
Control: 
47.5% 
Intervention: 
64.23 (11.05) 
Control: 64.29 
(11.96) 
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Author, 
country, 
year 
Name of 
study 
Patient inclusion Number of 
participants 
(lost to follow-
up) 
% of male 
patients 
Age of 
patientsa 
- ≥ one public primary 
clinic visit before 
participation 
- No diabetes, cancer, 
chronic lung disease, and 
psychological conditions 
Law et al., 
Canada, 
2014212 
The 
PARADIGM 
Study 
- Ambulatory men (≥40 
years) and women (≥ 50 
years) 
- No CVD or diabetes 
- No lipid-lowering 
medications at baseline 
Patients: 3015 
 
Physicians: 105 
59% 56 
Lowensteyn 
et al., 
Canada, 
1998213 
CHAS Study - 30-74 years 
- No CVD 
Patients: 
Intervention: 
782 (580) 
Control: 176 
(87) 
 
Physician: 
Intervention: 
170 (73) 
Control: 83 
(51) 
Intervention: 
64.8% 
Control: 
64.8% 
Intervention: 
50.5 (10.8) 
Control: 50.7 
(11.3) 
Mehta et al., 
New 
Zealand, 
2014214 
PREDICT 
CVD-16 
- 30-80 years 
- First risk assessment 
using PREDICT 
conducted between 
January 1, 2006, and 
October 15, 2009 
- No CVD-related 
hospitalization 
- No anti-anginal 
medication dispensement 
Patients: 
90,631 
56% 30-80 
Palmieri et 
al., Italy, 
2011215 
CUORE 
Project 
- 35-69 years 
- No CVD or prior 
cardiovascular event 
Patients: 
117,345 
(12427) 
 
Physicians: 
1032 
44.7% NA 
Powers et 
al., USA, 
2011216 
NA - ≥55 years 
- Enrolled in primary 
care for at least one year 
- ICD hypertension 
diagnosis with 
hypertensive medication 
prescription 
- Systolic blood pressure 
at least 140 mmHg or 
diastolic blood pressure 
at least 90 mmHg 
- Electrocardiogram 
within past five years 
Patients: 
Intervention: 44 
Control: 45 
 
General 
practice: 1 
98% Intervention: 68 
(9) 
Control: 65 (8) 
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Author, 
country, 
year 
Name of 
study 
Patient inclusion Number of 
participants 
(lost to follow-
up) 
% of male 
patients 
Age of 
patientsa 
- No CVD, stroke, 
myocardial infarction, 
psychosis or dementia 
Price et al., 
UK, 2011217 
Understanding 
Risk Study 
- Increased CVD risk 
(≥20%) 
- Fluent in English 
(reading/writing) 
- No CVD or physical 
disability 
Patients: 
Intervention: 99 
Control: 95 
9 patients lost 
to follow-up 
 
General 
practices: 4 
67% 62.3 
Romero et 
al., USA, 
2008218 
NA - CHD risk more than 
10% or diabetes with one 
other cardiac risk factor 
- Indication of prior 
CHD, bleeding risk, 
aspirin allergy, 
inadequate data, or low 
CHD risk 
Patients: 
Pre-
intervention: 
294 
Post-
intervention: 
202 
Pre-
intervention: 
62% 
Post-
intervention: 
54.5% 
Pre-
intervention: 71 
Post-
intervention: 71 
Usher-Smith 
et al., UK, 
2015219 
NHS Health 
Check 
- Attend NHS Health 
Check between April 1, 
2011 to December 1, 
2014 
- Risk between 10% to 
20% 
Patients: 410 
(310) 
56% 64.7 (6.11) 
Sorensen et 
al., 
Denmark, 
2011220 
DanRisk 
Study (Danish 
Risk Score 
Study) 
- Born in 1949 or 1959 
- Live in Southern 
Denmark 
- No CVD or diabetes 
Patients: 1156 
(81) 
Baseline: 
47.1% 
Follow-up: 
46.3% 
Baseline: 50-
year: 49.8% 
60-year: 54.0% 
Follow-up: 
50-year: 48.6% 
60-year: 51.4% 
Vagholkar 
et al., 
Australia, 
2014221 
NA - 45-69 years 
- No CVD 
- Fluent in English 
- No cognitive 
impairments 
Patients: 
Intervention: 
567 (92) 
Control: 507 
(76) 
 
General 
practices: 
Intervention: 20 
(2) 
Control: 16 
Intervention: 
45% 
Control: 
38.5% 
Intervention: 
56.2 (6.6) 
Control: 56.6 
(6.9) 
Volpe et al., 
Italy, 2007222 
ForLife Study - Diagnosed hypertension 
(both treated and 
untreated) 
Patients: 12792 
(1326) 
Treated: 7512 
Untreated: 
5280 
 
Physicians: 
1800 
Treated: 51% 
Untreated: 
49.6% 
Treated: 68 
Untreated: 64 
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Author, 
country, 
year 
Name of 
study 
Patient inclusion Number of 
participants 
(lost to follow-
up) 
% of male 
patients 
Age of 
patientsa 
Wind et al., 
Netherlands, 
2015223 
NA - Type 2 diabetes 
mellitus treated with 
lifestyle advice and/or no 
more than two oral blood 
glucose lowering drugs 
Patients: 933 
(220) 
 
Physicians: 117 
53.2% 64.4 (10.5) 
a Age presented in years as: mean (standard deviation), and range, where applicable. 
5.3.2 Intervention characteristics 
Overwhelmingly, the risk prediction models used as the intervention or as a component 
of the intervention in each study predicted the risk of cardiovascular diseases.  Twenty-
one of the twenty-two studies included predicted for the long-term risk of either 
cardiovascular disease, coronary heart disease, myocardial infarction, or stroke.  Of the 
21 studies, 4 were predictive of cardiovascular disease amongst patients with diabetes.  
Only one of the twenty-two studies included predicted for type 2 diabetes.  No studies 
examined risk prediction models that were predictive of either cancer or chronic 
respiratory diseases, two of the four WHO categorizations of chronic disease used in this 
systematic review. 
The actual prediction models used varied; the majority (n=12) used a Framingham 
equation or derivative thereof.  The next most common tool used was the UKPDS risk 
engine (n=3).  Other tools used were SCORE (n=1), QRisk (n=2), the European 
HeartScore (n=1), PreDx (n=1), the JADE Classification System (n=2), the 10-CR Score 
(n=1), the Anggard Modified Risk Score (n=1) and the IndiGO Prediction Tool (n=1).  
One study did not specify which tool was used, and one other study used an unnamed 
multilevel linear regression equation as a component of the NHS UK Health Check. 
Individual study designs were not always ascertainable because in some studies they were 
mixed.  However, the general study methods employed by researchers were: randomized 
controlled trial (n=8), pre-post study (n=5), prospective cohort (n=5), retrospective cohort 
(n=4), case-control study (n=2), and qualitative interviews (n=1). 
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Fifteen of the twenty-five studies reported on physician behaviour.  Patient behaviour 
was reported by 11 studies, and the patient health outcomes were reported by 17 studies.  
There is some overlap, with most studies reporting on multiple objectives.  Complete 
intervention characteristics are presented in below (Table 7). 
Table 7.  Characteristics of the interventions presented in the included studies. 
Author, 
year 
Study design Model Outcome of 
model 
Recruitment 
period 
Follow-up Study 
outcome(s)b 
Bach-
Nielsen et 
al., 2005199 
Qualitative 
(interview) 
Unknown CVD risk 1991 4 years - 2 
Bellows et 
al., 2014200 
Case-control 
(propensity 
score 
matched) 
IndiGO 
Prediction Tool 
5-year heart 
attack and 
stroke risk 
November 
2008-April 
2009 
3-6 months - 1 
- 3 
van den 
Brekel-
Dijkstra et 
al., 2016201 
Pre-post SCORE 10-year CVD 
risk 
2012-2013 6 months - 2 
Burgess et 
al., 2011202 
Pre-post  New Zealand 
Guidelines 
Group handheld 
chart (based on 
Framingham 
equations) 
5- and 10-
year CHD 
risk 
March 2005-
September 
2005 
3 years - 1 
- 2 
- 3 
Chang et 
al., 2016203 
Retrospective 
cohort 
QRISK2 10-year CVD 
risk 
April 1, 
2009-March 
31, 2013 
2 years 
(median) 
- 1 
- 2 
- 3 
Cochrane 
et al., 
2012204 
Randomized 
controlled 
trial 
Multilevel 
linear 
regression 
equation 
10-year CVD 
risk 
September 
2009-
February 
2010 
12 months - 3 
Courtney et 
al., 2015205 
Case-control 
study 
PreDx 5-year risk of 
type 2 
diabetes 
June 2010-
December 
2010 
Intervention: 
17 weeks 
(mean) 
Control: 15 
weeks 
(mean) 
- 1 
- 2 
- 3 
Engberg et 
al., 2002206 
Randomized 
controlled 
trial 
(population-
based) 
Modified 
Anggard Risk 
Score 
CVD December 
1991-June 
1992 
1 and 5 
years 
- 3 
Ford et al., 
2001207 
Retrospective 
cohort (pre-
post) 
Framingham 
equations 
10-year CHD 
risk 
1998 NA - 1 
Grover et 
al., 2007208 
 
Randomized 
controlled 
trial 
Based on 
Framingham 
equations 
10-year CVD 
risk 
May 10, 
2001-August 
25, 2003 
1 year (3 
month 
intervals) 
- 3 
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Author, 
year 
Study design Model Outcome of 
model 
Recruitment 
period 
Follow-up Study 
outcome(s)b 
Grover et 
al., 2008209 
Randomized 
controlled 
trial 
Based on 
Framingham 
equations 
10-year CVD 
risk 
After August 
2003 
Baseline: 2-
4 weeks 
following 
screening 
Follow-up 
visits: 3, 6, 
9, and 12 
months 
- 1 
Jiao et al., 
2014210 
 
Prospective 
cohort with 
matched 
exposure-non-
exposure 
groups 
JADE 
Classification 
System (Joint 
Asia Diabetes 
Evaluation 
Program) and 
10-year 
Framingham 
Risk Function 
for CVD, and 
UKPDS for 
CHD and stroke 
10-year 
CVD, CHD, 
and stroke 
risk 
August 
2009-June 
2010 
12 months - 1 
- 3 
Jiao et al., 
2015211 
 
Prospective 
cohort 
JADE 
Classification 
System (Joint 
Asia Diabetes 
Evaluation 
Program) 
Diabetes 
microvascular 
complications 
(CHD, heart 
failure, 
stroke) and 
mortality 
August 1, 
2009-July 
31, 2010 
3 years 
(median) 
- 1 
- 2 
- 3 
Law et al., 
2014212 
Prospective 
cohort 
Framingham 
risk score 
CVD March 2009-
March 2010 
NA - 1 
Lowensteyn 
et al., 
1998213 
Randomized 
controlled 
trial 
8-year CHD 
prevention 
model (based on 
Framingham 
equations) 
8-year CHD 
risk 
NA 3-6 months - 2 
- 3 
Mehta et 
al., 2014214 
Prospective 
cohort 
New Zealand 
adjusted risk 
score (based on 
Framingham 
risk score) 
5-year CVD 
risk 
January 1, 
2006-
October 15, 
2009 
Up to 3 
years (6 
month 
intervals) 
- 1 
Palmieri et 
al., 2011215 
Pre-post 
(retrospective) 
10-CR Score 
(from Progetto 
CUORE 
longitudinal 
studies) 
10-year risk 
of fatal and 
non-fatal 
CVD events 
January 
2007-May 
2010 
Within 1 
year of 
baseline 
- 3 
Powers et 
al., 2011216 
Randomized 
controlled 
trial 
Framingham 
Risk Score 
10-year CHD 
and stroke 
risk 
NA 3 months - 2 
- 3 
Price et al., 
2011217 
Randomized 
controlled 
trial 
UKPDS risk 
engine 
10-year CVD 
risk 
NA 1 month - 1 
- 2 
- 3 
Romero et 
al., 2008218 
Retrospective 
cohort 
Framingham 
risk score 
10-year CHD 
risk 
April 1, 
2003-June 
30, 2003 
October 1, 
2004-
- 1 
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Author, 
year 
Study design Model Outcome of 
model 
Recruitment 
period 
Follow-up Study 
outcome(s)b 
December 
31, 2004 
(18-21 
months after 
baseline; 11-
14 months 
after 
intervention) 
Usher-
Smith et al., 
2015219 
Retrospective 
cohort 
QRISK 10-year CVD 
risk 
After 
December 1, 
2014 
28.0 (SD 
10.3) 
months 
- 2 
- 3 
Sorensen et 
al., 2011220 
Pre-post Europe 
HeartScore 
10-year CVD 
mortality risk 
2009 6 months - 1 
- 2 
Vagholkar 
et al., 
2014221 
Cluster 
randomized 
controlled 
trial 
New Zealand 
CV risk 
calculator 
(based on 
Framingham 
risk score) 
CVD 2008-2010 12 months - 1 
- 3 
Volpe et al., 
2007222 
Prospective 
cohort 
Modified 
Framingham 
equations 
(modification to 
account for 
antihypertensive 
treatment) 
10-year 
stroke risk 
February 
2003-July 
2003 
4±1.5 
months 
- 3 
Wind et al., 
2015223 
Pre-post UKPDS 10-year non-
fatal and fatal 
CHD risk 
NA 1.0±0.2 
years 
- 1 
- 3 
b 1=physician behaviour; 2=patient behaviour; 3=patient health outcomes. 
5.3.3 Intervention descriptions 
The studies each incorporated the use of a risk prediction model as a main component of 
their intervention.  However, components in addition to the provision of absolute risk as 
derived by the risk prediction models were present in most of the studies such as 
providing measures of relative risk or threshold-dependent lifestyle advice.  These 
characteristics could have their own impact on the study outcomes, providing a degree of 
heterogeneity between included studies.  This section describes each study’s application 
of risk prediction models and how the impact of the models was determined.  A complete 
overview of each intervention is provided in Appendix D. 
The presentation of risk to either the physicians or patients varied between studies. 
Modes of presenting risk also varied. Paper-based presentation of risk was the most 
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common, with 13 studies providing a printed risk profile.  Second most common was a 
computer- or web-based presentation (n=8). In four of the studies, risk was 
communicated verbally between the physician and the patient.  Some studies used 
multiple formats.  For example, the risk may have been calculated using a computer-
based software, and was subsequently printed for patients to take home (n=6).  Lastly, in 
three studies it was not possible to determine how risk was presented. 
In addition to the absolute measure of risk, some studies chose to provide a relative or 
additional representations of risk (n=9).  Usher-Smith et al. provided patients with both 
the baseline QRisk score, as well as a projected score, demonstrating the effect of 
lifestyle changes.  Bellows et al. provided the absolute risk of heart attack or stroke as 
well as projected absolute risks if interventions were implemented.  Similarly, Price et al. 
provided the absolute risk as well as an achievable risk, an estimation of absolute risk if 
risk factor targets were met.  Grover et al. 2007 and 2008 provided the absolute risk as 
well as a relative risk, comparing the patient to other Canadians matched for age and sex.  
Courtney et al. provided patients with their absolute likelihood of developing type 2 
diabetes as well as compared to the general population.  Lowensteyn et al. presented the 
8-year coronary risk as well as how much the risk would be reduced if one or more risk 
factors were modified.  Palmieri et al. provided two additional measures of risk: first, a 
hypothetical risk for a person of the same age and sex as the patient with favourable 
modifiable risk factor levels, and secondly, the risk of a smoker one year after smoking 
cessation and with a decrease of 10% in modifiable risk factors.  Alongside their personal 
risk, Powers et al. also presented the average and optimal risk for the patient’s 5-year age 
group in graphical format. 
Eleven studies chose to incorporate lifestyle advice in addition to the provision of the 
patient’s absolute risk.  Cochrane et al. included consultation with lifestyle coaches who 
assisted in developing health improvement plans, in addition to setting priorities for 
lifestyle goals.  Usher-Smith et al. provided all participants with an information leaflet 
including recommendations for individuals to improve their lifestyle through smoking 
cessation, healthy diet, reduction in alcohol consumption, and physical activity.  Bach 
Nielsen et al. provided feedback, including lifestyle modification advice, to their patients 
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when their calculated risk and risk factor values fell outside of normal range.  van den 
Brekel-Dijkstra et al. personalized the lifestyle advice to each patient based on their risk 
profile, the associated risks and benefits of preventive action, and individual 
opportunities for lifestyle change depending on motivation, self-efficacy, and 
preferences.  Chang et al. 2016 evaluated the NHS Health Check, which provides a risk 
assessment allowing for a tailored strategy for patient management, including lifestyle 
advice.  Engberg et al. provided 45-minute consultations with a general practitioner 
where lifestyle-related goals were established for the following year as well as providing 
all patients with a pamphlet on leading health lifestyles as per the Danish Heart 
Foundation.  Palmieri et al. provided patients with lifestyle recommendations pertaining 
to nutrition, physical activity, and smoking cessation.  Strategies to improve risk through 
risk factor modification (e.g. medication, patient lifestyle factors) were presented to 
intervention patients by Powers et al.  Price et al. chose a more interactive format for 
patients to receive lifestyle advice, with a self-conducted slide show aimed at first setting 
goals to reduce risk, and the direction of behaviours towards achievement of goals.  The 
intervention used by Bellows et al. included a face-to-face discussion of options for risk 
reduction providing a more tailored approach.  Upon inclusion in the study, Burgess et al. 
provided a patient-centered consultation to discuss chronic disease care planning, which 
includes patient education and goal setting, in addition to consultations at each point of 
follow-up with either a remote access nurse or an Aboriginal health worker. 
Decision support was a component of three studies, providing physicians with 
recommendations regarding patient management given a specific threshold of risk (i.e. 
targeting high risk patients).  The JADE classification system stratifies patients as low, 
medium, or high risk; decision support was provided in terms of recommending 
appropriate interventions and education based on the risk threshold.  Romero et al. 
provided decision support in the form of a poster providing a visual representation of the 
guideline recommended thresholds for aspirin initiation to prevent CHD. 
Four studies incorporated referrals to other health care professionals as a component of 
the intervention.  van den Brekel-Dijkstra et al. provided links to local providers of 
lifestyle interventions with suggestions for individual activities, group activities, or online 
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services, allowing for a variety of evidence-based lifestyle programs to be pursued by 
participants.  The RAMP-DM intervention provided referrals to a team of healthcare 
professionals, including registered nurses, advanced practice nurses, optometrists, 
dietitians, podiatrists, physiotherapists amongst others dependent upon the patient’s 
stratified risk level.  Cochrane et al. provided referrals to free support sessions regarding 
weight management, physical activity, dietary counselling, and positive thinking upon 
request by participants. 
Lastly, only three studies specifically reported that training was provided to physicians 
regarding the implementation of the intervention.  Physicians in the Vagholkar et al. 
study were provided a 3-hour workshop regarding the use of the risk calculator, as well as 
the corresponding guideline-based recommendations for the risk strata.  Physicians in the 
Palmieri et al. study incorporated training as per a national program regarding the 
assessment of cardiovascular risk using the 10-CR score, methods for identifying patients 
eligible for counseling or treatment, promoting shared decision-making, and evaluating 
and discussing collected data.  Study sponsors in the Wind et al. study instructed 
physicians on how to use the UKPDS risk engine, interpretation of CHD risk, and 
appropriate prescription of medication. 
5.4 Outcome descriptions 
Presented in this section is an overview of the outcomes of each included study as they 
correspond to the three objectives of this systematic review.  First is a summary of studies 
that assessed for changes in physician behaviour (n=15), then an overview of study 
outcomes pertaining to patient behaviour (n=11), and lastly a summary of changes in 
patient health outcomes (n=17). 
5.4.1 Physician behaviour 
Eleven studies assessed for the impact of risk prediction model use on physician 
behaviour.  Each of these studies chose to measure the impact of prediction model use 
specifically on prescribing patterns.  Differences or changes in prescription pattern were 
measured for several types of drugs, but primarily in five categories: lipid-lowering 
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medications (n=10), antihypertensives (n=9), antidiabetics including insulin and glucose-
lowering medications (n=5), aspirin (n=3), and antiplatelets (n=2).  Of these 11 studies, 9 
found a statistically significant improvement in prescription with at least one of the risk 
reducing medications.  One study also measured the monitoring of risk factors between 
the intervention and control group. 
Sorensen et al. examined the change in prescription of antiplatelets, antihypertensives, 
and lipid-lowering medications from baseline to the six month follow-up.220  Amongst 
patients with low risk (n=842), defined as <5% 10-year cardiovascular mortality risk, 
prescription with antiplatelets increased from 18 patients at baseline to 19 at follow-up 
(p=0.71), prescription with lipid-lowering medication increased from 84 to 94 patients 
(p=0.07), and prescription with antihypertensives increased from 151 to 163 patients 
(p=0.04).  Amongst patients with high risk (n=233), defined as ≥5% 10-year 
cardiovascular mortality risk, prescription with antiplatelets increased from 14 to 17 
patients (p=0.32), prescription with lipid-lowering medication increased from 25 to 44 
patients (p<0.0001), and prescription with antihypertensives increased from 55 to 74 
patients (p=0.0009).  Overall (n=1075), prescription with antiplatelets increased from 32 
to 36 patients (p=0.32), lipid-lowering medication from 109 to 138 (p<0.0001), and 
antihypertensives from 206 to 237 (p=0.0002). 
Chang et al. compared the prescription for statins or antihypertensive medication between 
the intervention group (n=29,672) and the control group (n=109,116).  The crude 
numbers of prescription with antihypertensives and statins is presented in Appendix E.  
After propensity score matching, the intervention was associated with significantly 
greater increases in percentage of participants being given a statin (3.83%, 95% CI 3.52, 
4.14) and antihypertensive prescription (1.37%, 95% CI 1.08, 1.66).   
Vagholkar et al. assessed for changes in antihypertensive and lipid-lowering medications 
at baseline and a 12-month follow-up in both the intervention and control group, as well 
as treatment intensification or reduction.  Amongst intervention patients (n=475), 
antihypertensive prescription increased from 136 (28.6%) to 148 patients (31.2%), with 
56 patients (11.8%) having their prescription intensified and 32 (6.7%) having reductions.  
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Lipid lowering increased from 101 (21.3%) to 108 (22.7%), with 37 (7.8%) intensified 
and 24 (5.1) reduced.  59 patients (12.4%) were prescribed both at baseline and 63 
(13.3%) at follow-up.  Amongst control patients (n=431), antihypertensives increased 
from 133 (30.9%) to 148 (34.3%) at follow-up, with 46 (10.7%) having their prescription 
intensified and 25 (5.8%) having it reduced.  For lipid-lowering medications, 120 
(27.8%) were prescribed at baseline and 130 (30.2%) at follow-up, with 41 experience 
intensifications (9.5%) and 26 experiencing reductions (6.0%).  60 control patients 
(13.9%) were prescribed both at baseline, and 69 (16.0%) at follow-up.  Changes in 
pharmacologic management were not statistically significant except for the increase in 
patients on antihypertensives within the control group (30.9% to 34.3%, p=0.03). 
Grover et al. (2008) assessed for the initiation and intensification of antihypertensive 
medication between the risk profile group (n=629) and the control group (n=668).  34.9% 
of risk profile patients increased treatment compared to 27.7% of control patients, with a 
difference of 7.2% (95% CI 1.1, 13.3; p<0.05).  For treatment initiation, 31.4% of risk 
profile patients started antihypertensives compared to 24.1% of control patients, with a 
difference of 7.3% (95% CI -1.4, 15.9).  Overall, 33.8% of risk profile patients initiated 
or increased treatment compared to 26.7% of control patients with a difference of 7.1% 
(95% CI 2.1, 12.1; p<0.01).   
Courtney et al. found that there were higher rates of prescription amongst risk-tested 
patients for all medications examined (antihypertensives, lipid-lowering, antidiabetics, 
and aspirin) during the follow-up period compared to the control group; no numeric 
figures were provided.  They also found that patients who received the risk test were 
more likely to receive follow-up measurements of risk factors compared to control 
patients, including blood pressure (91.5% versus 42.7%), weight (91.1% versus 42.8%), 
LDL-cholesterol (71.8% versus 24%), HDL-cholesterol (72.7% versus 24.3%), HbA1c 
(58.6% versus 11.5%), triglycerides (96.8% versus 82.8%) and fasting glucose (98.4% 
versus 72.4%).  All differences reached statistical significance (p<0.001), and indicate 
more careful and targeted monitoring for risk-tested patients compared to control 
patients. 
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In a pre-post study design, Ford et al. found that at baseline, 10.7% of patients (97/906) 
were prescribed with statins, and 11% (100/906) after coronary heart disease risk 
assessment.  Amongst those with a 10-year CHD risk of <30% (n=825), 62 patients were 
already taking a statin, 4 patients discontinued statin use, and 4 patients began statin use.  
Amongst patients with a 10-year CHD risk of 30% or greater (n=81), 35 patients were 
already taking a statin, and 3 patients began a statin.  
Jiao et al. (2015) assessed the prescription of 4 medications (glucose-lowering, 
antihypertensive, and lipid-lowering drugs, and insulin) at baseline and following the 
implementation of the RAMP-DM intervention for both the risk profile group (n=9094 
baseline; n=8892 follow-up) and the control group (n=9094 baseline; n=8542 follow-up).  
At baseline, 87.3% of intervention patients were prescribed glucose-lowering drugs at 
baseline compared to 87.2% of control patients (p=0.755); at follow-up, 90.0% of 
intervention patients were compared to 83.6% of control patients (p<0.001).  For 
antihypertensive drugs, 73.0% of intervention patients were prescribed compared to 
73.4% of control patients at baseline (p=0.547), while at follow-up, 80.0% of intervention 
patients were prescribed compared to 76.0% of control patients (p<0.001).  13.1% of 
intervention patients were prescribed lipid-lowering drugs at baseline compared to 13.5% 
of control patients (p=0.431), while at follow-up 51.2% of intervention patients were 
prescribed compared to 45.7% of control patients (p<0.001).  Lastly, 1.2% of intervention 
patients were prescribed insulin at baseline compared to 1.4% of control patients 
(p=0.101) and at follow-up, 6.0% of intervention patients were prescribed insulin 
compared to 4.5% of control patients (p<0.001).   
Jiao et al. (2014) assessed the RAMP-DM intervention and its impact of prescription with 
glucose-lowering drugs, insulin, antihypertensive drugs, and lipid-lowering drugs as well 
from baseline to a 12-month follow-up within the intervention and control arm.  Only 
differences in insulin prescription were significant at both baseline and follow-up 
(baseline: p<0.001; follow-up: p<0.001).  Differences in prescription at baseline and 
follow-up for glucose-lowering medications (baseline: p=0.593; follow-up: p=0.207), 
antihypertensive drugs (baseline: p=0.382; follow-up: 0.302), and lipid-lowering drugs 
(baseline: p=0.437; follow-up: p=0.354) were not statistically significant. 
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Price et al. made note of risk-reduction prescriptions from baseline to follow-up amongst 
intervention and control groups, and found a greater number of prescriptions were given 
to those for whom risk was calculated.  Amongst the intervention patients, there were 17 
new prescriptions in 12 individuals compared to 5 new prescriptions in 5 individuals in 
the control group (p=0.01).  Specifically, in the intervention group, there were new 
prescriptions for aspirin (n=2), antihypertensives (n=8), glucose-lowering medications 
(n=3), and lipid-lowering medications (n=4). 
Romero et al. assessed for changes in aspirin prescription in a retrospective analysis.  
They found that at baseline, 63.5% (127/202) patients used aspirin for the primary 
prevention of CHD, while the post-intervention rate of aspirin use was 72.8% (147/202), 
representing a 9.3% (p=0.054) absolute increase in rate of aspirin use, indicating a 
marginally insignificant result. 
Bellows et al. reported on the impact of the IndiGO individualized clinical guidelines on 
new prescription of statins and antihypertensives.  Though no difference was found 
between intervention (n=489) and control (n=489) groups with regards to 
antihypertensive medication (17% versus 15%, p=0.39), patients in the intervention 
group were significantly more likely to be prescribed statins compared to control patients 
(39% versus 8%; p<0.01). 
Burgess et al. examined the impact of the Aboriginal and Torres Strait Islander Adult 
Health Check on prescription of medications related to CVD risk reduction in a pre-post 
study design.  At baseline (n=64), 18 patients (28%) were prescribed, and at follow-up 
(n=63), 56 patients (89%) were prescribed.  Significant increases in prescription from 
baseline to follow-up were found for antiplatelets (4.7% to 68.3%, p<0.001), lipid 
lowering medication (6.3% to 65.1%, p<0.001), angiotensin converting enzyme 
inhibitors/angiotensin receptor blockers (25% to 63.5%, p<0.001), and oral hypoglycemic 
medications (17.2% to 33.3%, p=0.04) were found.  No significant increase in 
prescription with beta blockers (4.7% to 12.7%, p=0.09), nitrates (3.1% to 4.8%, p=0.49), 
thiazide diuretics (0% to 3.2%, p=0.24), or calcium channel blockers (1.6% to 1.6%, 
p=0.75) were found. 
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5.4.2 Patient behaviour 
Risk reducing patient behaviours as a result risk prediction models use were examined in 
11 studies.  A greater number of measures were studied when compared to practitioner 
behaviours.  Most common was cigarette smoking, with eight studies evaluating the 
impact of risk prediction models use on smoking cessation.  Other measures evaluated 
included changes in physical activity (n=4), diet (n=2), medication use (n=2), continuity 
of care or return for follow-up visit (n=2), and alcohol consumption (n=1).  Of the eight 
studies examining smoking cessation, two studies found a significant result, while six 
were non-significant.  Of the six studies, three studies demonstrated a non-significant 
absolute reduction of smoking prevalence, while one study reported a significant 
reduction in number of cigarettes smoked per day.  Though all the studies reporting 
changes in physical activity noted increases in exercise levels, none reported a significant 
change; two stated there was a non-significant effect, one was conducted qualitatively, 
and one only reported the change in proportions. 
van den Brekel-Dijkstra et al. examined patient behaviour through use of a pre-post study 
design.  Of the patients that responded to the follow-up questionnaire (56%), 40 of 129 
(31%) patients reported initiations of health behaviour change, 41 (32%) reported 
improvements in physical activity, and 36 (28%) improved their diet.  23 of 96 (24%) 
current drinks reduced their alcohol intake.  Forty four percent (6/16) current smokers 
reduced or quit smoking. 
Usher-Smith et al. conducted a study examining the change of statin prescription 
threshold from 20% absolute cardiovascular risk to 10%, the corresponding provision of 
a cardiovascular risk score to the patient, and subsequently the patients’ decision 
regarding statin prescription.  In this fashion, the onus of statin prescription fell unto the 
patients.  Among 410 statin-naïve patients, 45 (11%) chose to start a statin.  An 
association was found between increasing QRisk score and statin initiation (OR 1.34 
(1.13, 1.60)). 
Sorensen et al. examined smoking cessation amongst participants.  At baseline, 253 of 
1075 (24%) participants were current smokers.  At follow-up, 39 participants had quit 
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smoking, while 10 subjects started smoking again.  The number of active smokers 
decreased to 224 (p<0.0001).  Similarly, Wind et al. found that among their participants 
in a pre-post study design (n=713), the percentage of smokers decreased from 18.3% at 
baseline to 15.0% at follow-up (p<0.05). 
Chang et al. also examined smoking cessation between the intervention and the control 
group.  Complete smoking prevalence is presented in Appendix E.  Smoking prevalence 
decreased more in the intervention group than in the control group; after propensity score 
matching, the difference in prevalence was -0.11% (95% CI -0.35, 0.13), though not 
statistically significant. 
Jiao et al. (2015) assessed patients for smoking status at both baseline and follow-up in 
the intervention and control groups, and found no significant change in smoking status at 
the end of follow-up between groups (smoking prevalence of 10.2% and 10.0% at 
baseline for the intervention and control groups, respectively, p=0.605; smoking 
prevalence of 9.0% and 8.6% at follow-up for intervention and control groups, 
respectively, p=0.651), though both groups did experience a reduction in smoking 
prevalence. 
Lowensteyn et al. noted the absolute change in number of smokers among those who 
were reassessed between intervention (n=202) and control groups (n=89).  20.8% of 
intervention groups were smokers at baseline; at follow-up, 3 had quit smoking for an 
absolute change of -1.5%.  Comparatively, in the control group, at baseline there were 21 
smokers (23.6%); at follow-up, 2 people had quit smoking (absolute change: -2.3%).  The 
difference in absolute change between intervention and control groups was 0.8% 
(p=0.64).  Though a greater absolute change was noted in the control group, it was 
statistically non-significant. 
Though the Australian Health Check found a decrease in percentage of smokers from 
83% at baseline to 78% at follow-up, the decrease was not significant (p=0.51).  
However, the number of cigarettes smoked per day did decrease significantly (p<0.001), 
from 3.5 (SD 0.1) to 2.6 (SD 0.2) according to smoking categories. 
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Bach Nielsen et al. conducted a qualitative study examining the effect of cardiovascular 
risk scores on lifestyle changes.  Several participants made radical changes, contacting 
dietitians and reorganizing their diets, involving their families and cooking different types 
of food for different family members, and began exercising.  These changes were only to 
the extent that their perceived quality of life wouldn’t suffer, what the authors referred to 
as the “pain limit”.  Others took an active interest in their progress over time, asking their 
general physician for examinations to determine whether their efforts had any effect. 
Courtney et al. reported that patients assessed for risk of diabetes (n=696) as determined 
by the PreDx risk score were more likely to return for a follow-up visit than the control 
group (n=2002).  80% of the risk group (557/696 patients) returned for a visit compared 
to the control group, where 42.7% (800/2002) returned, indicating the intervention 
positively influenced the likelihood of continuity of care. 
Powers et al. reported on three aspects of patient behaviour: self-reported medication 
adherence, current exercise level, and smoking.  They then compared the intervention and 
control arms for between-group differences.  For self-reported medication adherence, at 
baseline, 50% of the intervention arm reported medication adherence compared to 51% 
of the control patients; at 3 months, 46% in the intervention arm compared to 49% in the 
control arm reported medication adherence (p=0.55).  Patients in both arms improved the 
amount of exercise they engaged in (48% to 57% from baseline to follow-up in 
intervention arm, 42% to 53% from baseline to follow-up in the control arm, p=0.77).  
Smoking cessation occurred in the intervention group, decreasing from 18% to 14%, 
while it remained at 18% at both baseline and follow-up in the control arm (p=1.00).  
Overall, no significant differences were noted when comparing self-reported medication 
adherence, current exercise levels, and smoking status between intervention and control 
arms. 
Price et al. monitored physical activities in all participants using a hip-worn 
accelerometer measuring the amount and intensity of human activity.  Though 53% of 
participants increased their physical activity, there was a non-significant net 0.5% (95% 
CI -0.6, 1.8) increase in accelerometer counts in the intervention group (p=0.56). 
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5.4.3  Patient health outcomes 
Fourteen studies explored the impact of prediction models on patient health outcomes.  
Commonly assessed were the impact on biometric, or risk factor, values (n=13) as well as 
on estimated absolute risk of health outcome (n=13).  Specific risk factor values 
evaluated were: systolic blood pressure (n=10), diastolic blood pressure (n=8), HDL 
cholesterol (n=8), total cholesterol (n=7), BMI (n=7), LDL cholesterol (n=6), total 
cholesterol to HDL cholesterol ratio (n=4), HbA1c levels (n=4), weight (n=2), and two 
studies examined blood pressure without specification of diastolic or systolic.  Only three 
studies examined event rates, specifically cardiovascular disease (n=2), coronary heart 
disease (n=2), stroke (n=1), heart failure (n=1), all-cause mortality (n=1), and type 2 
diabetes mellitus (n=1). 
Chang et al. compared to the absolute reduction in cardiovascular risk between the 
intervention group and control group, finding the intervention group (n=29,672) reduced 
their 10-year cardiovascular risk from 6.7% (SD 5.9) to 6.2% (SD 5.3) with a difference 
of -0.48% (95% CI -0.5, -0.46), while the control group (n=109,116) reduced their risk 
from 5.1% (SD 5.3) to 4.9% (SD 5.0), with a difference of -0.19% (95% CI -0.19, -0.18).  
The crude differences-in-differences between the intervention and control group was -
0.29% (95% CI -0.31, -0.27), and after propensity-score matching, was -0.21 (95% CI -
0.24, -0.19). 
Chang et al. also reported on changes in risk factors, namely systolic blood pressure, 
diastolic blood pressure, body mass index, and total cholesterol.  The crude levels of risk 
factors are provided in Appendix E.  After propensity score matching, the following 
reductions in risk factor values comparing the intervention group to the control group 
were found to be significant: systolic blood pressure (-2.51 mm Hg, 95% CI -2.77, -2.25), 
diastolic blood pressure (-1.46, 95% CI -1.62, -1.29), BMI (-0.27, 95% CI -0.34, -0.20), 
and total cholesterol (-0.15 mmol/L, 95% CI -0.18, -0.13). 
Cochrane et al. had two groups: the NHS Health Check group and the NHS Health Check 
plus additional support group.  Baseline and 1-year follow-up measures were collected 
for both trial arms.  Both groups showed similar beneficial reductions in risk factors: 
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about 7 mmHg in systolic blood pressure, 4 mmHg in diastolic blood pressure, 0.65 
mmol/L in total cholesterol, 0.5 in total cholesterol/HDL ratio, and 2 cm in waist 
circumference.  Changes in HDL cholesterol, weight, and BMI were negligible, though a 
small significant reduction in overall BMI was noted (0.3 kg/m2).  Complete figures are 
available in Appendix F. 
Cochrane et al. also noted changes in absolute CVD risk from baseline to 1-year follow-
up (Appendix F).  In the Health Check group, absolute risk was reduced from a mean of 
32.9% (SD 9.7) at baseline (n=365) to 29.4% (SD 9.7) at follow-up (n=295).  In the 
Health Check plus group, absolute risk was reduced from 31.9% on average amongst 236 
participants to 29.2% (SD 10.1) at follow-up (n=191).  This difference corresponds to a 
relative risk of 0.89 (95% CI 0.87, 0.92) amongst the Health Check group, and a relative 
risk of 0.91 (95% CI 0.88, 0.94) amongst the Health Check plus group. 
Courtney et al. found that significantly more risk-tested patients experienced 
improvements in risk factor levels, including weight, blood pressure, LDL-cholesterol, 
HDL-cholesterol, triglycerides, glucose, and HbA1c levels (all differences were 
statistically significant at p<0.001).  The total percentages of patients with improved risk 
factors was not provided. 
Grover et al. (2007) conducted a randomized controlled trial comparing patients receiving 
a risk profile (n=1510 baseline; n= 1344 follow-up) to usual care patients (n=1543 
baseline; n=1343 follow-up).  Changes in risk factor levels from baseline to the 12-month 
follow-up were reported, as well as the difference in changes between intervention and 
control patients.  Intervention patients showed absolute changes of -58.4 mg/dL (SD 
34.1) for total cholesterol, -51.2 mg/dL (SD 29.5) LDL cholesterol, 1.0 mg/dL (SD 6.0) 
HDL cholesterol, -1.5 TC:HDL cholesterol ratio (SD 1.1), -6.3 mmHg (SD 13.5) systolic 
blood pressure, and -3.8 mmHg (SD 7.9) diastolic blood pressure.  Control patients 
showed absolute changes of: -54.5 mg/dL (SD 35.4) total cholesterol, -48.0 mg/dL (SD 
29.7) LDL cholesterol, 0.8 mg/dL (SD 5.7) HDL cholesterol, -1.3 (SD 1.0) TC:HDL 
cholesterol ratio, -5.3 mmHg (SD 13.2) systolic blood pressure, and -3.6 mmHg (SD 7.7) 
diastolic blood pressure.  Difference between the intervention and usual care group were: 
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-3.9 (p=0.02) total cholesterol, -3.3 (p=0.02) LDL cholesterol, 0.2 (p=0.37) HDL 
cholesterol, -0.1 (p=0.002) TC:HDL ratio, -0.9 (p=0.005) systolic blood pressure, and -
0.2 (p=0.01) diastolic blood pressure. 
Grover et al. (2007) also assessed the likelihood of high risk patients in either the 
intervention or control group reaching lipid target levels.  Intervention patients were more 
likely to reach their lipid targets (OR 1.26; 95% CI 1.04, 1.53).  They found that 70% of 
intervention patients were identified as high risk, and 57% reached their lipid targets, 
while 68% of control patients were identified as high risk, and 54% reached their lipid 
targets.  When patients of all risk levels were considered, the intervention group was no 
more likely to reach their target lipid levels than the control group (55.2% versus 52.2%; 
OR 1.13, 95% CI 0.98, 1.30).  For changes in 10-year cardiovascular disease risk, 
intervention patients experienced an absolute change of -5.9% (SD 4.5) while control 
patients experienced an absolute change of -5.3% (SD 4.3), with a difference between the 
two groups of -0.6% (p<0.001), indicating that intervention patients obtained a 
statistically significant reduction in absolute risk when compared to control patients. 
Jiao et al. (2015) assessed for changes in risk factor levels from baseline to the 3-year 
follow-up point between intervention and control groups, including BMI, systolic blood 
pressure, diastolic blood pressure, HbA1c, total cholesterol, both HDL and LDL 
cholesterol, triglyceride levels, and estimated glomerular filtration rates.  Though 
baseline characteristics with comparable between both arms, the intervention group 
experienced significant changes (p<0.001) for both systolic and diastolic pressure, 
HbA1c levels, total cholesterol, and both HDL and LDL cholesterol levels.  Further, a 
greater percentage of intervention patients achieved treatment targets for blood pressure 
and HbA1c levels compared to control patients (p<0.001).  Complete figures are 
available in Appendix G. 
Jiao et al. (2015) also reported the rates of cardiovascular disease, coronary heart disease, 
stroke, heart failure, and all-cause mortality at 36 months in both study arms.  4.39% of 
intervention patients developed CVD compared to 6.69% of control patients; 1.87% 
experienced CHD compared to 3.08% of control patients; 2.25% of intervention patients 
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experienced a stroke compared to 3.40% of control patients; 0.79% of intervention 
patients experienced heart failure compared to 1.37% of control patients; and lastly, all-
cause mortality incidence was 2.22% in the intervention group compared to 6.07% in the 
control group.  Jiao et al. (2015) also constructed a multivariable Cox proportion hazard 
regression model comparing the intervention to the control group, adjusting for 
sociodemographic and clinical characteristics.  The following hazard ratios were 
calculated: CVD (0.629, 95% CI 0.554, 0.715, p<0.001), CHD (0.570, 95% CI 0.470, 
0.691, P<0.001), stroke (0.652, 95% CI 0.546, 0.780, p<0.001), heart failure (0.598, 95% 
CI 0.446, 0.802, p=0.001), and all-cause mortality (0.363, 95% CI 0.308, 0.428, 
p<0.001).  
Jiao et al. (2014) examined the effect of the RAMP-DM from baseline to follow-up in the 
intervention arm of their study compared to the control arm for changes in biomedical 
outcomes, predicted cardiovascular risk, and percent of participants reaching treatment 
targets.  In a fully adjusted model, differences between groups for changes in HbA1c 
levels (p<0.05), diastolic blood pressure (p<0.05), reaching treatment targets for diastolic 
blood pressure (p<0.05), the UKPDS 10-year CHD risk (p<0.05), the UKPDS 10-year 
stroke risk (p<0.01) were found to be significant, with intervention patients experiencing 
greater improvements.  Cardiovascular events found to be significant were observed 
CHD (p<0.001) and total CVD (p=0.003), with RAMP-DM patients experiencing 
significantly fewer events. 
Lowensteyn et al. reported the absolute changes in risk factors and 8-year coronary risk 
from baseline to follow-up in both the intervention arm (n=202) and the control group 
(n=89) amongst patients who were reassessed.  Statistical significance was found for 8-
year coronary risk (difference in absolute change between intervention and control group: 
-1.426%, p<0.01).  Intervention patients compared to control patients also experienced a 
greater absolute change for total cholesterol (-0.49 mmol/L (SD 0.99) versus -0.09 (SD 
0.87); estimated group difference -0.238, p<0.05), LDL-cholesterol (-0.40 (SD 0.87) 
versus -0.01 (SD 0.80); estimated group difference -0.226, p<0.05), and the total-
cholesterol/HDL-cholesterol ratio (-0.6 (SD 1.3) versus -0.2 (SD 1.2); estimated group 
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difference -0.287, p<0.05).  Non-significant changes were found for HDL-cholesterol, 
systolic and diastolic blood pressure, and BMI. 
Palmieri et al. obtained complete data on 5,948 patients (3185 men, 2763 women).  
Amongst the men, 305 (10%) improved their risk factors, shifting from the high- or 
moderate-risk category to the low-risk category.  162 women (6%) shifted from high or 
moderate risk to low risk.  Overall numbers for all participants was not reported. 
Powers et al. reported on changes in systolic and diastolic blood pressure, and changes in 
10-year CHD and stroke risk from baseline to follow-up amongst intervention and control 
groups.  The between-group differences were not significant for any of the changes, 
indicating that the intervention did not have an effect in this study.  The risk estimate for 
CHD was found to have increased at follow-up for both the intervention (25.0% (SD 1.6) 
to 26.9% (SD 1.8)) and control (24.1% (SD 1.5) to 24.6% (SD 1.8)) as well as the risk 
estimate for stroke (intervention: 21.0% (SD 2.3) to 23.3% (SD 2.7); control: 17.9% (SD 
2.3) to 18.0% (SD 2.6)).  Further, diastolic blood pressure was found to have increased at 
follow-up for both groups (intervention: 73.5 mmHg (SD 1.9) to 74.9 mmHg (SD 2.0); 
control: 76.6 mmHg (SD 1.8) to 76.7 mmHg (SD 1.9)).  Only systolic blood pressure 
decreased in both arms (intervention: 128.4 mmHg (SD 2.7) to 128.2 mmHg (SD 2.9); 
control: 126.0 mmHg (SD 2.7) to 125.0 mmHg (SD 2.8)). 
Price et al. also reported on changes in risk factor levels from baseline to follow-up in the 
intervention and control arms.  Non-significant within or between group differences were 
found for weight, blood pressure, HDL cholesterol, triglyceride levels, or estimated 10-
year CVD risk (no values were provided).  However, a net 7% (95% CI -11.7, -3.2, 
p=0.004) decrease in mean LDL-cholesterol was found in the intervention arm. 
Volpe et al. sought to determine the impact of a systematic stroke risk assessment on 
patients with hypertension that are treated (n=6971) and untreated (n=4718).  They 
reported a significant decrease is both systolic and diastolic blood pressure from baseline 
to follow-up in both the treated and untreated patients.  The treated group presented with 
baseline blood pressure (systolic/diastolic) of 150.1/87.4 mmHg and a follow-up of 
136.7/81.0 mmHg, while untreated groups presented with a baseline blood pressure of 
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158.9/93.2 mmHg and a follow-up of 135.6/81.5 mmHg, with both differences highly 
significant (p<0.0001).  Amongst all patients, there was a significant reduction of 13.3% 
in absolute stroke risk score, which the researchers attributed to the reduction in blood 
pressure.  
Wind et al. examined the effect of the UKPDS risk engine on clinical management of 
coronary heart disease in a pre-post study design.  At baseline, patients (n=713) had a 10-
year CHD risk of 18.7% (SD 11.7); at follow-up, the absolute risk increased to 20.1% 
(SD 13.7).  The increase in absolute risk was significant (p<0.05).  Significant decreases 
(p<0.05) were also noted from baseline to follow-up for systolic blood pressure (139.8 
mmHg (SD 17.7) to 138.3 mmHg (SD 16.4)), total cholesterol (4.5 mmol/L (SD 1.0) to 
4.4 mmol/L (SD 1.0)), and BMI (31.1 (SD 5.2) to 30.8 (SD 5.3)).  Nonsignificant 
changes in HbA1C (6.7% (SD 0.8) to 6.6% (SD 0.9)) and HDL cholesterol (1.2 mmol/L 
(SD 0.3) to 1.2 mmol/L (SD 0.3)) were reported as well. 
The IndiGO clinical guidelines as assessed by Bellows et al. was assessed for its impact 
on predicted 5-year risk of heart attack or stroke.  The intervention group experienced a 
reduction in risk from 6.7% at baseline to 5.1% at follow-up, a significant reduction 
compared to the control group, which experienced a reduction from 7.5% to 6.5% 
(p=0.015).  Non-significant reductions in LDL cholesterol and systolic blood pressure 
were also noted, with LDL reductions of 114 to 106 in the intervention group and 114 to 
109 in the control group (p=0.37), and systolic blood pressure reductions from 134 to 125 
in the intervention group and 137 to 131 in the control group (p=0.07).  No units were 
provided for blood pressure or LDL cholesterol levels.  Though numeric values were not 
provided, there were no significant between-group differences in BMI change. 
Burgess et al. examined the impact of prediction models on risk factors for CVD, 
specifically BMI, waist circumference, systolic blood pressure, total and HDL 
cholesterol, ratio of total to HDL cholesterol, and type 2 diabetes.  Reductions from 
baseline to follow-up were significant for waist circumference (n=56; 98.3 cm (SD 1.8) 
to 96.4 cm (SD 1.8), p=0.04), HDL cholesterol (1.01 mmol/L (SD 0.03) to 1.11 mmol/L 
(SD 0.04), p=0.001), and ratio of total to HDL cholesterol (5.7 (SD 0.2) to 5.0 (SD 0.2), 
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p<0.001).  Non-significant changes were reported for BMI (n=56; 27.3 (SD 0.9) to 27.3 
(SD 0.8), p=0.81), systolic blood pressure (128 mmHg (SD 2.6) to 124 mmHg (SD 3.0), 
p=0.2), and total cholesterol (5.5 mmol/L (SD 0.2) to 5.3 mmol/L (SD 0.2), p=0.07).  
Type 2 diabetes status remained constant from baseline to follow-up. 
Further, Burgess et al. assessed difference in absolute 5- and 10-year CVD risk.  They 
first calculated the expected risk at follow-up calculated by modifying only age, and 
compared it to the observed risk.  Expected 5-year risk was 4.6% (0.4), and the observed 
risk was 3.6% (0.4), and the 1.0% (SD 0.4) difference was significant (p<0.001).  
Similarly, the expected 10-year risk was 10.2% (SD 0.8), and the observed risk was 8.2% 
(SD 0.7), with a difference of 2.0% (SD 0.7) was significant (p=0.004). 
5.5 Subgroup 
The subgroup of interest for this systematic review are those determined to be at high risk 
for the predicted health outcome.  Four studies demonstrated the difference in effect 
between low and high risk groups. 
Sorensen et al. compared to the prescription of antiplatelets, lipid-lowering and 
antihypertensive medications between patients at low-risk (<5% 10-year cardiovascular 
mortality risk) with patients at high-risk (≥5% 10-year cardiovascular mortality risk).  
They found that a high risk scores were associated with a 3-fold greater likelihood of 
being prescribed lipid lowering agents (OR 2.9; 95% CI 1.6, 5.5; p<0.0008), an almost 
3.5-fold greater likelihood of being prescribed antihypertensive treatment (OR 3.4; 95% 
CI 1.9, 6.0; p<0.0001), and a 2-fold greater likelihood of being prescribed antiplatelet 
medication (OR 2.3; 95% CI 0.8, 6.6; p=0.14). 
Chang et al. found that absolute risk reduction (-0.54%, 95% CI -0.93, -0.15) for 
participants with high risk (20% or greater) was not significantly greater than those with 
moderate risk (10% to 20%: -0.34%, 95% CI -0.44, -0.24) or low risk (<10%: -0.14%, 
95% CI -0.16, -0.12).   
Vagholkar et al. examined prescription of medications (antihypertensives, lipid-lowering, 
or both), treatment intensification, and treatment reduction between low, moderate, or 
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high risk groups and between intervention and control patients.  Both between- and 
within-group analyses showed no significant differences in the 12-month medication 
proportions and changes in therapy. 
Mehta et al. examined the prescription of both antihypertensive and lipid-lowering 
medications amongst patients at baseline and six month follow-up periods for up to three 
years within the low (<10%), moderate (10-14%) and high risk (≥15%) strata.  
Dispensing rose most sharply in the six month period following baseline and 
implementation of the intervention, and differed between risk strata. 
5.6 Conclusion 
In conclusion, many studies examining the impact of risk prediction model use on 
physician behaviour, patient behaviour, and patient health outcomes found that there 
were some improvements.  The majority of studies identified a significant increase in 
prescription of preventive medications; changes not found to be statistically significant 
may still be clinically relevant.  Several unique outcomes were categorized as patient 
behaviour.  Though some studies identified an effect of prediction model use on patient 
behaviour, overall the outcome was too heterogenous to determine whether or not an 
impact exists.  Lastly, though few studies examined event rates, several identified 
improvements in soft outcomes such as blood pressure or total cholesterol, indicating that 
risk prediction model use may ultimately result in some improvements in patient health 
outcomes.  The following chapter will present the results of the quantitative assessment, 
or the meta-analysis, of the data. 
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Chapter 6 
6.0 Meta-analysis 
In this chapter, the results of the meta-analyses are presented.  Though as a whole, 
numerous forms of model impact were described in the systematic review, only five 
outcomes were found to be meta-analyzable: 1) new prescription with antihypertensive 
medications, 2) new prescription with lipid-lowering medication, 3) smoking cessation, 
4) absolute changes in systolic blood pressure, and 5) absolute changes in diastolic blood 
pressure.  Two main types of data were concluded to be appropriate for meta-analysis: 
dichotomous data, or the number of events and non-events, and continuous data, or 
changes in mean values.  As such, the two summary effect measures calculated for this 
study were summary odds ratios and standardized mean differences.  Studies reporting on 
similar outcomes were combined in a summary effect measure and visually depicted 
using a forest plot.  Lastly, the results of the risk of bias assessment using the Downs and 
Black tool are presented. 
6.1 Results of individual studies 
This systematic review and meta-analysis sought to address what the impact of risk 
prediction models was on: 1) practitioner behaviour, 2) patient behaviour, and 3) patient 
health outcomes.  Upon completion of the systematic review, five outcomes were 
identified as being appropriate for the conduct of a meta-analysis as per the three main 
study objectives.  Changes in practitioner behaviour (defined as prescription of 
antihypertensive or lipid-lowering medications) were found in four studies, patient 
behaviour change (expressed as smoking cessation) was found in four studies, and patient 
health outcomes (defined as changes in blood pressure (both systolic and diastolic)) were 
found in five studies.   
6.2 Physician prescribing patterns 
The meta-analyses for the outcomes of new prescriptions with antihypertensive and lipid-
lowering medications from baseline to follow-up are presented below. 
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6.2.1 New prescriptions with antihypertensives  
Four studies reported the changes in prescription with antihypertensives in patients 
following the use of a prediction model; the information presented in each study is 
displayed in Table 8. 
Table 8.  Reported changes in proportions of patients prescribed with antihypertensive 
medications from baseline to follow-up in both the intervention and control group. 
 Intervention Control 
Author (year) Baseline Follow-up Baseline Follow-up 
Chang (2016) 1424/29672 2938/29672 1964/109116 4801/109116 
Jiao (2015) 6637/9094 7112/8892 6673/9094 6493/8542 
Jiao (2014) 833/1072 871/1072 818/1072 852/1072 
Vagholkar 
(2014) 
136/475 148/475 133/431 148/431 
 
For the purposes of the meta-analysis, the number of events and non-events in both arms 
of the studies were required.  To derive the number of events, the difference between the 
number of patients at follow-up prescribed antihypertensives was subtracted by the 
number of patients prescribed antihypertensives at baseline (Table 9). 
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Table 9.  The calculated number of events (new prescription with an antihypertensive 
medication) from baseline to follow-up in both the intervention and control group. 
 Intervention Control 
Author (year) Follow-up — 
baseline  
Number of 
events 
Follow-up — 
baseline  
Number of 
events 
Chang (2016) 2938 - 1424 1514 4801 – 1964 2837 
Jiao (2015) 7112 - 6637 475 6493 – 6673 -180 
Jiao (2014) 871 - 833 38 852 – 818 34 
Vagholkar 
(2014) 
148 - 136 12 148 – 133 15 
 
The number of non-events was calculated by subtracting the number of total participants 
per treatment arm by the number of events (Table 10).  Of particular note is Jiao et al. 
(2015) where both the intervention and control arms experienced some attrition.  When 
calculating the number of events, the method of calculating the number of events in 
tandem with the loss to follow-up results in a number of -180.  This poses a significant 
problem for the interpretation and analysis of the data; this value would be interpreted as 
180 negative events and not fall within the confines of event or non-event.   
The conduct of a complete case analysis was used to account for attrition as 
recommended by the Cochrane Handbook, ultimately ameliorating the issue of negative 
events.190  The complete case analysis was conducted using the methods proposed by Akl 
et al.224  A complete case analysis seeks to exclude patients for whom data are missing at 
follow-up, therefore only analyzing data from patients with available data, followed by a 
sensitivity analysis using both the best and worst case scenarios where all patients with 
missing data are classified as either events or non-events.  This creates a range of possible 
effect sizes, accounting for the range of uncertainty.  First, the complete case analysis 
will be presented, followed by the worst- and best-case analysis. 
To conduct a complete case analysis, Akl et al. recommends using the following 
equation: 
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𝐸𝑣𝑒𝑛𝑡𝑠
[𝑃𝑎𝑡𝑖𝑒𝑛𝑡𝑠] 𝑟𝑎𝑛𝑑𝑜𝑚𝑖𝑧𝑒𝑑 − [𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠] 𝑤𝑖𝑡ℎ 𝑚𝑖𝑠𝑠𝑖𝑛𝑔 𝑜𝑢𝑡𝑐𝑜𝑚𝑒 𝑑𝑎𝑡𝑎
 
The formula applies to both the intervention and control arm.  To provide a measure of 
events and non-events, attrition was first accounted for.  Firstly, in the intervention arm at 
baseline, approximately 72.98% of patients were prescribed antihypertensive medications 
(6637/9094).  Two hundred and two patients were lost to follow-up.  Assuming non-
differential attrition, this indicates that of the 202 patients lost, 72.98% (~147 patients) 
were those who were prescribed antihypertensive medications, and thus 55 patients were 
not.  Subtracting 147 from the previously stated baseline number (6637) and subtracting 
the full 202 from the denominator (9094), a new prevalence, accounting for attrition, of 
baseline antihypertensive medication prescription is established (6490/8892).  The same 
method of accounting for attrition was used for the control arm, resulting in a new 
prevalence of baseline antihypertensive medication prescription (6268/8542). 
The calculation of events was completed by subtracting the original follow-up count of 
patients prescribed with antihypertensives by the new baseline count of patients 
prescribed.  The number of non-events were calculated by using the denominator of the 
equation as per Akl et al.: 
𝐼𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝑎𝑟𝑚: 
6637 −  6490
9094 − 202
=
147
8892
 
𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑎𝑟𝑚: 
6493 − 6268
9094 − 552
=  
225
8542
 
The values for the denominator represent the total number of participants for whom data 
is complete.  When calculating the number of non-events, this was the value used as the 
number of total participants as per a complete case analysis.  The number of non-events 
for each study is presented below (Table 10). 
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Table 10.  The calculated number of non-events (no new prescription with 
antihypertensive medication) using a complete case analysis for both the intervention and 
control group. 
 Intervention Control 
Author (year) Total number – 
number of 
events 
Number of 
non-events 
Total number – 
number of 
events 
Number of 
non-events 
Chang (2016) 29672 - 1514 28158 109116 – 2837 106279 
Jiao (2015) 8892 – 147 8745 8542 – 225 8317 
Jiao (2014) 1072 – 38 1034 1072 – 34 1038 
Vagholkar 
(2014) 
475 – 12 463 431 – 15 416 
The calculated numbers allow us to establish the number of events and non-events, 
allowing for the conduct of a meta-analysis (Table 11). 
Table 11.  The number of events and non-events for the intervention and control groups 
of the studies eligible for meta-analysis. 
 Intervention Control 
Author (year) Events Non-events Events Non-events 
Chang (2016) 1514 28158 2837 106279 
Jiao (2015) 147 8745 225 8317 
Jiao (2014) 38 1034 34 1038 
Vagholkar 
(2014) 
12 463 15 416 
 
The meta-analysis was conducted using a random-effects model as opposed to a fixed-
effects model to account for the variations in effect size between studies, allowing us to 
account for the heterogeneity when comparing the studies.  A correction factor of 0.5 was 
used to account for any zero values.  Given the discordant odds ratio in Jiao et al. (2015), 
a concurrent sensitivity analysis was also employed allowing us to derive the overall 
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summary effect measure in addition to the summary effect measure excluding Jiao et al. 
(2015).  The results of the meta-analysis are presented below (Figure 3). 
 
Figure 4.  Forest plot depicting the impact of risk prediction models on new prescription 
with antihypertensive medications. 
The overall summary effect indicates that the odds of prescribing are 1.02 times greater 
(95% CI 0.47, 2.22) in the prediction model group.  The confidence interval spans the 
null value (1.0), and thus the effect is considered statistically non-significant. 
6.2.1.1 Sensitivity analysis 
The effect size for Jiao et al. (2015) essentially assumes that all the attrition (in both the 
treatment and control groups) constituted participants who represented non-events.  The 
result of this is striking particularly in the control group, where the assumption of zero 
events leads to an infinite estimated effect size (made finite through smoothing).  As 
recommended by the Cochrane Handbook, a sensitivity analysis was conducted to 
provide a range of values to account for the missing data in using a method referred to as 
the ‘best-case” and “worst-case” scenarios.  The best-case scenario is where all 
intervention patients with missing data are inferred to have experienced the event, and 
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those in the control group with missing data are inferred to not have experienced the 
event.  The inverse would then be labelled the worst-case scenario.  Only one study (Jiao 
et al., 2015) reported attrition.  The calculated events and non-events for both the best- 
and worst-case scenarios are presented below (Table 12).  
Table 12.  The absolute frequencies as per the best- and worst-case scenarios to account 
for attrition and allow for the conduct of sensitivity analyses for Jiao et al. 2015. 
Scenario Group Type of event Absolute frequency 
Best-case 
Intervention 
Events 675 
Non-events 8419 
Control 
Events 0 
Non-events 9094 
Worst-case 
Intervention 
Events 475 
Non-events 8619 
Control 
Events 372 
Non-events 8722 
 
Using the number of events and non-events as per the best- and worst-case scenarios for 
the Jiao et al. (2015) study, we find that the study presents with an odds ratio range from 
1.29 (95% CI 1.12, 1.48) to 1459.31 (95% CI 91.17, 23358.39), and an overall summary 
effect range from 1.34 (95% CI 0.92, 1.94, I2 = 93.0%, p<0.001) to 3.29 (95% CI 0.77, 
14.16, I2 = 96.7%, p<0.001).  Full forest plots are provided in Appendix H. 
6.2.1.2 Subgroup analysis: Antihypertensive medication naïve patients 
The previous analysis assessing the impact of prediction models on new prescription with 
antihypertensive medications was conducted on the entire sample.  It included patients 
for whom the event had already occurred.  A subgroup analysis was conducted to address 
the impact of prediction models amongst antihypertensive medication naïve patients (i.e. 
patients who were not prescribed antihypertensive medications at baseline). 
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The number of events, or new prescription with antihypertensives, remained constant as 
previously derived.  The number of non-events is given by the number of patients 
randomized to the intervention group who are not taking antihypertensives at baseline 
and who do not receive a new prescription.  The number of non-events was calculated by 
first subtracting the total number of participants by those who were taking 
antihypertensive medications at baseline, and then subtracting that figure by the number 
of events.  For example, in Chang et al. (2016), the intervention arm had 29,672 patients, 
1424 patients taking antihypertensives at baseline, and a total number of events of 1514.  
Through simple subtraction, the number of non-events was calculated to be 26734, as 
demonstrated here: 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑛𝑜𝑛 − 𝑒𝑣𝑒𝑛𝑡𝑠: 29672 − 1424 − 1514 = 26734 
To conduct a complete case analysis and account for the loss to follow-up in the Jiao et 
al. (2015) study, the number of non-events was calculated using the modified baseline 
numbers that account for attrition.  The number of non-events was then calculated using 
the same methods used for the other studies, as follows: 
𝑁𝑜𝑛 − 𝑒𝑣𝑒𝑛𝑡𝑠𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛: 8892 − 6490 − 147 = 2255 
𝑁𝑜𝑛 − 𝑒𝑣𝑒𝑛𝑡𝑠𝑐𝑜𝑛𝑡𝑟𝑜𝑙: 8542 − 6268 − 225 =  2049 
Inputting all the values into a table allows us to conduct a subgroup analysis in STATA 
(Table 13).  The results of the meta-analysis are presented in Figure 4. 
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Table 13.  The number of events and non-events from baseline to follow-up in both the 
intervention and control groups amongst patients who were antihypertensive medication 
naïve at baseline. 
 Intervention Control 
Author (year) Events Non-events Events Non-events 
Chang (2016) 1514 26734 2837 104315 
Jiao (2015) 147 2255 225 2049 
Jiao (2014) 38 201 34 220 
Vagholkar 
(2014) 
12 327 15 283 
 
 
Figure 5.  Forest plot depicting the impact of risk prediction models on new prescriptions 
with antihypertensive medications amongst antihypertensive medication naive patients. 
Therefore, amongst patients who were antihypertensive medication naïve, the odds of 
prescription with an antihypertensive medication was 1.03 times greater (95% CI 
0.45,2.35) amongst those who received the intervention than those who did not. 
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6.2.2 New prescriptions with lipid-lowering medications 
The same methods employed in section 6.2.1 were used to derive the number of events 
and non-events for new prescription with lipid-lowering medication.  Four studies were 
determined to be eligible for the conduct of a meta-analysis.  The information presented 
in each article is displayed in Table 14. 
Table 14.  Reported changes in proportion of patients prescribed with lipid-lowering 
medications at baseline and follow-up in both the intervention and control group. 
 Intervention Control 
Author (year) Baseline Follow-up Baseline Follow-up 
Chang (2016) 2878/29672 4540/29672 3383/109116 4691/109116 
Jiao (2015) 1189/9094 4551/8892 1225/9094 3903/8542 
Jiao (2014) 866/1072 935/1072 880/1072 949/1072 
Vagholkar 
(2014) 
101/475 108/475 120/431 130/431 
 
The derived number of events and non-events was calculated in the same manner as in 
section 6.2.1 (“New prescription with antihypertensives”), and the values are presented in 
Table 15, which were subsequently used to conduct the meta-analysis (Figure 5). 
Table 15.  The number of events and non-events for the intervention and control groups 
of the studies eligible for meta-analysis. 
 Intervention Control 
Author (year) Events Non-events Events Non-events 
Chang (2016) 1662 28010 1308 107808 
Jiao (2015) 3388 5504 2752 5790 
Jiao (2014) 69 1003 69 1003 
Vagholkar 
(2014) 
7 468 10 421 
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Figure 6.  Forest plot depicting the impact of risk prediction models on new prescription 
with lipid-lowering medications. 
Therefore, the overall summary effect measure indicates that the odds of new prescription 
with lipid-lowering medications is 1.49 times greater (95% CI 0.58, 3.81) amongst 
patients who received the intervention compared to those that did not. 
6.2.2.1 Sensitivity analysis 
A sensitivity analysis as per the best- and worst-case scenario method was conducted as 
per the figures presented in Table 16. 
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Table 16.  The absolute frequencies as per the best- and worst-case scenarios to account 
for attrition and allow for the conduct of sensitivity analyses for Jiao et al. 2015. 
Scenario Group Type of event Absolute frequency 
Best-case 
Intervention 
Events 3564 
Non-events 5530 
Control 
Events 2678 
Non-events 6416 
Worst-case 
Intervention 
Events 3362 
Non-events 5732 
Control 
Events 3230 
Non-events 5864 
 
Using the number of events and non-events as per the best- and worst-case scenarios for 
the Jiao et al. (2015) study, we find that the study presents with an odds ratio range from 
1.06 (95% CI 1.00, 1.13) to 1.54 (95% CI   1.45, 1.64).  The summary effect range is 
from 1.40 (95% CI 0.48, 4.05, I2 = 99.7%, p<0.001) to 1.58 (95% CI 0.69, 3.63, I2 = 
99.5%, p<0.001).  Full forest plots are provided in Appendix I. 
6.2.2.2 Subgroup analysis 
The subgroup assessed for with regards to lipid-lowering medications was new 
prescriptions with lipid-lowering medications amongst those that are medication naïve.  
The number of events and non-events was calculated similarly to section 6.2.2.  The 
calculated figures are presented below (Table 17).  The results of the corresponding meta-
analysis are presented below (Figure 6). 
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Table 17.  The number of events and non-events from baseline to follow-up in both the 
intervention and control groups amongst patients who were lipid-lowering medication 
naïve at baseline. 
 Intervention Control 
Author (year) Events Non-events Events Non-events 
Chang (2016) 1662 25132 1308 104425 
Jiao (2015) 3388 4341 2752 4639 
Jiao (2014) 69 137 69 123 
Vagholkar 
(2014) 
7 367 10 301 
 
 
Figure 7.  Forest plot depicting the impact of risk prediction models on new prescription 
with lipid-lowering medications amongst medication naive patients. 
Overall, it was found that the odds of new prescription with lipid-lowering medication 
amongst medication naïve patients favoured the intervention (OR 1.45, 95% CI 0.54, 
3.91), though the result was statistically non-significant. 
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6.3 Patient behavioral outcomes 
Though several articles assessed for patient behavioural outcomes as a result of 
prediction model use, including changes in physical activity and diet, or continuity of 
care, there were only a sufficient number of studies to conduct a meta-analysis for 
smoking cessation. 
6.3.1 Smoking cessation 
Four studies reported baseline and follow-up proportions of smokers in both the 
intervention and control groups.  The information presented in the articles is displayed 
below (Table 18). 
Table 18.  Reported changes in proportions of smokers from baseline to follow-up in both 
the intervention and control groups. 
 Intervention Control 
Author (year) Baseline Follow-up Baseline Follow-up 
Chang (2016) 5311/29672 4837/29672 24224/109116 22692/109116 
Jiao (2015) 927/9094 346/8892 906/9094 235/8542 
Lowensteyn 
(1998) 
42/202 39/202 21/89 19/89 
Powers (2011) 8/44 6/44 8/45 8/45 
 
Similar to the previous two outcomes (prescription with antihypertensive and lipid-
lowering medications), the number of events and non-events was calculated.  Events were 
defined as patients who had quit smoking from baseline to follow-up.  The method of 
calculating the number of events differed from the previous two dichotomous outcomes 
in that the event of smoking cessation decreases the number from baseline to follow-up, 
while prescription with antihypertensive or lipid-lowering medications increases the 
number from baseline to follow-up.  Hence, as opposed to the calculation of events used 
previously (follow-up – baseline), the difference from baseline to follow-up was used to 
calculate the number of events (Table 19).  Note that again for Jiao et al. (2015), the 
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baseline numbers were modified to account for attrition, resulting in baseline proportions 
of smokers of 906/8892 in the intervention arm and 851/8542 in the control arm. 
Table 19.  The calculated number of events (i.e. number of patients who quit smoking) 
from baseline to follow-up in both the intervention and control groups. 
 Intervention Control 
Author (year) Baseline – 
follow-up 
Number of 
events 
Baseline – 
follow-up 
Number of 
events 
Chang (2016) 5311 – 4837 474 24224 – 22692 1532 
Jiao (2015) 906 – 346 560 851 – 235 616 
Lowensteyn 
(1998) 
42 – 39 3 21 – 19 2 
Powers (2011) 8 – 6 2 8 – 8 0 
 
Calculating the number of non-events was conducted in the same fashion as in previous 
examples, where the total number of participants was subtracted by the number of events 
(Table 20). 
Table 20.  The calculated number of non-events from baseline to follow-up in both the 
intervention and control groups. 
 Intervention Control 
Author (year) Total number – 
number of 
events 
Number of 
non-events 
Total number – 
number of 
events 
Number of 
non-events 
Chang (2016) 29672 - 474 29198 109116 – 1532 107584 
Jiao (2015) 8892 – 560 8332 8542 – 616  7926 
Lowensteyn 
(1998) 
202 – 3 199 89 – 2  87 
Powers (2011) 44 – 2  42 45 – 0  45 
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Compiling the list of events and non-events for smoking behaviour allows us to conduct a 
meta-analysis (Table 21; Figure 7). 
Table 21.  The number of events and non-events for the intervention and control groups 
of the studies eligible for meta-analysis. 
 Intervention Control 
Author (year) Events Non-events Events Non-events 
Chang (2016) 474 29198 1532 107584 
Jiao (2015) 560 8332 616 7926 
Lowensteyn 
(1998) 
3 199 2 87 
Powers (2011) 2 42 0 45 
 
 
Figure 8.  Forest plot depicting the impact of risk prediction models on smoking 
cessation. 
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Overall, there appeared to be no impact of risk prediction model use on the patient 
behaviour of smoking cessation when examining all participants (OR 1.00, 95% CI 0.77, 
1.29). 
6.3.1.1 Sensitivity analysis 
A sensitivity analysis to provide a range of potential effect values accounting for the 
attrition in Jiao et al. (2015) was conducted using the best- and worst-case scenarios, as 
previously described in section 6.2.1.1.  The values used are presented below (Table 22).   
Table 22.  The absolute frequencies as per the best- and worst-case scenarios to account 
for attrition and allow for the conduct of sensitivity analyses for Jiao et al. 2015. 
Scenario Group Type of event Absolute frequency 
Best-case 
Intervention 
Events 581 
Non-events 8513 
Control 
Events 119 
Non-events 8980 
Worst-case 
Intervention 
Events 379 
Non-events 8715 
Control 
Events 671 
Non-events 8423 
 
Using the numbers of events and non-events as per the best- and worst-case scenarios for 
the Jiao et al. (2015) study, we find that the study presents with an odds ratio range from 
0.55 (95% CI 0.48, 0.62) to 5.15 (95% CI 4.22, 6.29), and an overall summary effect 
range from 0.84 (95% CI 0.43, 1.63, I2 = 96.1%, p<0.001) to 2.04 (95% CI 0.59, 6.97, I2 
= 98.3%, p<0.001).  Full forest plots are provided in Appendix J. 
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6.3.1.2 Subgroup analysis: Smoking cessation amongst smokers 
The number of non-events in the previous section includes non-smoking patients, 
allowing us to estimate the impact of prediction models on smoking behaviour in the 
population.  To garner a sense of the impact of prediction models on smoking cessation 
amongst smokers, a subgroup analysis was conducted.  Similar to the previous subgroup 
analyses, the number of events remained constant, while the number of non-events 
excluded non-smokers.  The completed number of events and non-events is presented 
below (Table 23).  The results of the meta-analysis are presented in Figure 8. 
Table 23.  The number of events and non-events from baseline to follow-up in both the 
intervention and control groups amongst patients who were smokers at baseline. 
 Intervention Control 
Author (year) Events Non-events Events Non-events 
Chang (2016) 474 4837 1532 22692 
Jiao (2015) 560 346 616 235 
Lowensteyn 
(1998) 
3 39 2 19 
Powers (2011) 2 6 0 8 
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Figure 9.  Forest plot depicting the impact of risk prediction models on smoking cessation 
amongst smokers. 
 
When examining smokers, there appears to be no impact of risk prediction model use on 
smoking cessation (OR 1.01, 95% CI 0.46, 2.18). 
6.4 Changes in systolic blood pressure 
Four studies identified through the systematic review process assessing the impact of 
prediction models on changes in systolic blood pressure were identified as being 
appropriate for a meta-analysis.  Table 24 displays the information presented in each 
article. 
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Table 24.  The reported changes in systolic blood pressure from baseline to follow-up in 
both the intervention and control groups.  Mean and absolute change values are presented 
in mmHg; parenthesized values are the reported standard deviations. 
 Intervention Control 
Author 
(Year) 
Sample 
size 
Baseline 
mean 
Follow-
up 
mean 
Absolute 
change 
Sample 
size 
Baseline 
mean 
Follow-
up 
mean 
Absolute 
change 
Chang 
(2016) 
29672 131.9 
(17.4) 
130.0 
(12.7) 
NA 109116 128.5 
(13.6) 
129.3 
(11.3) 
NA 
Jiao (2015) 9094 135.41 
(17.05) 
130.12 
(14.68) 
NA 9094 135.45 
(16.56) 
132.35 
(15.51) 
NA 
Lowensteyn 
(1998) 
202 133.0 
(15.8) 
NA -2.0 
(14.2) 
89 129.2 
(15.5) 
NA -1.2 
(14.1) 
Powers 
(2011) 
44 128.4 
(2.7) 
128.2 
(2.9) 
NA 45 126.0 
(2.7) 
125.0 
(2.8) 
NA 
 
Three of the four studies did not report the absolute change in SBP from baseline to 
follow-up.  The sample mean difference (D), otherwise referred to as the absolute change, 
was calculated by subtracting the baseline mean (?̅?1) by the follow-up mean (?̅?2) in 
studies where only the baseline and follow-up means were provided.  Using the equation:  
𝐷 =  ?̅?1 −  ?̅?2, 
the absolute change in SBP was calculated for both the intervention and control groups 
(Table 25). 
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Table 25.  The calculation of absolute change in systolic blood pressure from baseline to 
follow-up in both the intervention and control groups. 
 Intervention Control 
Author (year) ?̅?1 −  ?̅?2 Absolute 
change 
?̅?1 −  ?̅?2 Absolute 
change 
Chang (2016) 131.9 – 130.0 1.9 128.5 – 129.3 -0.8 
Jiao (2015) 135.41 – 
130.12 
5.29 135.45 – 
132.35 
3.1 
Powers (2011) 128.4 – 128.2 0.2 126.0 – 125.0 1.0 
 
In order to calculate the standard deviation of the difference, the following equation as 
per Borenstein et al. was applied: 
𝑆𝑑𝑖𝑓𝑓 =  √𝑆1
2 + 𝑆2
2 − 2 × 𝑟 × 𝑆1 × 𝑆2   .
194 
The correlation coefficient, r, was not provided.  Using the Cochrane Handbook for 
Systematic Reviews of Interventions, r was imputed based on the absolute change for 
SBP and DBP as calculated by Lowensteyn et al. based on the equation: 
𝑟 =  
𝑆𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
2 + 𝑆𝑓𝑖𝑛𝑎𝑙
2 − 𝑆𝑐ℎ𝑎𝑛𝑔𝑒
2
2 × 𝑆𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒  × 𝑆𝑓𝑖𝑛𝑎𝑙
 . 190,213 
The article by Lowensteyn et al. only provided the standard deviation S for the baseline 
SBP and the absolute change.  However, as per the Cochrane Handbook, “Where either 
the baseline or final standard deviation is unavailable, then it may be substituted by the 
other, provided it is reasonable to assume that the intervention does not alter the 
variability of the outcome measure”  (p. 487).190  Therefore, the final SBP standard 
deviation was substituted by the baseline standard deviation.  Thus, the correlation 
coefficient values for the intervention and control groups were calculated as follows: 
𝑟𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 =  
15.82 +  15.82 −   14.22
2 ×15.8 ×15.8
 ~ 0.60  
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𝑟𝑐𝑜𝑛𝑡𝑟𝑜𝑙 =  
15.52 +  15.52 − 14.12
2 ×15.5 ×15.5
 ~ 0.59 
Because the correlation coefficient values are greater than 0.5, it is indicated that 
assessing the change score from baseline to follow-up provides greater value and 
precision than analyzing the final values of blood pressure.  The calculated r was imputed 
to calculate the standard deviation of the absolute change in SBP for the additional three 
studies (Table 26). 
Table 26.  The calculated standard deviation of the absolute change in systolic blood 
pressure from baseline to follow-up in both the intervention and control groups using the 
imputed correlation coefficient values derived from Lowensteyn et al. 
 Intervention Control 
Autho
r 
(year) 
√𝑆1
2 +  𝑆2
2 − 2 × 𝑟 × 𝑆1 × 𝑆2   
𝑆𝑑𝑖𝑓𝑓 √𝑆1
2 +  𝑆2
2 − 2 × 𝑟 × 𝑆1 × 𝑆2   
𝑆𝑑𝑖𝑓𝑓 
Chang 
(2016) 
√17.42 +  12.72 − 2 × 0.6 ×17.4 ×12.7 14.1
0 
√13.62 + 11.32 − 2 ×0.59 ×13.6 ×11.4 11.3
9 
Jiao 
(2015) 
√17.052 +  14.682 − 2 ×0.6 ×17.05 ×12.7 15.7
0 
√16.562 +  15.512 − 2 ×0.59 ×16.56 ×15.51 14.5
5 
Power
s 
(2011) 
√2.72 +  2.92 − 2 ×0.6 ×2.7 ×2.9 2.51 √2.72 + 2.82 − 2 ×0.59 ×2.7 ×2.8 2.49 
 
Completing the initial table (Table 27) provides the data necessary required to conduct a 
meta-analysis comparing the mean difference in systolic blood pressure from baseline to 
follow-up between the intervention and control groups (Figure 9). 
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Table 27.  The absolute change values in standard deviation (mmHg) and associated 
standard deviations for both the intervention and control groups. 
 Intervention Control 
Author 
(Year) 
Sample 
size 
Absolute 
change 
Standard 
deviation 
Sample 
size 
Absolute 
change 
Standard 
deviation 
Chang 
(2016) 
29672 -1.9 14.10 109116 0.8 11.39 
Jiao (2015) 9094 -5.29 15.70 9094 -3.1 14.55 
Lowensteyn 
(1998) 
202 -2.0  14.20 89 -1.2  14.10 
Powers 
(2011) 
44 -0.2 2.51 45 -1.0 2.49 
 
 
Figure 10.  Forest plot depicting the impact of risk prediction models on absolute changes 
in systolic blood pressure. 
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The forest plot indicates that overall, the absolute change of systolic blood pressure is 
0.16 mmHg (95% CI -0.24, -0.08) lower in patients who receive the intervention 
compared to those who do not. 
6.5 Changes in diastolic blood pressure 
Similarly, four studies were identified that were considered to be appropriate for meta-
analysis for changes in diastolic blood pressure (DBP).  Table 28 presents the information 
provided in each of these four studies. 
Table 28.  The reported changes in diastolic blood pressure from baseline to follow-up in 
both the intervention and control groups.  Mean and absolute change values are presented 
in mmHg; parenthesized values are the reported standard deviations. 
 Intervention Control 
Author 
(Year) 
Sample 
size 
Baseline 
mean 
Follow-
up 
mean 
Absolute 
change 
Sample 
size 
Baseline 
mean 
Follow-
up 
mean 
Absolute 
change 
Chang 
(2016) 
29672 80.2 
(10.5) 
78.5 
(7.7) 
NA 109116 78.7 
(8.2) 
78.7 
(6.7) 
NA 
Jiao (2015) 9094 75.11 
(10.34) 
71.6 
(10.26) 
NA 9094 75.08 
(9.77) 
73.23 
(9.72) 
NA 
Lowensteyn 
(1998) 
202 82.3 
(10.2) 
NA 0.9 (8.1) 89 79.8 
(11.2) 
NA -0.1 
(9.8) 
Powers 
(2011) 
44 73.5 
(1.9) 
74.9 
(2.0) 
NA 45 76.6 
(1.8) 
76.7 
(1.9) 
NA 
 
The absolute change in DBP was calculated for the three articles that did not present 
them using the formula as presented in section 6.4 (Table 29). 
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Table 29.  The calculation of absolute change in diastolic blood pressure from baseline to 
follow-up in both the intervention and control groups. 
 Intervention Control 
Author (year) ?̅?1 −  ?̅?2 Absolute 
change 
?̅?1 −  ?̅?2 Absolute 
change 
Chang (2016) 80.2 – 78.5 1.7 78.7 – 78.7 0 
Jiao (2015) 75.11 – 71.6 3.51 75.08 – 73.23 1.85 
Powers (2011) 73.5 – 74.9 -1.4 76.6 – 76.7 -0.1 
 
The correlation coefficient (r) was calculated for both the intervention and control group 
using the data presented by Lowensteyn et al., and imputed to calculate the standard 
deviation of the mean difference (Table 30). 
𝑟𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 =  
10.22 +  10.22 −  8.12
2 ×10.2 ×10.2
 ~ 0.68 
𝑟𝑐𝑜𝑛𝑡𝑟𝑜𝑙 =  
11.22 +  11.22 −  9.82
2 ×11.2 ×11.2
 ~ 0.62 
Table 30.  Calculation of the standard deviation of the change in diastolic blood pressure. 
 Intervention Control 
Author 
(year) √𝑆1
2 + 𝑆2
2 − 2 × 𝑟 × 𝑆1 × 𝑆2   
𝑆𝑑𝑖𝑓𝑓  √𝑆1
2 + 𝑆2
2 − 2 × 𝑟 × 𝑆1 × 𝑆2   
𝑆𝑑𝑖𝑓𝑓  
Chang 
(2016) 
√10.52 +  7.72 − 2 × 0.68 ×10.5 ×7.7 7.72 √8.22 +  6.72 − 2 ×0.62 ×8.2 ×6.7 6.12 
Jiao 
(2015) 
√10.342 +  10.262 − 2 ×0.68 ×10.34 ×10.26 8.24 √9.772 +  9.722 − 2 ×0.62 ×9.77 ×9.72 7.80 
Powers 
(2011) 
√1.92 +  2.02 − 2 ×0.68 ×1.9 ×2.0 1.56 √1.82 +  1.92 − 2 ×0.62 ×1.8 ×1.9 1.48 
Again, given that r exceeds 0.5, we proceeded to conduct the meta-analysis (Figure 10) 
based on the absolute change in diastolic blood pressure using the figures provided in 
Table 31. 
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Table 31.  The calculated absolute changes in diastolic blood pressure and associated 
standard deviations and sample sizes for both the intervention and control groups. 
 Intervention Control 
Author 
(Year) 
Sample 
size 
Absolute 
change 
Standard 
deviation 
Sample 
size 
Absolute 
change 
Standard 
deviation 
Chang 
(2016) 
29672 1.7 7.72 109116 0.0 6.12 
Jiao (2015) 9094 3.51 8.24 9094 1.85 7.80 
Lowensteyn 
(1998) 
202  0.9 8.1 89 -0.1 9.8 
Powers 
(2011) 
44 -1.4 1.56 45 -0.1 1.48 
 
 
Figure 11.  Forest plot depicting the impact of risk prediction models on absolute changes 
in diastolic blood pressure. 
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The summary effect measure indicates that patients who receive the intervention 
experience a 0.18 mmHg (95% CI 0.10, 0.27) greater increase in diastolic blood pressure 
compared to those who did not. 
6.6 Conclusion 
The results of the meta-analysis found that risk prediction model use favourably impacts 
practitioner behaviour, specifically prescription of antihypertensive and lipid-lowering 
medications, though neither effect was statistically significant.  There appeared to be no 
impact of prediction model use on the patient behaviour of smoking cessation.  Lastly, 
though intervention patients did experience a slight increase in diastolic blood pressure 
when compared to control patients, there was a small improvement in the patient health 
outcome of systolic blood pressure, with intervention patients experiencing a statistically 
significant greater reduction in systolic blood pressure. 
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Chapter 7 
7.0 Discussion 
The use of risk prediction models in primary care settings provides an objective, 
evidence-based estimate of a patient’s absolute risk of having (diagnostic) or developing 
(prognostic) an outcome.  Though not intended to replace a physician’s clinical judgment, 
they have the potential to complement the clinical decision-making process.  Their 
incorporation in numerous guidelines indicates a growing movement towards using risk 
prediction models in routine clinical practice.  However, the evidence regarding their 
impact is sparse and dispersed. 
This study sought to collect, collate, and present evidence regarding the impact of chronic 
disease risk prediction model use in primary care settings on both patient and physician 
behaviour, and patient health outcomes.  Few studies have attempted to define the impact 
of risk prediction models and the literature remains sparse regarding their effects, 
necessitating a need for an objective, comprehensive systematic review and meta-analysis 
to compile the presently available evidence.  Through a systematic search of the 
literature, a narrative summary of the results, and where possible, a meta-analysis of 
changes in behavioral and health outcomes, the present evidence regarding the impact of 
risk prediction models is presented, forming a foundation from which future studies 
examining the impact of prediction models may be conducted. 
As far as it is known, this is one of the first systematic reviews and the first meta-analysis 
addressing the impact of risk prediction model use in primary care settings.  Previous 
systematic reviews have focused primarily on the development and validation of existing 
models for single health outcomes.  For example, Damen et al. sought to provide an 
overview of existing risk prediction models for CVD.24  Another systematic review 
examined the existing models for melanoma incidence, reporting what the possible risk 
factors were as well as measures of model performance, such as sensitivity and 
specificity.225  Of the limited number of studies that have addressed the potential impact 
of model use, assessments of impact were often conducted secondary to assessments of 
development or validation.226,227  Further, no studies were identified that have attempted 
103 
 
to conduct a meta-analysis for clinically relevant outcomes associated with model use in 
primary care settings.33  By providing an overview of all identified studies examining the 
impact of risk prediction models, this systematic review has helped to address this gap in 
the literature. 
This chapter summarizes the results obtained from the systematic review and meta-
analysis, discussing possible reasons for any existent or non-existent effects.  The 
strengths and limitations will also be discussed, and where possible, methods for 
overcoming any limitations will be explored.  Lastly, suggestions and guidance for future 
exploration in this area will be explored. 
7.1 Overview of study results 
There have been few studies that have examined the impact of risk prediction models in 
primary care settings for chronic diseases.  Though the initial systematic search identified 
well over 8,000 articles, only 22 studies met the eligibility criteria for this review.  Not all 
the included studies reported on each of the three primary outcomes; most frequently, the 
impact was assessed for patient health outcomes (77%), followed by physician behaviour 
(68%) and lastly patient behaviour (50%). 
Generally, the evidence does not strongly support the use of risk prediction models for 
the primary prevention of chronic disease.  Physician behaviour appeared to be most 
strongly affected, with the majority of included studies experiencing some increases in 
prescription of preventive medications, though the effect becomes non-significant when 
meta-analyzed.  Risk-reducing patient behaviours were the least affected by prediction 
model use, with few studies indicating a significant effect on changes in physical activity 
or smoking cessation, and the effect tending towards the null when combined.  Lastly, 
overall event rates for cardiovascular- or diabetes-related health outcomes were only 
reported in a limited number of study.  Though generally it appeared that recipients of the 
prediction model experienced fewer events, the study samples were highly homogenous, 
reducing the generalizability of the finding.  When examining proxy measures for health 
outcomes, such as levels of risk factors, though a statistically significant effect was noted 
for changes in blood pressure (both systolic and diastolic), these results may not have 
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clinical significance given their small magnitude.  The meta-analyses did demonstrate I2 
values ranging from 77.2% to 99.6%, indicating a higher degree of inconsistency of study 
findings across studies, suggesting heterogeneity between studies.  Section 5.3.3 lists the 
variations in intervention used; though each study used the risk prediction model as a 
main component of their intervention, some provided relative measures of risk in addition 
to the absolute measure, the format of risk presentation varied, while others still in a more 
directive approach provided lifestyle consultations with other healthcare providers.  
Given the possibility of bias and the heterogeneity present in the meta-analysis, these 
findings should be interpreted with caution. 
7.2 Physician behaviour  
Risk prediction models are intended to ultimately improve the health of patients, a goal 
that is achieved, at least in part, through modification of the providers’ behaviour.  The 
prescription of preventive medications, a form of physician behaviour, is indicated for 
patients at high risk of disease as they may reduce the patients’ absolute risks.  The 
results of this study indicate there may be some changes in physician prescribing patterns.  
Eleven studies reported the impact of prediction model use on an aspect of physician 
behaviour, largely changes in prescription patterns.  A meta-analysis was only considered 
appropriate for changes in two medications, namely antihypertensives and lipid-lowering 
medications.  It was found through the meta-analysis that physicians who used a risk 
assessment tool were more likely to prescribe these medications, though these changes 
were not statistically significant (Figure 3 and Figure 5).  However, the impact of model 
use on prescribing patterns may still be clinically relevant. 
The meta-analysis may have been prone to issues of representativeness; though changes 
in prescription were identified in nine and ten studies for antihypertensives and lipid-
lowering medications respectively, less than half reported data appropriate for a meta-
analysis.  Indeed, through simple vote counting, increases in antihypertensive 
prescription were found to be statistically significant in five studies (55.6%), while 
increases in lipid-lowering medication prescription were found to be significant in six 
studies (60%).  Further, an effect in favour of prediction model use, though not 
significant, was noted in three additional studies for antihypertensive prescriptions and 
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four additional studies for lipid-lowering medications.  If all the identified studies had 
data reported allowing for their incorporation in the meta-analysis, it is possible that that 
a significant change may have been obtained.  As it stands, this indicates that the meta-
analysis may have been underpowered to detect a significant change in favour of new 
prescription with preventive medications, and the inclusion of additional studies may lend 
credence to the belief that risk prediction models positively influence physician 
behaviour. 
The event rates to calculate measures of effect were in many cases extrapolated and may 
not have been entirely accurate.  For example, several participants were already 
prescribed antihypertensive medications at baseline.  The number of events was 
calculated by subtracting the counts of persons prescribed medication at follow-up by 
those prescribed at baseline, which may be problematic.  For example, if one patient were 
de-prescribed and two new patients were prescribed during the follow-up period, the 
arithmetic would conclude that only one new prescription was given, when in reality, two 
were.  Though an unlikely scenario, given the nature of a secondary analysis, it is 
difficult without the original data to ensure that all prescriptions were amongst new 
participants.  Further, though an available case analysis was used to account for attrition 
in the meta-analysis, again, without the original data, assumptions were made to estimate 
the number of events and non-events, namely that the participants that were lost to 
follow-up did not differ from those that remained in the study.  Despite this potential 
limitation, without the original data, this remains the most appropriate method to account 
for attrition and calculate the number of events. 
This thesis defined physician behaviour primarily as changes in preventive medications, 
such as antihypertensive or lipid-lowering medications.  This was inherently flawed an 
increase in prescription in and of itself does not necessarily indicate an improvement in 
clinical patterns.  Indeed, a more useful measure of improvements in physician behaviour 
may have been quantified as the appropriate prescription with preventive medications, 
where medications are given in accordance to clinical guidelines or thresholds of risk.  
However, there is evidence to suggest preventive medications for chronic diseases are 
underutilized where recommended.228,229,230  Given that preventive medications are 
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under-prescribed, any increases in their prescription may be viewed as beneficial.  For 
greater accuracy in terms of benefits of model use, future studies should draw attention to 
the appropriateness of prescription with preventive medications rather than adopting an 
all-encompassing approach. 
7.3 Patient behaviour 
Patient behaviour outcomes were found to be the most variably examined in model 
impact analysis studies, with measures used inconsistently across studies.  The most 
common aspect of patient behaviour assessed in this review was smoking cessation, 
examined in eight studies and most consistently defined, especially when compared to the 
next most common measure, physical activity, which was assessed in four studies and 
measured in four different ways.  The impact of risk prediction models on these two areas 
of patient behaviour remains inconclusive.  Though some changes in physical activity 
were noted at the individual study level, it was difficult if not impossible to determine if 
an effect existed at the review level.  Interestingly, though there exists no impact of risk 
prediction models on smoking cessation in the meta-analysis, at the individual study 
level, several studies found decreases in smoking prevalence, indicating that there may be 
an effect but the meta-analysis was underpowered to detect a change.  Overall, the 
evidence does not support that model use has an impact on patient behaviour, but given 
some effects noted at the study level, this relationship warrants further investigation to 
more quantitatively and accurately to be determined.   
Though there are several health-related behaviours that patients may initiate to reduce 
their risk of chronic disease, no evidence of impact for risk prediction model use was 
found on patient behaviour.  This relationship, or rather lack thereof, may be 
understandable.  One study examined the clustering of five health-related behaviours (not 
smoking, engaging in physical activity, consuming no to moderate amounts of alcohol, 
maintaining normal body weight, and obtaining daily sufficient sleep), finding that 
amongst US adults, only 6.3% of participants engaged in all of the behaviours, with 
variations of prevalence for each behaviour.231  The researchers proposed that the five 
behaviours were not equal in health consequence or in terms of amenability to 
intervention, indicating a multifaceted approach through several avenues is necessary to 
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positively affect changes in individual behaviour.231  Though several studies included in 
this review incorporated aspects of lifestyle advice in the intervention (section 5.2.3), the 
scope of the advice was limited in terms of content and modes of delivery; some only 
provided a leaflet of information, while only three included verbal consultations with 
health care professionals.  The limited nature of lifestyle intervention may explain, at 
least in part, why health-related patient behaviours were not found to be affected by 
prediction model use. 
Further, the present body of research assumes equivalence regarding patient perception of 
risk, though this is not necessarily the case.  For example, the acceptable risk of nuclear 
meltdown through the lens of the public, or the risk at which no further safety 
improvements are deemed necessary, is often considered to be approximately one in a 
million.232  However, this level of acceptable risk is derived from risk perceptions, which 
encompass not just the probability of the outcome but also the magnitude of harms, the 
latter which may differ greatly from person to person, affecting individual levels of 
acceptable risk.233  Depending on the patient and the physician’s level of numeracy, the 
interpretation of risk may also vary and affect behavioural outcomes.234  Applied to risk 
prediction models and measures of absolute risk, the acceptable, or tolerable, risk may 
differ from person to person, with a spectrum of associated behavioural responses 
ranging from apathy to anxiety with regards to preventive measures, providing a possible 
explanation for the consequent patient behaviours found in this study.  
7.4 Patient health outcomes 
One of the primary outcomes of interest of this systematic review and meta-analysis was 
to assess the impact of risk prediction models on patient health outcomes.  The definition 
of patient health outcomes was intentionally left broad to provide a full spectrum of 
possible outcomes, from hard outcomes, such as incidence of stroke, to proxies for health 
outcomes or soft outcomes, such as changes in systolic blood pressure.  The studies 
included in this review focused primarily on changes in absolute risk and changes in risk 
factor levels.  At the individual study level, there was a lack of consistency in terms of 
the findings.  For example, though risk prediction model use is expected to improve a 
patient’s absolute risk of experiencing a chronic disease, decreases in absolute risk were 
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found in fewer than half the included studies.  This trend of uncertainty was consistent 
across most reported health outcomes, including changes in blood pressure or cholesterol 
levels. 
Several of the studies identified in the systematic review were not considered meta-
analyzable given the inconsistency in data reporting.  Only two soft outcomes were meta-
analyzable: changes in systolic and diastolic blood pressure.  The results of the meta-
analysis indicate that there is a small but significant decrease in systolic blood pressure.  
Our results suggest that risk prediction models may have an impact on reducing systolic 
blood pressure amongst patients, though caution must be used when generalizing the 
results due to concerns of representativeness, heterogeneity, and the small magnitude of 
effect; the small decrease in systolic blood pressure may not have any effect on the 
patient’s absolute risk of disease.  Interestingly, in terms of diastolic blood pressure, a 
significant increase was found.  Though this may appear to be contradictory given that 
model use should, theoretically speaking, result in a decrease in diastolic blood pressure, 
again, this effect should be interpreted cautiously as once again, there exists the potential 
for unrepresentativeness and the small magnitude of effect may have no impact on 
absolute risk.  In other words, though the changes in blood pressure were statistically 
significant, given their small magnitude, they may not be clinically significant. 
The inconsistency of evidence may be attributed to a few key factors.  The pathway from 
risk prediction model use to changes in patient health outcomes requires changes in 
behaviour, both physician and patient.  Preventive interventions may be enacted by the 
physician, such as the prescription with preventive medications, with patients making the 
necessary corresponding changes in health-related behaviours, such as adhering to the 
medication schedule, but without the health-related behavioural modifications, the impact 
of model use on health outcomes may be muted.  Further, the studies included varied in 
terms of follow-up periods, possibly not allowing enough time for changes to be noted or 
at least providing some explanation for heterogeneity in terms of the magnitude of 
change.  Given the novelty of impact analysis studies, future research in the area would 
benefit from quantifying the impact of model use on behavioural modifications and 
adopting a consistent length of follow-up period of sufficient time. 
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Most studies reporting on changes in risk factor values reported baseline and follow-up 
values without a measure of change.  In many circumstances, analyses conducted on the 
follow-up values can provide a measure of effect assuming that at baseline, both the 
intervention and control group are equivalent, and therefore, any differences at follow-up 
are a measure of treatment effect.  However, this does not allow us to examine the 
magnitude of impact.  In other words, by providing the baseline and follow-up values, the 
researchers seek to resolve whether there is any effect of intervention use; by calculating 
the absolute change from baseline to follow-up, the researchers would be resolving a 
different question, namely how large is the impact of risk prediction models?  Though the 
two purposes may differ, by only assessing for significant changes in follow-up values, 
the assumption is that values are the same at baseline, an assumption which may be void 
in some cases.  A measure of statistical “sameness” does not indicate that the values at 
baseline are identical, but rather that they are similar.  A more accurate measure of effect 
would be to determine whether the absolute change in the intervention and control arm 
differs, allowing readers to more meaningfully determine if an impact exists, and if so, 
whether the magnitude is of clinical significance. 
7.5 Strengths 
There exists a growing movement towards using risk prediction models in clinical 
settings as indicated by the incorporation of prediction models in several guidelines 
internationally.  However, there exists a lack of evidence regarding the potential 
impact(s) of the models on clinical practice and on patient health outcomes.  This 
strongly indicates that research is required in this field, a need that has been expressed by 
several researchers.  This study is among the first systematic reviews to extensively 
examine the literature for studies investigating the impact of chronic disease risk 
prediction models.  This is also the first meta-analysis to quantify the impact of model 
use on physician behaviour, patient behaviour, and patient health outcomes.  As such, this 
study sought to provide the strongest level of evidence examining the impact of model 
use. 
Though previously conducted systematic reviews have focused specifically on 
cardiovascular diseases, our eligibility criteria allowed us to expand our scope to include 
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other chronic diseases, providing a more holistic perspective of the impact of prediction 
models.  Though this study may have identified studies assessing primarily the impact of 
cardiovascular risk prediction models, this review has identified the need for impact 
analysis studies of models predictive of other chronic diseases.  The Gail model, for 
example, was developed in 1989, and yet no studies assessing for its impact on breast 
cancer risk were identified, despite almost 30 years since its inception.26  In identifying 
this gap in the literature, future studies may be conducted to further expand the scope of 
the literature and provide insights regarding model impact for chronic diseases presently 
unexamined. 
7.6 Limitations 
There exists the possibility that not all the literature pertaining to model impact was 
identified.  This may be attributable to the lack of database specific terms for concepts 
such as ‘risk prediction models’.  Further, though the WHO categorizations of chronic 
diseases encompass approximately 80% of presently prevalent chronic diseases, not all 
diseases are captured within the categories of cardiovascular diseases, diabetes, cancers, 
and chronic respiratory diseases.  To ameliorate this potential limitation, the search 
strategy was completed in consultation with a research librarian to help ensure its 
comprehensiveness.  The existence of a MeSH term for the concept of risk prediction 
models would enable a more directed, comprehensive search within this field, allowing 
for the identification of a greater number of studies.    
The outcomes examined in this systematic review may also present some concerns, 
specifically the outcome of patient behaviour.  Though it has been characterized in 
existing studies through behaviours or actions such as smoking cessation or changes in 
physical activity, one possible area that should be emphasized that exists on the pathway 
from medication prescription to health outcome is medication accessibility and 
subsequent medication adherence.  For example, antihypertensive medications may 
reduce a patient’s risk of stroke by almost 40% through reductions in in systolic and 
diastolic blood pressure (by 10-12 mmHg and 5-6 mmHg, respectively).235  These 
decreases are possible only if patients are taking the medications as prescribed.  Measures 
of medication accessibility and adherence would provide a strong measure of patient 
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behaviour, but also provide some explanation for any changes or lack thereof for patient 
health outcomes. 
This review may also have been prone to some biases.  The risk of bias summary (Figure 
11) indicates that this study may have been prone to biases in terms of confounding and 
external validity, and was potentially statistically underpowered.  This study may also 
have been susceptible to publication bias.  Publication bias occurs in a systematic review 
when studies that fulfill the eligibility criteria are not identified because they have not 
been published, resulting in a biased perspective of the literature.190,236  Further, an 
assessment of publication bias was not possible as there were an insufficient number of 
studies to conduct a formal assessments as per the Cochrane Handbook.190  Other biases 
may have been introduced during the conduct of the meta-analyses as well.  For example, 
though 10 studies reported the impact of model use on systolic blood pressure, only 4 
were included in the meta-analysis, which could introduce bias if these 4 studies are not 
representative of the entire evidence base.236  Though measures to reduce the risk of 
biases were enacted, such as grey literature searches and having multiple reviewers, the 
potential for bias still exists.  
Variations in terms of study conduct may pose as issues of heterogeneity.  For example, 
nearly half of all studies in this review provided lifestyle advice in addition to the 
patient’s absolute risk of developing disease.  Additional studies also provided referrals 
to other healthcare providers, and in some cases, provided multiple training opportunities 
to physicians regarding model use and intent.  Because of these additional intervention 
components, it becomes difficult to discern with certainty to what extent the effect is a 
result of model use.  Risk presentation also varied between studies, with some studies 
providing absolute risk in paper format, with others communicating risk verbally or 
through use of a computer- or tablet-based platform.  Further, in some studies, relative 
measures of risk were provided in addition to the absolute measures, potentially 
influencing both the physician and patient response to risk.  Differences in length of 
follow-up may also account for variations in changes in risk factor levels.  Indeed, Price 
et al. followed their patients for one month, while the period of follow-up for Jiao et al. 
(2015) was three years.  The combination of these two studies, hypothetically, indicates 
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that the magnitude of effect remains constant across the period of follow-up, a potentially 
unfair assumption.  Given the sparsity of model impact studies, all identified studies that 
met the eligibility criteria were included.  As the field develops, however, additional 
criteria may be applied to future systematic reviews to reduce the risks associated with 
study heterogeneity. 
7.7 Implications for future research and practice 
This systematic review and meta-analysis was most limited by the heterogeneity of 
studies.  Inspection of the I2 values for the meta-analyses indicates the analyses and thus 
the variation across studies was due to heterogeneity, not chance.  To strengthen the body 
of literature, there is a strong need for consistent, overarching guidance of the appropriate 
conduct for impact analysis studies.  The Cochrane Collaboration Prognosis Reviews 
Methods Group was formed to evaluate the growing body of literature pertaining to 
prediction models, and the group developed the CHARMS checklist, a critical appraisal 
and data extraction checklist for systematic reviews of prediction models.60  However, the 
checklist only accounts for development and validation studies, with little to no 
applicability to impact analysis studies given the difference in aims, study designs, and 
reporting.60   
A tool guiding the conduct of impact analysis studies would ensure the methodological 
rigour of studies and strengthen the body of evidence exploring the impact of risk 
prediction models.  The present body of literature indicates several inconsistencies that 
should be addressed.  Firstly, a significant amount of heterogeneity in study design exists, 
with existing studies ranging from pre-post observational studies to cluster randomized 
trials, which, while not necessarily precluding the possibility of, reduces the 
comparability between studies.  Interventions are also uniquely presented across studies, 
such as providing lifestyle advice additional to the model-derived risk.  Pertaining to 
study conduct, periods of follow-up are non-uniform, ranging from a period of weeks to 
years, both reducing the comparability of studies as well as possibly not allowing for 
changes in behaviour or health outcomes.  The reporting of impact studies is also 
inconsistent, with diversity in measurement and presentation of study outcomes.  The 
development of such a tool could help inform the conceptualization, conduct, analyses, 
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and reporting associated with impact analysis studies, creating greater consistency in the 
literature, and allowing for the meaningful interpretation of study findings. 
Future studies should also examine the implementation of risk prediction models in 
primary care settings.  The use of risk prediction models in clinical practice faces several 
barriers, including those of time and uncertainty.  The physician-patient interaction is 
already temporally restricted, reducing the amount of time available for preventive 
services.153  Further, models exist for several health outcomes, and each model is 
designed for a specific target population.  As such, there exists uncertainty about which 
models are appropriate for a physician’s patients.70  This problem may be compounded 
by the rising prevalence in multimorbidity, which would necessitate multiple models 
being used for a single patient, significantly increasing the time spent in preventive 
services.  In recognition of these time constraints, uncertainty, and the rise in 
multimorbidity globally, there exists the need to streamline the process.  This may be 
accomplished through the incorporation of models in routine electronic medical records 
allowing for automated calculation of absolute risk, or the creation of models capable of 
predicting for multiple health outcomes (multimorbidity risk prediction models).  By 
streamlining this process, the process of implementing risk prediction models in clinical 
practice may be eased. 
7.8 Conclusion 
This systematic review and meta-analysis brought to light the inconsistencies in the 
conduct of impact analysis studies, and inconsistencies in general within the growing 
field of prediction modelling.  This study identified a small group of studies that 
examined the impact of prediction models on clinical and behavioural outcomes.  Though 
these studies may have been affected by methodological discrepancies and the review 
would be strengthened by a unified method for conducting model impact studies, they do 
provide some measure of support for the use of prediction models in primary care 
settings, and indicate that future research must be undertaken to ascertain the most 
effective methods of implementing these tools in clinical practice.   
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Appendix A: The Gusto-I Model predicting risk of mortality at 30 days for patients who 
experience myocardial infarction. 
Probability of death within 30 days = 1 / [1 + exp(-L)], where L is given by: 
L= 3.812 + 0.07624*age - 0.03976*minimum(SBP, 120) + 2.0796[Killip class II] + 
3.6232[Killip class III] + 4.0392[Killip class IV] - 0.02113*heart rate + 0.03936(heart 
rate-50) - 0.5355[inferior MI] - 0.2598[other MI location] + 0.4115[previous MI] - 
0.03972*height + 0.0001835(height-154.9)  + 3 - 0.0008975(height-165.1) + 3 + 
0.001587(height - 172.0) + 3-0.001068(height-177.3) + 3 + 0.0001943 (height-185.4) + 3 
+ 0.09299 (time to treatment)-0.2190[current smoker]-0.2129[former smoker] + 
0.2497[diabetes] - 0.007379*weight + 0.3524[previous CABG] + 0.2142[SK and 
intravenous heparin] + 0.1968[treatment with SK and subcutaneous heparin] + 
0.1399[combination TPA and SK plus IV heparin] + 0.1645[hx of hypertension] + 
0.3412 [hx of cerebrovascular disease] - 0.02124 age*[Killip class II] - 0.03494 
age*[Killip class III] - 0.03216 age · [Killip class IV] 
 
 
 
 
 
 
 
 
 
 
141 
 
Appendix B: Search strategies and citations retrieved 
Embase 
 
Step Search Terms Results 
1 Risk/ or Patient Risk/ or Expectancy/ or Risk Factor/  1792018 
2 limit 1 to (human and english language and yr="1976 -Current")  1455591 
3 ((Risk adj3 (adjust* or factor*)) or Probabilit* or Likelihood).mp. 
[mp=title, abstract, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, 
keyword, floating subheading]  
1416454 
4 limit 3 to (human and english language and yr="1976 -Current")  1091256 
5 1 or 3 2225620 
6 2 or 4 1740409 
7 Cardiometabolic Risk/ or Cardiovascular Risk/ or Coronary Risk/ or 
Reynolds risk score/ or Framingham risk score/ or CHADS2 Score/ 
or PROCAM Score/ or QRISK Score/ or Receiver Operating 
Characteristic/ or exp Area Under the Curve/ or exp "prediction and 
forecasting"/ or survival prediction/ or survival rate/ or exp decision 
support system/ or clinical decision making/ or medical decision 
making/  
1720383 
8 limit 7 to (human and english language and yr="1976 -Current")  1289143 
9 ("Risk scor*" or risk tool* or risk estimat* or risk assess* or risk 
function* or risk equation* or risk calc* or risk scor* or risk predict* 
or risk factor calc* or risk chart* or risk engine* or risk appraisal* or 
prediction model* or risk algorithm* or scoring* method* or scoring 
scheme* or roc curve or area under curve or AUC or c-statistic* or C 
index* or C indices*).mp. [mp=title, abstract, heading word, drug 
trade name, original title, device manufacturer, drug manufacturer, 
device trade name, keyword, floating subheading]  
586636 
10 limit 9 to (human and english language and yr="1976 -Current")  477129 
11 7 or 9 2100566 
12 8 or 10 1590351 
13 Chronic Disease/ or Cardiovascular Disease/ or Heart Disease/ or 
Vascular Disease/ or Lung Disease/ or Chronic Lung Disease/ or 
Chronic Obstructive Lung Disease/ or Asthma/ or Diabetes Mellitus/ 
or Insulin Dependent Diabetes Mellitus/ or Non Insulin Dependent 
Diabetes Mellitus/ or exp Neoplasm/  
5711682 
14 limit 13 to (human and english language and yr="1976 -Current")  3678673 
15 (Chronic disease* or Chronic illness* or chronically ill or non-
communicable disease* or cardiovascular disease* or vascular 
disease* or heart disease* or stroke or respiratory disease* or asthma 
or COPD or chronic obstructive pulmonary disease* or diabetes or 
diabetes mellitus or diabetic or cancer* or neoplasm* or metastatic* 
or metastisi* or metastases or carcinoma* or tumo?r*).mp. [mp=title, 
6617097 
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abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword, 
floating subheading]  
16 limit 15 to (human and english language and yr="1976 -Current")  4218997 
17 13 or 15 7255289 
18 14 or 16 4569682 
19 exp Primary Health Care/ or General Practice/  221104 
20 limit 19 to (human and english language and yr="1976 -Current")  159278 
21 (Primary health care or primary care or primary healthcare or primary 
medical care or family practice or family medicine or general 
practi*).mp. [mp=title, abstract, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade 
name, keyword, floating subheading]  
330910 
22 limit 21 to (human and english language and yr="1976 -Current")  232874 
23 19 or 21 330910 
24 20 or 22 232874 
25 5 and 11 and 17 and 23 8318 
26 6 and 12 and 18 and 24 7311 
 
Medline 
Steps Search terms Results 
1 Risk/ or Risk Factors/ or Risk Adjustment/  782446 
2 limit 1 to (english language and humans and yr="1976 -Current")  669642 
3 ((Risk adj3 (adjust* or factor*)) or Probabilit* or Likelihood).mp. 
[mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique 
identifier, synonyms]  
1202769 
4 limit 3 to (english language and humans and yr="1976 -Current")  903884 
5 1 or 3 1290060 
6 2 or 4 973836 
7 Algorithms/ or Probability/ or Bayes Theorem/ or Likelihood 
Functions/ or Proportional Hazards Models/ or "Sensitivity and 
Specificity"/ or ROC Curve/ or exp Decision Support Techniques/ 
or Area Under Curve/ or Clinical Decision-Making/ or exp Risk 
Assessment/  
900317 
8 limit 7 to (english language and humans and yr="1976 -Current")  661515 
9 ("Risk scor*" or risk tool* or risk estimat* or risk assess* or risk 
function* or risk equation* or risk calc* or risk scor* or risk 
predict* or risk factor calc* or risk chart* or risk engine* or risk 
appraisal* or prediction model* or risk algorithm* or scoring* 
method* or scoring scheme* or roc curve or area under curve or 
AUC or c-statistic* or C index* or C indices*).mp. [mp=title, 
abstract, original title, name of substance word, subject heading 
375007 
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word, keyword heading word, protocol supplementary concept 
word, rare disease supplementary concept word, unique identifier, 
synonyms]  
10 limit 9 to (english language and humans and yr="1976 -Current")  300610 
11 7 or 9  989961 
12 8 or 10 712702 
13 Chronic Disease/ or Cardiovascular Diseases/ or exp Heart Diseases/ 
or exp Vascular Diseases/ or exp Lung Diseases, Obstructive/ or 
Diabetes Mellitus/ or Diabetes Mellitus, Type 1/ or exp Diabetes 
Mellitus, Type 2/ or Neoplasms/ or exp Neoplasms by Histologic 
Type/ or exp Neoplasms by Site/  
5281905 
14 limit 13 to (english language and humans and yr="1976 -Current")  3414820 
15 (Chronic disease* or Chronic illness* or chronically ill or non-
communicable disease* or cardiovascular disease* or vascular 
disease* or heart disease* or stroke or respiratory disease* or 
asthma or COPD or chronic obstructive pulmonary disease* or 
diabetes or diabetes mellitus or diabetic or cancer* or neoplasm* or 
metastatic* or metastisi* or metastases or carcinoma* or 
tumo?r*).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept 
word, unique identifier, synonyms]  
4887214 
16 limit 15 to (english language and humans and yr="1976 -Current")  3031693 
17 13 or 15 6516965 
18 14 or 16 3962675 
19 Primary Health Care/ or Comprehensive Health Care/ or exp 
General Practice/  
133832 
20 limit 19 to (english language and humans and yr="1976 -Current")  92993 
21 (Primary health care or primary care or primary healthcare or 
primary medical care or family practice or family medicine or 
general practi*).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, 
protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier, synonyms]  
231332 
22 limit 21 to (english language and humans and yr="1976 -Current")  1588565 
23 19 or 21 236748 
24 20 or 22 160459 
25 5 and 11 and 17 and 23 2696 
26 6 and 12 and 18 and 24 2396 
 
CINAHL 
 
Step Search Terms and options Results 
144 
 
1 (MH “Risk Factors+”) OR (MH “Health Screening+”) OR (MH 
“Patient Assessment+”)  
Search modes - Boolean/Phrase  
176674 
2 (MH “Risk Factors+”) OR (MH “Health Screening+”) OR (MH 
“Patient Assessment+”)  
 
Limiters - Published Date: 19760101-20170331; English Language; 
Human  
Search modes - Boolean/Phrase  
85634 
3 Risk adj3 (adjust* OR factor*) OR Probabilit* OR Likelihood  
 
Search modes - Boolean/Phrase  
36531 
4 Risk adj3 (adjust* OR factor*) OR Probabilit* OR Likelihood  
 
Limiters - Published Date: 19760101-20170331; English Language; 
Human  
Search modes - Boolean/Phrase  
27669 
5 1 or 3 109548 
6 2 or 4 208539 
7 (MH "Predictive Value of Tests") OR (MH “Predictive Research”) 
OR (MH “Models, Statistical”) OR (MH “Decision Support 
Techniques+”) OR (MH “Decision Making, Clinical”) OR (MH 
“Clinical Assessment Tools”) OR (MH “Risk Assessment”) OR 
(MH “ROC Curve”) OR (MH “Survival Analysis+”)  
 
Search modes - Boolean/Phrase  
201806 
8 (MH "Predictive Value of Tests") OR (MH “Predictive Research”) 
OR (MH “Models, Statistical”) OR (MH “Decision Support 
Techniques+”) OR (MH “Decision Making, Clinical”) OR (MH 
“Clinical Assessment Tools”) OR (MH “Risk Assessment”) OR 
(MH “ROC Curve”) OR (MH “Survival Analysis+”)  
Limiters - Published Date: 19760101-20170331; English Language; 
Human  
Search modes - Boolean/Phrase  
146268 
9 “Risk scor*” OR risk tool* OR risk estimat* OR risk assess* OR 
risk function* OR risk equation* OR risk calc* OR risk scor* OR 
risk predict* OR risk factor calc* OR risk chart* OR risk engine* 
OR risk appraisal* OR prediction model* OR risk algorithm* OR 
scoring* method* OR scoring scheme* OR roc curve OR area 
under curve OR AUC OR c-statistic* OR C index* OR C indices*  
Search modes - Boolean/Phrase  
90777 
10 “Risk scor*” OR risk tool* OR risk estimat* OR risk assess* OR 
risk function* OR risk equation* OR risk calc* OR risk scor* OR 
risk predict* OR risk factor calc* OR risk chart* OR risk engine* 
OR risk appraisal* OR prediction model* OR risk algorithm* OR 
56570 
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scoring* method* OR scoring scheme* OR roc curve OR area 
under curve OR AUC OR c-statistic* OR C index* OR C indices*  
Limiters - Published Date: 19760101-20170331; English Language; 
Human  
Search modes - Boolean/Phrase  
11 7 or 9 235929 
12 8 or 10 167860 
13 (MH “Chronic Disease”) OR (MH “Cardiovascular Diseases”) OR 
(MH “Heart Diseases”) OR (MH “Vascular Diseases”) OR (MH 
“Lung Diseases”) OR (MH “Lung Diseases, Obstructive+”) OR 
(MH “Diabetes Mellitus”) OR (MH “Diabetes Mellitus, Type 1”) 
OR (MH “Diabetes Mellitus, Type 2”) OR (MH “Neoplasms”) OR 
(MH “Neoplasms by Site+”) OR (MH “Neoplasms by Histologic 
Type+”)  
Search modes - Boolean/Phrase  
359492 
14 (MH “Chronic Disease”) OR (MH “Cardiovascular Diseases”) OR 
(MH “Heart Diseases”) OR (MH “Vascular Diseases”) OR (MH 
“Lung Diseases”) OR (MH “Lung Diseases, Obstructive+”) OR 
(MH “Diabetes Mellitus”) OR (MH “Diabetes Mellitus, Type 1”) 
OR (MH “Diabetes Mellitus, Type 2”) OR (MH “Neoplasms”) OR 
(MH “Neoplasms by Site+”) OR (MH “Neoplasms by Histologic 
Type+”)  
Limiters - Published Date: 19760101-20170331; English Language; 
Human  
Search modes - Boolean/Phrase  
129339 
15 Chronic disease* OR Chronic illness* OR chronically ill OR non-
communicable disease* OR cardiovascular disease* OR vascular 
disease* OR heart disease* OR stroke OR respiratory disease* OR 
asthma OR COPD OR chronic obstructive pulmonary disease* OR 
diabetes OR diabetes mellitus OR diabetic OR cancer* OR 
neoplasm* OR metastatic* OR metastisi* OR metastases OR 
carcinoma* OR tumo?r*  
Search modes - Boolean/Phrase  
521893 
16 Chronic disease* OR Chronic illness* OR chronically ill OR non-
communicable disease* OR cardiovascular disease* OR vascular 
disease* OR heart disease* OR stroke OR respiratory disease* OR 
asthma OR COPD OR chronic obstructive pulmonary disease* OR 
diabetes OR diabetes mellitus OR diabetic OR cancer* OR 
neoplasm* OR metastatic* OR metastisi* OR metastases OR 
carcinoma* OR tumo?r*  
Limiters - Published Date: 19760101-20170331; English Language; 
Human  
Search modes - Boolean/Phrase  
194062 
17 13 or 15 200021 
18 14 or 16 39265 
19 (MH “Primary Health Care”) OR (MH “Family Centered Care+”) 39265 
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Search modes - Boolean/Phrase  
20 (MH “Primary Health Care”) OR (MH “Family Centered Care+”) 
Limiters - Published Date: 19760101-20170331; English Language; 
Human  
Search modes - Boolean/Phrase   
13019 
21 Primary health care OR primary care OR primary healthcare OR 
primary medical care OR family practice OR family medicine OR 
general practi*  
Search modes - Boolean/Phrase  
78566 
22 Primary health care OR primary care OR primary healthcare OR 
primary medical care OR family practice OR family medicine OR 
general practi*  
Limiters - Published Date: 19760101-20170331; English Language; 
Human  
Search modes - Boolean/Phrase  
32297 
23 19 or 21 83275 
24 20 or 22 33712 
25 5 and 11 and 17 and 23 857 
26 6 and 12 and 18 and 24 555 
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Appendix C: Study eligibility criteria 
 
Title/abstract level 
 
Inclusion criteria: 
- Intervention is or includes a risk prediction model 
- The model is prognostic 
- The model generates a predicted risk for a chronic disease 
- The study must test the effect of the intervention (i.e. model impact) 
- Include articles with no age, geographic, or sex restrictions 
 
Exclusion criteria: 
- Model is diagnostic 
- Model assesses for behavioural, mental, or acute health outcomes (i.e. risk of STI 
infection, risk of schizophrenia, risk of fracture) 
- Patients are generally symptomatic for the outcome of the model (>20%) 
- The study does not occur in a primary care setting 
- The healthcare professional is not a physician 
- The citation is for an editorial or opinion piece 
- The study describes only the development or validation of risk prediction models 
 
Full-text level 
 
- Confirmation of criteria from title/abstract level of screening 
 
Inclusion criteria: 
- The study assesses the effect of the intervention on physicians and/or patients 
- Include studies with a control group 
 
Exclusion criteria: 
- The study does not include some form of a control group (i.e. no pre- data in a pre-post 
study) 
- Exclude studies that only evaluate economic impact of model use 
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Appendix D: Brief description of interventions administered 
Author, 
year 
Description of intervention 
van den 
Brekel-
Dijkstra et 
al., 2016201 
Patients completed web-based questionnaire. Those identified at increased risk 
based on personal information (e.g. sociodemographic, personal health) 
completed biometric and laboratory testing, generating 10-year CVD risk. 
Patients receive health plan containing: 1) outcome of risk assessment (normal, 
moderately elevated risk, seriously elevated risk), 2) explanation of health risk 
and benefits of preventive action, 3) individual opportunities for lifestyle 
change, and 4) links to local providers of lifestyle interventions. Follow-up 
electronic questionnaire sent six months after receiving tailored advice. 
 
Usher-
Smith et al., 
2015219 
Patients informed of change in NICE guidelines (change in statin prescription 
threshold from 20% absolute risk to 10%), provided information leaflet 
regarding recommendations, risk calculation, statins, and lifestyle advice. 
Leaflet encourages lifestyle modifications and invited to visit clinics to discuss 
statins. At clinic appointment, patients told QRISK score, discuss statins, and 
offered opportunity for further review in the future if hesitant. Data were 
retrieved from practice electronic records. 
 
Sorensen et 
al., 2011220 
Patients underwent medical history interview regarding previous disease, and 
tobacco and medication use.  Risk factors were measured and CVD risk was 
calculated. Participants and their general physicians received written reports.  If 
at elevated risk, participants were notified to contact their physician.  Follow-up 
questionnaires were mailed to patients six months following screening 
examination. 
 
Bach-
Nielsen et 
al., 2005199 
A previous study recruited participants, who were randomly allocated to either a 
control group, where lifestyle questions were asked, or an intervention group, 
where a health screening, including calculation and written provision of 
cardiovascular risk, was conducted.  The subject of the present article was a 
qualitative study, where patients were interviewed regarding their participation 
in screening, their experiences and findings, assessments of their own health, 
views regarding health promotion and screening, and opinions on consultations 
with their physician. 
 
Chang et 
al., 2016203 
Data were extracted for patients registered at a practice participating in the 
Clinical Practice Research Datalink.  Patients were categorized as either Health 
Check attendees and nonattendees.  Patients during the Health Check received 
their cardiovascular risk as well as tailored management strategies including 
lifestyle advice. 
 
Cochrane et 
al., 2012204 
Patients from 38 general practices were recruited, and practices were 
randomized to the NHS Health Check group or the NHS Health Check plus 
additional lifestyle support group.  The NHS Health Check included usual 
general care, such as smoking cessation or medication services and provision of 
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risk score.  Lifestyle support included consultation with lifestyle coaches, the 
development of health improvement plans, and lifestyle priorities with referrals 
to free support sessions for weight management, physical activity, dietary 
support, and positive thinking.  One year follow-up measures were obtained. 
 
Vagholkar 
et al., 
2014221 
Randomization occurred at the level of the practice.  Physicians were trained (3-
hour workshop) in the use of the New Zealand CV risk calculator and 
recommendations for cardiovascular risk based on Australian and New Zealand 
guidelines. Intervention patients received 20-30 minute consultations where risk 
was calculated, and were provided appropriate management based on risk levels 
and current guidelines.  Control patients received a general health check.  
Physicians reassessed cardiovascular risk at the 12-month health check. 
 
Grover et 
al., 2008209 
Patients were stratified by risk level (very high, high, or moderate) and 
randomized to receive either printed, individualized risk profiles or usual care.  
Risk profiles display probability of coronary disease risk over an 8-year period 
as well as cardiovascular age, a life expectancy adjusted for risk of coronary 
disease and stroke based on average life expectancy of Canadians of the same 
age and sex.  Risk profiles were mailed to physicians prior to the next patient 
visit, and shown to intervention patients at their visit as well as provided to 
patients to take home.  Biometric measures (blood pressure, lipids) were taken 
2-4 weeks prior to and at each follow-up visit.  Updated risk profiles were 
discussed with intervention patients at each visit. 
 
Courtney et 
al., 2015205 
Patients who received PreDx results were identified from a comprehensive 
electronic medical database in the Dallas-Fort Worth area.  A comparison group 
matched for age, sex, selected diagnoses (similar to intervention group), and 
metabolic risk factors was also selected from the same database.  A report was 
provided to patients including the PreDx results, a numerical score 
distinguishing risk of type 2 diabetes, as well as the individual patient’s risk 
compared to the general population, and the levels of the patient’s individual 
biomarkers with their normal ranges.  Data were also collected regarding 
intensity of care, risk factor monitoring, and prescription medication. 
  
Engberg et 
al., 2002206 
Patients randomly selected from one district in Denmark, and received a 
questionnaire about general demographic information and lifestyle, as well as 
questions about psychosocial status and psychosocial life events.  Patients 
randomly allocated to 1 of 3 groups: 1) questionnaire (includes healthy lifestyle 
pamphlet) only, 2) questionnaire and health screening, and 3) questionnaire, 
health screening, and follow-up health discussions.  Health screenings provided 
each patient with an estimate of cardiovascular risk.  If at elevated risk, patients 
received feedback relating to lifestyle changes, and were encouraged to see their 
general practitioner.  Health discussions were 45 minute consultations with 
general physicians, where patient concerns were addressed and lifestyle goals 
were established.  Health discussion groups were offered annual consultations; 
all other groups had follow-ups at 1 and 5 years post-baseline. 
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Ford et al., 
2001207 
The Clinical Biochemistry laboratory database at Birmingham Heartlands 
Hospital was searched for all CHD risk requests made in 1998.  Physicians 
made requests by providing a laboratory request form with a blood sample, the 
cardiovascular risk is calculated.  Researchers visited practices to review patient 
case notes for those a risk request was made for.  Risk results were confirmed, 
as well as reasons why tests were ordered, prescribed drugs both before and 
after the risk request, and any other management changes. 
 
Grover et 
al., 2007208 
 
Physicians attended a regional investigator meeting, which included training on 
interpreting risk profiles, national lipid guidelines, and the study protocol.  
Patients were screened with a complete medical evaluation.  Patients were 
randomized to usual care or ongoing feedback regarding calculated coronary 
risk.  Risk profiles including 10-year coronary risk were discussed with patients 
by study physicians in the intervention arm, while usual care patients did not 
receive risk profiles.  Risk profiles were computer printouts with disease risk as 
well as cardiovascular age, and contained relative risks as well as absolute risk.  
Patients were followed for one year with biometric measures taken before and 
during each follow-up visit (3 month intervals).   
 
Jiao et al., 
2015211 
 
Patients (in the RAMP-DM group) of public general outpatient clinics 
underwent risk factor screening for diabetes-related complications and were 
stratified according to JADE classification (high, medium, low risk).  RAMP-
DM subjects received appropriate interventions and education according to risk.  
Usual care patients were managed by physicians without risk assessment and 
stratification. 
 
Jiao et al., 
2014210 
 
Patients (in the RAMP-DM group) entering the program underwent risk factor 
assessment and potential existing diabetic complications upon enrolment, and 
were stratified as low, medium, or high risk.  Different management strategies 
were provided to them, such as consultation with allied health professionals.  
Patients under usual care were managed solely by physicians without risk 
assessment and stratification. 
 
Law et al., 
2014212 
Physicians prospectively collected data amongst ambulatory patients.  
Physicians determined patient cardiovascular risk, and reported subsequent 
treatment decisions. 
 
Lowensteyn 
et al., 
1998213 
Community-based family physicians were invited for participation, and 
assigned a study site.  Study sites were allocated to the profile group or the 
control group.  Physicians then invited patients.  Physicians inputted risk factor 
data, then patient completed a questionnaire outlining attitudes and knowledge 
of CVD as well as current lifestyle and medical problems.  Profile patients 
received a printed copy of their risk profile.  Patients were scheduled for a 
follow-up visit 3 to 6 months later.  New risk factor data were collected at 
151 
 
follow-up.  Profiles provide 8-year coronary risk, and risk reductions for 
modifications of risk factors. 
 
Mehta et 
al., 2014214 
Patients recruited upon their physician’s use of PREDICT, a web-based clinical 
decision program that generates an absolute risk for patients.  Patients were 
stratified according to cardiovascular risk (high, moderate, or low risk).  
PREDICT database was linked to the Pharmaceutical Collections to collect data 
on dispensing of medications. 
 
Palmieri et 
al., 2011215 
Physicians were trained in the USE of the 10-CR score, and downloaded the 
CUORE.EXE software, which allows users to calculate CVD risk based on 
patient characteristics.  It also provides a hypothetical risk based on 
modifications of risk factors to favourable levels, and present risk reductions for 
behaviour changes.  Information is printed along with lifestyle 
recommendations, and presented to patients, and sent to a central database.  
Updated information on risk factor levels, absolute risk, prescribed therapies 
and lifestyle recommendations were sent to the same database.  Cardiovascular 
events were recorded during follow-up. 
  
Powers et 
al., 2011216 
Patients who agreed to participate received a baseline survey, and patients were 
randomized to either a standard risk factor education group or a personalized 
risk communication group.  Standard education included written patient 
education materials covering established risk factors and how factors can be 
improved.  Personalized risk communication patients received the standard 
education as well as information based on their personal CHD and stroke risk 
scores, both verbally and graphically.  The average and optimal scores were 
published alongside their personal risk.  Patients were provided with strategies 
to improve their risk (risk factor modification and lifestyle factors).  Data were 
collected from medical records and interviews. 
 
Price et al., 
2011217 
Participants were recruited from four general practices in Oxfordshire, and were 
randomized to either the risk factor group or personalized risk group.  Risk 
factor group patients received their blood pressure, total cholesterol and fasting 
glucose values and were told if they were elevated.  Personalized risk group 
patients received their cardiovascular disease risk estimate.  In a 2 x 2 factorial 
design, patients were also randomized to receive or not receive lifestyle advice.  
The personalized risk information displayed current risk and achievable risk, a 
hypothetical risk if all targets for risk factors are obtained. 
 
Romero et 
al., 2008218 
Medical records of patients from the Internal Medicine Clinic at the Naval 
Medical Center San Diego were reviewed to identify eligible patients.  Baseline 
data were recorded.  A poster including the Framingham Risk Score was placed 
in examination rooms of the clinic, and physicians were encouraged through 
semi-regular announcements to improve guideline adherence.  Outpatient 
medical records of another patient sample were reviewed and data were 
recorded. 
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Volpe et al., 
2007222 
General physicians recruited patients with a diagnosis of hypertension.  Patient 
blood pressure levels and estimated stroke risk was measured at both the initial 
visit and during the follow-up visit.  Risk factor data were recorded directly in a 
computerized scoring algorithm.  No recommendations were made to physicians 
regarding therapeutic interventions. 
 
Wind et al., 
2015223 
Study sponsors recruited general physicians, who then recruited 10 consecutive 
patients.  Data were collected from the patients’ medical records.  At baseline, 
physicians estimated patient 10-year CHD risk based on their own subjective 
judgement, and then using the UKPDS risk engine.  Study sponsors trained 
physicians on how to use the risk engine, interpret CHD risk, and determine 
whether differences between subjectively calculated risk and UKPDS derived 
risk warranted medication adjustment.  Data on risk estimates, risk factor levels, 
and medication adjustments were recorded. 
 
Bellows et 
al., 2014200 
Physicians at two clinics in Hawaii were selected.  IndiGO guidelines were 
implemented using automatic data extraction for all adult patients, which 
automatically calculated risk scores.  Physicians selected patients, who were 
shown videos explaining the guidelines.  Physicians and patients then used 
IndiGO in a shared decision-making session with a printed summary displaying 
all chosen interventions, and predicted risks of heart attack and stroke if 
interventions are implemented.  Propensity score matching was used to identify 
a control group of patients receiving usual care. 
 
Burgess et 
al., 2011202 
The Aboriginal and Torres Strait Islander Adult Health Check (AHC) was 
implemented in remote communities.  During the AHC, cardiovascular risk was 
assessed identifying patients with elevated CVD risk, and other behavioural risk 
factor values were collected via questionnaire.  The AHC also consisted of 
chronic disease care planning, with patient education and intervention delivery, 
treatment goals are negotiated with patients, and follow-up monitoring and care 
planning.  Patients were followed for three years at six month intervals. 
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Appendix E: Comparison of baseline and follow-up measures as per Chang et al. 
(2015).203 
 
Risk factor Group 
Before 
intervention 
After 
intervention 
QRISK2, % 10-year 
risk 
Intervention 6.7±5.9 6.2±5.3 
Control 5.1±5.3 4.9±5.0 
Systolic blood pressure, 
mmHg 
Intervention _ 131.9±17.4 130.0±12.7 
Control 128.5±13.6 129.3±11.3 
Diastolic blood 
pressure, mmHg 
Intervention 80.2±10.5 78.5±7.7 
Control 78.7±8.2 78.7±6.7 
Body mass index 
(kg/m2) 
Intervention 27.7±5.1 27.7±5.0 
Control 26.9±4.1 27.2±4.0 
Total cholesterol, 
mmol/L 
Intervention 5.5±1.0 5.3±0.8 
Control 5.3±0.6 5.3±0.6 
Smoking prevalence, % 
of group 
Intervention 17.9 16.3 
Control 22.2 20.8 
Statin prescribed, % of 
group 
Intervention 9.7 15.3 
Control 3.1 4.3 
Antihypertensive 
prescribed, % of group 
Intervention 4.8 9.9 
Control 1.8 4.4 
Values are presented as mean ± standard deviation, where available. 
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Appendix F: Comparison of baseline and follow-up measures as per Cochrane et al. 
(2012)204 
 
Risk factor Group Baseline Follow-up 
CVD risk (%) 
Health Check 32.9±9.7 29.4±9.7 
Health Check Plus 31.9±10.0 29.2±10.1 
Systolic blood pressure, 
mmHg 
Health Check 146.0±17.0 138.3±14.7 
Health Check Plus 144.4±16.2 138.7±14.6 
Diastolic blood 
pressure, mmHg 
Health Check 84.9±9.5 80.5±8.8 
Health Check Plus 85.3±9.6 81.5±8.9 
Total cholesterol 
(mmol/L) 
Health Check 5.7±0.9 5.0±1.0 
Health Check Plus 5.7±0.9 5.1±1.0 
Total cholesterol/HDL 
cholesterol, mmol/L 
Health Check 4.8±1.0 4.2±1.1 
Health Check Plus 4.9±1.1 4.4±1.1 
Weight (kg) 
Health Check 82.6±13.8 82.8±13.5 
Health Check Plus 85.0±14.5 84.3±14.5 
Body mass index 
(kg/m2) 
Health Check 27.5±4.1 27.6±4.1 
Health Check Plus 28.7±5.0 28.4±4.9 
Waist circumference 
(cm) 
Health Check 99.5±11.8 97.9±10.7 
Health Check Plus 101.3±11.2 99.1±11.4 
Values are presented as mean ± standard deviation. 
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Appendix G: Comparison of baseline and follow-up measures for Jiao et al. (2015)211 
Risk factor Group 
Before 
intervention 
After 
intervention 
BMI (kg/m2) 
Intervention 25.33±3.74 25.07±3.79 
Control 25.33±3.90 25.11±3.92 
Systolic blood pressure, 
mmHg 
Intervention 135.41±17.05 130.12±14.68 
Control 135.45±16.56 132.35±15.51 
Diastolic blood 
pressure, mmHg 
Intervention 75.11±10.34 71.60±10.26 
Control 75.08±9.77 73.23±9.72 
HbA1c (%) 
Intervention 7.24±1.23 7.13±1.09 
Control 7.24±1.24 7.25±1.26 
Total cholesterol, 
mmol/L 
Intervention 5.08±0.94 4.43±0.82 
Control 5.08±0.95 4.49±0.86 
HDL-C (mmol/L) 
Intervention 1.22±0.32 1.28±0.34 
Control 1.22±0.32 1.31±0.35 
LDL-C (mmol/L) 
Intervention 3.13±0.82 2.51±0.69 
Control 3.14±0.83 2.55±0.72 
Triglyceride (mmol/L) 
Intervention 1.64±1.10 1.43±0.87 
Control 1.64±1.05 1.43±0.97 
Current smoker 
Intervention 927 (10.2) 346 (9.0) 
Control 906 (10.0) 235 (8.6) 
On glucose-lowering 
drugs 
Intervention 7943 (87.3) 7999 (90.0) 
Control 7929 (87.2) 7143 (83.6) 
On antihypertensive 
drugs 
Intervention 6637 (73.0) 7112 (80.0) 
Control  6673 (73.4) 6493 (76.0) 
On lipid-lowering drugs 
Intervention 1189 (13.1) 4551 (51.2) 
Control 1225 (13.5) 3903 (45.7) 
On insulin 
Intervention 105 (1.2) 534 (6.0) 
Control 130 (1.4) 386 (4.5) 
Values are presented as mean ± standard deviation or n (%). 
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Appendix H: Forest plots for best- and worst-case scenarios (antihypertensive medication 
prescription) 
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Appendix I: Forest plots for best- and worst-case scenarios (lipid-lowering medication 
prescription) 
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Appendix J: Forest plots for best- and worst-case scenarios (smoking cessation) 
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